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The increase in life expectancy has profoundly increased the ageing population, which, unfortunately, 
is also accompanied by a rise in age-related disorders, including Alzheimer’s Disease (AD). The most 
common form of dementia is AD, which was first described over a century ago, however, to date, there 
still exists a lack of understanding the molecular changes specific to the disease, a clinically established 
robust blood-based biomarker for accurate disease diagnosis and a lack of treatments.   
This thesis begins by investigating microarray gene expression profiling from Asymptomatic AD 
(AsymAD) human brains, who were clinically free from dementia; however, upon autopsy, they were 
observed to consist of hallmark AD pathology. A significant increase of transcriptomic activity in the 
frontal cortex (FC) brain region of AsymAD subjects was detected, suggesting fundamental changes in 
AD may initially begin within the FC brain region prior to symptoms of AD. In addition, overactivation 
of the brain “glutamate-glutamine cycle” and disruption to the brain energy pathways in both AsymAD 
and AD subjects were identified, suggesting these may be the earliest biological pathways disrupted in 
the disease, providing potential targets for early disease intervention.  
Secondly, existing and novel microarray gene expression studies of human AD brains were integrated 
into the largest known AD meta-analysis to date and is the first to incorporate numerous non-AD 
neurological disorders to identify AD-specific molecular changes. Seven genes were observed to be 
specifically and consistently perturbed across AD brains, with SPCS1 gene expression pattern found to 
replicate in RNA-Seq data. The cerebellum brain region is often regarded to be free from hallmark AD 
pathology and was incorporated into the analysis as a secondary control to identify an additional 
nineteen genes that may be involved with hallmark AD pathology. Furthermore, biological processes 
often reported as disrupted in AD were observed to be tissue-specific, and viral components were 
found to be specifically enriched across AD brains. 
Thirdly, an automated transcriptomic based drug repositioning pipeline was developed to query the 
reprocessed Connectivity Map to identify candidate compounds for disease intervention. Drug 
repositioning the AsymAD gene expression profile identified several candidate compounds that are 
already FDA approved for the treatment of AD and cognitive impairment, suggesting these compounds 
may be effective in the early stage of the disease. Drug repositioning the AD gene expression profile 
identified an anti-biotic compound for disease intervention.  
Finally, a machine learning approach was used to identify a blood-based 28 gene expression profile, 
which is enriched for “herpes simplex infection”, and can distinguish AD from Parkinson’s Disease, 
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Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Bipolar Disorder, Schizophrenia, Coronary Artery 
Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease, and cognitively healthy subjects 
with 66.3% PPV and 90.6% NPV.  
Overall, the work undertaken in this thesis provides new insight into the molecular changes occurring 
in both the asymptomatic and symptomatic phase of the disease, demonstrates a framework for a 
possible blood-based transcriptomic diagnosis test, provides new potential therapeutic targets, 
identifies candidate compounds that require further investigation for disease intervention and provides 
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 Chapter 1: Introduction 
 
1.1 Alzheimer’s disease 
In 1906, a clinical psychiatrist and neuroanatomist named Alois Alzheimer first described a 50-year-old 
patient with memory issues, paranoia, disorientation, and deteriorating psychological changes until her 
death. Post mortem examination identified dramatic changes to the brain, including shrinkage and 
abnormal altercations. Alois identified a further three patients with similar clinical and histopathological 
symptoms, and by 1909, the illness was referred to as Alzheimer’s disease (AD) (Hippius and 
Neundörfer, 2003). 
AD falls under the umbrella term dementia, which is characterised by loss of cognitive function, 
behavioural changes and social functioning. An estimated 50 million people worldwide are living with 
dementia (Patterson, 2018), of which AD is estimated to account for 60-80% (Gaugler et al., 2016), 
making it the most common cause of dementia. In the UK alone, an estimated 200,000 new cases of 
dementia are diagnosed every year (Matthews et al., 2016), which has a significant economic impact, 
costing an approximate £26 billion to care for patients and has been forecasted to double by 2050 
(Lewis et al., 2014). 
1.1.1 Disease progression 
Ageing is an ongoing natural process of living, where structural, biochemical, physiological and 
functional changes lead to increased vulnerability and frailty. As everyone is expected to experience 
cognitive decline during ageing while exhibiting different symptoms, the transition from normal ageing 
to AD is very subtle and is modelled in Figure 1.1  (Sperling et al., 2011). Cognitive decline can be 
measured by several different tests and generally involves a series of questions to assess an individual’s 
short and long term memory, concentration, attention, language and orientation (Hunt et al., 2017). 
The rate of decline varies between AD subjects and has been suggested to take a few years to a couple 
of decades for dementia to manifest (Thalhauser and Komarova, 2012). As the disease progresses, the 
brain progressively becomes damaged, with the severity of symptoms a typical reflection of the degree 
of neuronal loss. Individuals with the disease may exhibit multiple symptoms that change over several 
years. In addition, everyone may not experience the condition in the same manner, making symptoms 
challenging to distinguish from healthy ageing and other disorders such as depression (Gaugler et al., 
2016). Nevertheless, AD can be generalised into three distinct stages based on symptoms; the 











1.1.2 Genetic causes 
AD can be generalised as either early-onset AD (EOAD), where the disease manifests before the age of 
65 and is inherited in a Mendelian dominant fashion, or late-onset AD (LOAD), where the disease 
manifests after the age of 65 and is driven by a combination of genetic and environmental factors. 
Approximately 95% of all AD cases are LOAD, while 5% are EOAD. No single genetic mutation has been 
identified to account for all AD cases. However, mutations in either the amyloid precursor protein (APP), 
presenilin 1 (PSEN1) or presenilin 2 (PSEN2) gene will result in EOAD. 
1.1.3 Risk factors  
A number of genetic and environmental factors have been found to increase the risk of AD. These 
factors increase the risk of developing AD but do not necessarily imply an individual with these risk 
factors will be guaranteed to develop the disease. 
1.1.3.1 Non-genetic risk factors 
The most significant risk factors for LOAD are age and gender. The prevalence of AD significantly 
increases with age and females are at greater risk. A typical 65-year old female is estimated to be at 
12% risk, while a male of the same age has a risk of 6.3% (Podcasy and Epperson, 2016). The difference 
in disease prevalence in genders has been suggested to be attributed to women’s longevity in 
combination with young female mitochondria being protected against amyloid-beta (Aβ) toxicity, 
generating less reactive oxygen species, and releasing less apoptogenic signals than from males (Viña, 
Viña and Lloret, 2010). 
Figure 1.1: Model of clinical trajectory of AD with three distinct stages based on symptoms; 1) 
preclinical stage, 2) MCI and 3) Dementia due to AD.  Reproduced from (Sperling et al., 2011). 
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Approximately 25% of all AD patients have a family history of AD. Individuals whose parents or siblings 
have AD have an increased likelihood to develop the disease and are at even more risk if they have 
more than one first-degree relative with AD (Bird, 2018).  
The risk factors associated with cardiovascular disease (CVD), such as smoking, obesity, diabetes and 
hypertension, have also been shown to increase the risk of AD. Although the direct connection between 
the two diseases remains unclear, the general hypothesis suggests a healthy brain’s demand for energy 
supply is hampered by CVD, resulting in decreased nutrient and oxygen-rich blood reaching the brain 
for normal functionality, causing nerve cell death. 
Individuals who have more years in education, a mentally stimulating occupation or engage in social 
activities have been suggested to build “cognitive reserves” and reduce the risk of AD (Wang, Xu and 
Pei, 2012; Iacono et al., 2015; Grzywacz, Segel-Karpas and Lachman, 2016). These “cognitive reserves” 
are the brain's ability to create flexible cognitive neuronal networks, which have been suggested to 
optimise normal cognition and compensate for brain changes such as accumulation of Aβ and tau, 
enabling an individual to continue to carry out cognitive tasks (Stern, 2002).  
Traumatic brain injury (TBI) is a blow, jolt or penetration of the skull caused by a foreign object, which 
disrupts normal brain function and can result in a loss of consciousness and post-traumatic amnesia. 
Studies have generated a growing body of evidence to suggest that TBI’s and repeated head injuries 
(e.g. boxers, and football players) increase the risk of MCI, dementia and neurodegenerative diseases 
including AD (Guskiewicz et al., 2005; Davis et al., 2015).  
1.1.3.2 Genetic risk factors 
Multiple susceptibility genes have been shown to increase the risk of LOAD, with the APOE gene, 
located on chromosome 19, being the most significant. The APOE gene has three major allelic variants 
(e2, e3, and e4), which encode for different isoforms of a cholesterol transporting protein. The e3 
variant is the most common, followed by the e4 and then the e2 variant (Mahley and Rall, 2000). An 
individual inherits one APOE gene from each parent and therefore, can have any one of the six different 
allele combinations (e2/e2, e2/e3, e2/e4, e3/e3, e3/e4, e4/e4). Individuals who inherit one copy of the 
e4 have a 3-fold increase in developing AD, while inheriting two copies of the e4 form increases the risk 
to 15-fold when compared to two copies of the e3 form. Approximately 25% of the general population 
and up to 65% of AD patients have the e4 variant (Bird, 2018). In contrast, inheriting the e2 variant may 
decrease the risk of developing AD when compared with the e3 variant (Iacono et al., 2015). 
An additional nineteen variants have been identified to increase the risk of AD, but collectively only 
account <2% of all cases. These genes are ABCA7, AKAP9, BIN1, CASS4, CD2AP, CD33, CLU, EPHA1, 
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FERMT2, HLA-DRB5/DRB1, INPP5D, MEF2C, MS4A6A/MS4A4E, PICALM, PLD3, PTK2B, SORL1, TREM2 
and UNC5C. Many of these genes are involved in various brain development, cytoskeleton organisation, 
and immune functions (Bird, 2018). 
1.1.4 Current understanding of the disease pathology 
Although the exact cause of the disease remains a mystery, many hypotheses exist, with amyloid and 
tau hypotheses arguably being the most common. Two proteins in the brain are associated with these 
hypotheses. The first is Amyloid Beta (Aβ), which accumulates between brain neurons to form insoluble 
structures known as plaques, and the second is tau, which collectively forms neurofibrillary tangles 
inside neurons. Plaques and tangles exist in all older adults; however, there is an abnormal 
accumulation in individuals with AD, which has been suggested to be a result of an imbalance in the 
production and removal of these proteins. Evidence has even suggested the abnormal accumulation of 
these proteins occur in AD brains 20 years prior to the onset of clinical symptoms (Reiman et al., 2012). 
1.1.4.1 The Amyloid hypothesis 
The Amyloid hypothesis assumes the abnormal accumulation of brain Aβ forms plaques, which trigger 
neurodegeneration and ultimately is the cause of AD (Makin, 2018). Aβ is a peptide consisting of 40 
amino acids, which is derived from sequential cleavage of the Amyloid Precursor Protein (APP). The APP 
is a single-pass transmembrane protein that is highly expressed in brain neurons. The exact function of 
APP is unknown; however, studies suggest APP modulates cell growth, promotes neuronal survival, 
neurite outgrowth and is involved in general cell health (O’Brien and Wong, 2011). 
In normal processing, the APP is sequentially cleaved into several peptides by enzyme activities. APP is 
first cleaved within the lumenal domain by β- secretase (BACE1) or α-secretase (complex consisting of 
presenilin), resulting in a membrane-tethered β- or α- C-terminal fragments respectively. These 
fragments are further cleaved by γ-secretase to release Aβ40 or Aβ42 residues outside the cell. 
As illustrated in Figure 1.2, Aβ can be cleared by astrocytes, or they aggregate to form Aβ-plaques, 
which can be cleared by macrophage degradation, phagocytic clearance by microglia or by 
endoproteases from astrocytes. However, some oligomers dissociate from the Aβ plaques to form 
insoluble forms of Aβ plaques which cannot be cleared. These plaques primarily consist of the Aβ42 
isoform, and it interferes with neighbouring synapses to induce tau aggregation in neurons by unknown 
mechanisms, which causes neuronal damage  (Masters et al., 2015).  
Plaque burden has been found to be weakly correlated to the disease severity, and since plaques are 
naturally found in the brains of the elderly with normal cognition, the amyloid hypothesis has been 




Figure 1.2: Pathway leading to the accumulation of plaques and tangles form the basis of AB theory. Aβ is cleaved from an 
amyloid precursor protein (APP; step 1) and is released into the extracellular milieu — by a process that is unclear — as diffusible 
oligomers (Aβo). Aβo can be cleared by mechanisms that involve APOE or can be taken up by astrocytes via low-density 
lipoprotein receptor-related protein 1 (LRP1; step 2). Aβo can also aggregate in the intercellular space to form fibril lary 
constructs, which in turn assemble into plaques (step 3). Aβ plaques can be cleared from the brain via degradation by endocytic 
or phagocytic clearance (in macrophages and microglia), or by endoproteases from astrocytes (such as an insulin-degrading 
enzyme (IDE), neprilysin (NEP) and matrix metalloproteinase (MMP); step 4). However, some conformational oligomers that 
dissociate from Aβ fibrils and plaques may not be cleared and are toxic to adjacent synapses (step 5) and induce tau aggregat ion 
by as yet unknown mechanisms. Tau damage occurs in neurons and is mediated by the development of tau-positive 
neurofibrillary tangles (which extend into the dendrites; step 6). Fibrillar tau can be released and taken up by healthy neurons, 
triggering tau damage in the up taking cell (step 7). In addition, Aβ oligomers might drive α-synuclein aggregation in the 
plaques. Reproduced from (Masters et al., 2015). 
these subjects may be in the presymptomatic stage of AD, where the accumulation of plaques is not 
yet sufficient to cause enough neuronal disruption for the appearance of clinical symptoms (Makin, 
2018). 
1.1.4.2 The Tau hypothesis 
Cognitive symptoms of AD are more correlated with the severity and location of tau pathology 
compared to Aβ plaques. Furthermore, human autopsy examinations have observed neurofibrillary 
tangles (NFT) formation without Aβ plaques, suggesting these two proteins may arise independently in 
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AD or alternatively tangles may occur prior to amyloid plaques (Makin, 2018), fuelling NFT as the main 
cause of AD and giving rise to the tau hypothesis.  
Microtubule-associated protein (MAP) bind to the tubulin part of microtubules and regulate their 
organisation and turnover. There are a number of different MAPs which either stabilise microtubules 
to promote polymerisation or inhibit their depolymerisation. Binding of other MAPs can cause 
instability to the microtubule structure, preventing their assembly (Cassimeris, 2009). Tau is one of the 
MAPs that regulate the stability of tubulin assembly of normal mature neurons through 
phosphorylation. Six isoforms of the tau gene on chromosome 17 are found in the human brain,  
generated by alternative splicing of the pre-mRNA (Iqbal et al., 2010). Normal brain tau contains 2-3 
moles of phosphate per mole of the protein for optimal functionality; however, in AD, tau is 3-4-fold 
more phosphorylated (Köpke et al., 1993). Although the exact process is unknown, these 
hyperphosphorylated tau proteins accumulate as straight filaments or unique twisted fibrils to form an 
insoluble structure in neuronal bodies and are referred to as NFT (Kametani and Hasegawa, 2018). 
These NFTs have been suggested to cause synaptic dysfunction and neuronal death, leading to 
neurodegeneration.  
Brain tau pathology is measured using BRAAK staging, where BRAAK stages I-II represent early 
appearance in the entorhinal region, BRAAK stages III-IV refers to the compromise of the limbic region, 
and BRAAK stages V-VI are assigned when the neocortical areas are affected (Braak and Braak, 1991). 
In contrast to Aβ, several studies have identified a strong correlation of BRAAK with cognitive decline 
in AD, further implying the tau hypothesis as a causative role (Kametani and Hasegawa, 2018).  
1.1.4.3 Alternative AD pathology hypothesis 
The Amyloid and Tau hypotheses have been the mainstream causative concepts for AD; however, 
therapies targeting the accumulation of Aβ plaques and NFT have clinically failed, leading to suggestions 
of alternative causative theories (Kametani and Hasegawa, 2018; Makin, 2018). In addition to the 
accumulation of Aβ plaques and NFT, oxidative stress and inflammation have been reported in AD 
brains. A study suggested abnormalities in both the mitotic signalling and oxidative stress signalling 
pathways may propagate disease pathogenesis by releasing growth factors that activate the Ras-ERK 
pathway in susceptible neurons, resulting in the re-entry of the cell cycle and tau phosphorylation (Zhu 
et al., 2004). 
Brain mitochondrial dysfunction has been reported in AD on numerous occasions and combined with 
the strong maternal genetic contribution in AD, give rise to the mitochondrial cascade hypothesis 
(Swerdlow and Khan, 2004). The theory suggests that mitochondrial dysfunction contributes to 
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elevated ROS by generating Aβ, resulting in neuronal progenitors unsuccessfully entering cell-cycle and 
causing phosphorylation of tau and NFT formation. 
Several studies have also suggested that genetic mutations observed in AD increases an individual’s 
susceptibility to infections and viruses (Itzhaki et al., 1997; Porcellini et al., 2010), leading to the viral 
hypothesis. The concept suggests viruses travel to the brain by middle age due to the age-related 
weakening of the immune system, where it remains in a latent form until the virus reactivates by an 
unknown trigger. Herpes Simplex Virus Type 1 (HSV1) is one of many viruses observed in the brains of 
AD patients (De Chiara et al., 2012; Itzhaki, 2018; Readhead et al., 2018). In addition, Aβ is an innate 
immune protein that protects against viral infections and has been shown to bind glycoproteins of the 
HSV, accelerating Aβ deposition and resulting in protective entrapment of the virus (Eimer et al., 2018).  
The viral hypothesis suggests Aβ may play a protective role in the brain, and brain viral infections may 
directly promote Aβ amyloidosis, however, like the Amyloid hypothesis, the viral hypothesis cannot 
currently explain why NFT may be observed prior to Aβ plaques.  
1.1.5 The neuropathological spread of disease. 
The brain is a complex network consisting of over 100 billion neurons, each communicating through 
end terminals known as synapses. Over 100 trillion synapses exist in the brain, which allows information 
to pass in the form of small chemicals to create the cellular basis of memories, thoughts, sensation, 
emotions and movement (Gaugler et al., 2016). As illustrated in Figure 1.3, the brain can be 
compartmentalised into three regions; the cerebrum, cerebellum and brainstem.  
The cerebrum, which is also referred to as the 
cerebrum cortex, is the largest part of the brain 
and is composed of the right and left 
hemispheres, each controlling the opposite side 
of the body. Each hemisphere does not share 
functions, and in general, the left hemisphere is 
dominant for hand use and language while the 
right hemisphere controls creativity, spatial 
ability, artistic and musical skills. The cerebral 
hemispheres can be further compartmentalised 
into the temporal lobe, frontal lobe, parietal lobe 
and occipital lobe, with each being specialised in functionality. 
Nerve cell death, tissue loss and atrophy occur throughout the brain as AD progresses, leading to the 
manifestation of clinical symptoms associated with loss of normal brain function. Although the exact 





cause of pathology remains unknown, the general spread through the human brain occurs in a 
predictable pattern. In the initial phase of the disease, Aβ plaques and NFT’s accumulates in the 
cerebrum, specifically the hippocampus and entorhinal cortex which are housed in the temporal lobe 
and both primarily associated with learning and memory (Serrano-Pozo et al., 2011). Next, the frontal 
lobe is affected, a region associated with reasoning, motor skills, higher levels of cognition and 
expressive language, followed by the Parietal lobe, a region involved in processing sensory information 
such as pressure, touch and pain. In later stage AD, the occipital lobe can become affected, a region 
involved with the interpretation of visual information from the eyes. 
Eventually, the brain stem, which is involved in body movement and vital to autonomic functions such 
as blood pressure and breathing are affected, followed by the cerebellum. The cerebellum only 
accounts for 10% of the brain but contains over 50% of the brains total neurones and is often referred 
to as the “little brain”. The cerebellum is involved in motor movement and control, specifically posture, 
balance and coordination of voluntary movements. The cerebellum is generally considered to be 
partially spared from the disease as plaques are only occasionally seen, and tangles are generally not 
reported (Convit et al. 2000; (Jacobs et al., 2017). 
1.1.6 Symptoms and clinical diagnosis 
To date, there is no definitive diagnostic test for AD. The current clinical tests only suggest AD as a likely 
suspect, with confirmation only possible at autopsy (Bird, 2018). Establishing a clinical diagnosis of AD 
requires a time-consuming comprehensive combination of physical, mental and neuropsychological 
examinations.  
The National Institute on Aging and the Alzheimer’s Association have guidelines for diagnosing AD at 
three distinct stages; preclinical AD, MCI due to AD and Dementia due to AD.  Diagnosis of dementia is 
relatively simple and does not require any specialised brain scans, however, identifying the underlying 
cause is exceptionally complex as dementia can be caused by a number of different diseases and non-
diseased factors, such as AD, Vascular Dementia (VaD), Dementia with Lewy bodies (DLB), Parkinson’s 
Disease (PD), Frontotemporal Dementia (FTD), depression, drug intoxication, thyroid disease, vitamin 
deficiency, CNS infections and normal-pressure hydrocephalus (Gaugler et al., 2016).  
1.1.6.1 Preclinical AD 
Brain changes associated with AD have been suggested to occur up to 20 years prior to the appearance 
of clinical symptoms (Reiman et al., 2012). An estimated 20-30% of the ageing population with intact 
cognition have AD neuropathology, and it has been postulated these individuals are more likely to 
develop AD (Yvette et al., 2010). These individuals are often referred to as asymptomatic AD (AsymAD) 
or preclinical AD (Driscoll and Troncoso, 2011). Preclinical AD precedes MCI but does not necessarily 
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mean individuals will develop AD or even MCI (Sperling et al., 2011), nevertheless, identifying these 
patients can lead to early disease intervention such as the implementation of coordinated care plans, 
better management of symptoms and patient safety (Dubois et al., 2015). Preclinical AD can be 
diagnosed primarily for research purposes when subtle changes in cognitive decline are apparent but 
do not meet the criteria of MCI, carry one or more apolipoprotein E (APOE) e4 variant or are carriers of 
autosomal dominant mutations, which will almost certainly develop AD (Sperling et al., 2011).  
1.1.6.2 MCI 
MCI is generally an intermediate stage between cognitive decline due to normal ageing and cognitive 
decline due to dementia. There is no single cause or outcome for MCI; however, the risk of developing 
dementia, including AD, is increased. MCI is a heterogeneous condition with 16 different classifications 
used to define it (Arevalo-Rodriguez et al., 2015). In general, MCI is a state where individuals may exhibit 
mild memory complaints but have intact cognitive functions with little adverse effects on their daily 
life. An estimated 15-20% of 65-year olds or older have MCI (Roberts and Knopman, 2013), who over 
time, may experience a gradual cognitive decline and change in personality and behaviour. An 
estimated 33% of MCI have been reported to develop dementia within five years, while up to 10% do 
not progress to dementia in 10 years (Mitchell and Shiri-Feshki, 2009). 
Mild cognitive impairment is difficult to distinguish from healthy ageing and dementia due to subtle 
changes between the stages. MCI is generally diagnosed when cognitive decline is apparent, and the 
patient’s daily living is not affected. MCI due to AD is only diagnosed when evidence of progressive 
cognitive decline is apparent and other causes of cognitive impairments such as depression, trauma 
and medical comorbidity have been ruled out (Albert et al., 2011). 
1.1.6.3 Dementia due to AD 
A further cognitive decline from MCI can lead to dementia. Typical symptoms of dementia include; 
memory loss that disrupts daily activities, difficulty in planning, problem-solving, confusion with time 
and location, difficulty understanding visual and spatial relationships, difficulty with speaking and 
writing, withdrawal from social activities and changes in mood and personality (Gaugler et al., 2016). 
Based on the severity of symptoms, the disease can be further classified as mild, moderate or severe. 
In the mild stage, individuals are functioning independently but may require assistance with some 
activities. In the moderate stage, individuals may encounter difficulty performing routine tasks, become 
confused, and can start exhibiting personality and behavioural changes, including suspiciousness and 
agitation. In the severe stage of the disease, an individual’s communication becomes limited, and they 
are unable to perform basic activities without assistance, such as bathing (Gaugler et al., 2016). 
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Dementia due to AD can be further categorised into “probable AD dementia” and “possible AD 
dementia” within the clinical setting. Probable AD dementia is primarily diagnosed when the dementia 
criteria have been met, other common causes of dementia have been ruled out, and the patient has a 
clear history of gradual cognitive decline (McKhann et al., 2011). Possible AD dementia diagnosis is 
similar to probable AD, except a history of cognitive decline is absent, and onset is more sudden or 
where evidence of other causes of dementia are also present, such as cerebrovascular disease 
(McKhann et al., 2011). 
As mentioned by Bird (2018), AD can only be established at death by confirming:  
• Neuropathological Aβ plaques; plaques should stain positively with Aβ antibodies and negative 
for prion antibodies (which are diagnostic of prion diseases). 
• Intraneuronal neurofibrillary tangles; Aggregation of alpha-synuclein in the form of Lewy 
bodies may also be found in neurons in the amygdala; frequently, there is an accumulation of 
TDP-43 protein. 
• Amyloid angiopathy - the numbers of plaques and tangles must exceed those found in age-
matched controls without dementia. 
1.2 AD brain transcriptomic perturbations 
1.2.1 Gene expression 
The central dogma of molecular biology is the process of encoding instructions in the DNA to RNA and 
then to functional products. A disruption or change in this process can lead to disease. A gene is 
regarded as the nucleotide sequence in DNA that provides instructions for functional products such as 
proteins, which is expressed through the process of transcription and translation. During transcription, 
the DNA of a gene serves as a template for complementary base-pairing, forming a pre-mRNA molecule 
which is processed into mature mRNA. The mRNA is a single-stranded copy of the gene, which then 
undergoes translation to form a functional product. Measuring the mRNA levels can provide a snapshot 
of biological activity at a molecular scale which may reflect the number of functional products such as 
proteins. The number of human protein-coding genes has been estimated to range between 19,901-
21,306 (Salzberg, 2018). 
1.2.2 Microarray technologies 
Gene expression profiling is the measurement of mRNA from several genes in a sample, collectively, 
representing a profile of gene expression. Until the early 1990s, the traditional methods for measuring 
levels of mRNA involved northern blotting and reversed polymerase chain reaction (RT-PCR), a time 
consuming and restricted procedure. The invention of microarray’s revolutionised the genomic 
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research by allowing global gene expression of thousands of genes to be simultaneously be measured 
at a relatively lower cost. Several microarray platforms have been developed for measuring gene 
expression, with this thesis focusing on Affymetrix and Illumina technologies due to their high 
replicability across platforms (Barnes et al., 2005; Chen et al., 2007; Consortium, 2008; Maouche et al., 
2008). 
The basic principle of microarray technology involves immobilising thousands of pre-defined DNA spots 
(probes) to the surface of a plate (BeadArray). Each DNA spot contains many copies of the same probe. 
Complimentary sample nucleic sequence can hybridise to these DNA spots, which can be quantified by 
detection of fluorescent labelling. The measured fluorescence represents the abundance of a particular 
gene in the sample. 
1.2.3 Next-generation sequencing 
Next-generation RNA-sequencing (RNA-Seq) uses deep-sequencing technologies to provide a wider and 
comprehensive view of the whole transcriptome. The technologies have many benefit over microarray 
technologies, such as the ability to be free from pre-defined probes, detect sequence variations in 
transcribed regions, longer base pair reads (30-400bp) offer more precise mapping to the genome, as 
microarray short reads can be limited due to the repetitiveness of the genome, has a larger dynamic 
range of expression measurement and has been suggested to be more reproducible (Wang, Gerstein 
and Snyder, 2009).  
The reproducibility between microarrays and RNA-Seq have been suggested to be very high, with the 
exception for transcripts with extremely high or low expression (Sîrbu et al., 2012; Zhao et al., 2014; 
Chen et al., 2017). Therefore, results replicated by both microarray and RNA-Seq technologies using 
independent datasets can further strengthen the reliability of the results. Although RNA-Seq is superior 
to microarray technologies, the relatively high cost and lack of public availability of RNA-Seq data, this 
thesis focuses on microarray-based gene-expression data. 
1.2.4 Differentially expressed genes 
Many studies have undertaken gene expression profiling to identify specific genes that are significantly 
altered in AD brains when compared to normal aged brains. These genes are referred to as differentially 
expressed (DE). One major challenge with studies focusing on DE genes (DEG’s) in AD is the lack of 
replication across independent studies. For instance, two independent AD microarray gene expression 
studies identified DEG’s in the hippocampus brain regions. The first study (Miller et al., 2013) identified 
600 DEG’s, while the second (Hokama et al., 2014) identified 1071 DEG’s, from which 105 DEG’s 
overlapped between the two studies, however, none of which passed multiple corrections. The Miller 
study was based on 7 AD samples and 10 controls expression profiled on the Affymetrix platform, while 
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the Hakoma study contained 31 AD and 32 controls expression profiled on the Illumina platform. 
Replication between the Illumina and Affymetrix platform has been shown to be generally very high 
(Barnes et al., 2005; Chen et al., 2007; Consortium, 2008; Maouche et al., 2008); therefore, the lack of 
replication between the two studies is probably down to a range of other factors including low statistical 
power, sampling bias and disease heterogeneity. 
1.2.5 Biological pathways 
Approaches such as Gene Set Enrichment Analysis (GSEA) can be used to provide functional annotation 
for lists of DEG’s between two biological conditions. This providing an insight into biological processes 
or molecular functions which may be altered based on lists of perturbed genes. Numerous AD studies 
have highlighted disruptions in the immune response (Lambert et al., 2010; Li et al., 2012; Sekar et al., 
2015; Chen et al., 2016), protein transcription/translation regulation (Li et al., 2012, 2015; Liu et al., 
2013; Godoy et al., 2014; Sekar et al., 2015; Puthiyedth et al., 2016) calcium signalling (Blalock et al., 
2011; Ramanan et al., 2013; Sekar et al., 2015), MAPK signalling (Miller et al., 2013; Puthiyedth et al., 
2016), various metabolism pathways such as carbohydrates (Puthiyedth et al., 2016), lipids (Paolo and 
Kim, 2012; Puthiyedth et al., 2016), glucose (Ishii et al., 1997; Liang et al., 2008; Godoy et al., 2014), 
and iron (Oshiro, Morioka and Kikuchi, 2011; Li et al., 2012), chemical synapse (Blalock et al., 2011; 
Miller et al., 2013; Ramanan et al., 2013), neurotransmitter pathways (Blalock et al., 2011; Li et al., 
2012; Ramanan et al., 2013) and many infectious diseases pathways (Porcellini et al., 2010; De Chiara 
et al., 2012; Kumar et al., 2016). Concordance at the pathway level can sometimes replicate better than 
the individual gene level across studies (Maglietta et al., 2010). However, these biological pathways 
observed to be dysregulated in AD have also been observed to be disturbed in other neurological 
disorders; that is, the changes observed are possibly not specific to AD. For example, the dysregulation 
of calcium signalling, MAPK, chemical synapse and various neurotransmitter pathways have also been 
implicated in PD (Edwards et al., 2011; Chandrasekaran and Bonchev, 2013), glucose metabolism, and 
various neurotransmission pathways have been implicated in Bipolar Disease (BD) (Clelland et al., 2013; 
H. Chen et al., 2013; Khanzada, Butler and Manzardo, 2017), chemical synapse pathways have been 
shown to be altered in Schizophrenia (Khanzada, Butler and Manzardo, 2017; Liu et al., 2017), the 
immune response and protein transcriptional pathways have been suggested to be altered in HD 
(Labadorf et al., 2015), and a number of metabolism and synapse pathways have also been implicated 
in MDD (Zubenko et al., 2014). The molecular changes in AD brains are steadily becoming apparent; 
however, many other neurological disorders are showing similar biological pathway disruptions.  
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1.3 AD biomarkers 
Biomarkers can be used to detect the presence of a disease, rule out disease, determine disease risk 
and monitor treatment response. Currently, there is no definitive biomarker for AD, and confirmation 
of the disease can only be done at autopsy. Current challenges for biomarkers include (i) accurate 
diagnosis of AD, as a study observed 25% of patients clinically diagnosed with probable AD did not have 
pathological evidence of AD at autopsy (Sabbagh et al., 2017), (ii) predict the rate of disease progression 
and conversion likelihood between the different stages of the disease, for instance, whether a patient 
is likely to convert from MCI to AD, and (iii) diagnosis of the disease early, ideally during its preclinical 
phase when initial brain changes are at a level insufficient to manifest into clinical symptoms. This may 
allow interventions to halt further brain damage which may have later led to dementia, which ultimately 
may be more effective than attempting to reverse the pathology that already exists in AD.  
The primary focus for AD biomarker discovery revolved around neuroimaging and Cerebral Spinal Fluid 
(CSF), which have shown to be highly accurate in detecting pathophysiological and neurophysiological 
changes associated with AD. However, the high cost and invasiveness have shifted the field to increase 
research into cognitive assessments and blood-derived biomarkers that may serve as alternative 
biomarkers, or at the very least, be an initial screen for AD to reduce numbers of false positives (Hampel 
et al., 2018). 
1.3.1 Non-blood-based biomarkers 
1.3.1.1 Neuroimaging 
Neuroimaging is a process of producing images of the structure or activity of the brain or another part 
of the nervous system. Since AD is a disease of the brain, neuroimaging is understandably one of the 
obvious choices to further understand the anatomical and functional changes in AD brains. Autopsy 
studies have demonstrated positron emission tomography (PET) scans can accurately reflect brain Aβ 
levels (Ikonomovic et al., 2008; Fleisher et al., 2011), and as a result, can be used within the clinical 
environment to aid in AD diagnosis, however it cannot be used exclusively to confirm AD diagnosis. For 
instance, clinicians can use PET imaging to query whether an MCI patient is likely due to AD, allowing 
the clinician to explore alternative causes if the results are negative. 
Three additional imaging biomarkers are used for research purposes, which include elevated cortical 
tau as a biomarker for neurofibrillary tangles, which can be measured through PET scans (Villemagne 
et al., 2014); decreased glucose metabolism measured through fluoro-2-Deoxy-D-glucose (FDG) PET as 
a biomarker for decreased neuronal activity, which has been suggested to occur early in AD (Mosconi 
et al., 2010) and brain atrophy as a biomarker for neurodegeneration, which can be measured through 
structural magnetic resonance imaging (MRI) (McEvoy et al., 2009). 
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Additional neuroimaging investigations have also reported functional MRI (fMRI) can detect decreased 
activity in the medial prefrontal cortex of AD subjects when compared to MCI patients. While structural 
MRI (sMRI) can distinguish early AD brain atrophy from healthy ageing (Scheltens et al., 2002), brain 
atrophy is associated with cognitive decline and can be used as a marker for disease progression from 
cognitive normal to MCI and then further to AD (Cardenas et al., 2011; Del Sole, Malaspina and Magenta 
Biasina, 2016). 
Neuroimaging has been reported to accurately diagnosis the disease early whilst also being capable of 
monitoring disease progression; however, the high costs associated with the technologies limits its 
feasibility as a widespread diagnostic tool.  
1.3.1.2 Cerebral spinal fluid 
CSF is a clear, colourless liquid surrounding the brain and spinal cord which supports the brain by acting 
as a mechanical barrier against shock, maintains pressure within the cranium and provides lubrication 
between surrounding bones. CSF also provides nutrients and disposes the metabolic waste from the 
brain. It has been well established that a decrease in CSF Aβ42 accompanied by an increase total tau and 
phosphorylated tau at threonine 181 (ptau-181) levels in MCI and AD reflect neuropathology (El Kadmiri 
et al., 2018). The high diagnostic performance of CSF as a biomarker for AD has also been confirmed at 
autopsy and has even been demonstrated to outperform pure clinical diagnosis (Bittner et al., 2016). 
However, variability in Aβ measurements between batches and across clinical laboratories has hindered 
clinical utility. New fully automated procedures designed specifically to tackle this issue, such as 
electrochemiluminescence immunoassay for the quantitation of Aβ4, have demonstrated stable and 
very precise measurements that may improve the replication accuracy of CSF as an AD biomarker 
(Blennow, 2017). 
CSF fluid is extracted through a lumbar puncture, sometimes regarded as a relatively invasive 
procedure. The most common complication associated with a lumbar puncture is post-lumbar puncture 
headache, which has been shown to vary across different geographical sites and can be dependent on 
the procedure type. Although the reported incident rate is  <2%, patients in the general population 
have been reported to fear the pain and side-effects associated with the procedure (Dekker et al., 
2017). 
1.3.1.3 Cognitive assessments 
Cognitive tests can be used as part of a series of tests, to suggest dementia in the first instance, followed 
by further tests to suggest the underlying disease. There are a number of different cognitive tests, with 
the most widely used Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale (CDR), 
and the AD Assessment Scale-Cognitive Subscale (ADAS-Cog). 
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The MMSE was first developed by Folstein and others in 1974 as a bedside screening test for dementia 
(Folstein, Folstein and McHugh, 1975). The test is available in many languages, making it one of the 
most widely used short tests to measure overall cognitive impairment in both the clinical and research 
setting. The test consists of a series of tasks to calculate a score based on orientation, word registration 
and recall, attention and calculation, language abilities and visuospatial ability. Generally, the MMSE 
score ranges from 0-30, where ≥25 are considered normal, 19-24 indicates early dementia, 10-19 
indicates moderate dementia, and <10 is indicative of severe dementia. Scores typically decline with 
advancing age and increase with higher education level. The test is repeatedly used to assess cognitive 
decline in an individual over time, with AD subjects typically declining 3-4 points per year, and therefore 
can be effective at monitoring treatment effect.  
The CDR is an alternative approach used to measure cognitive decline based on a clinical interview. The 
CDR assesses six domains to calculate a score which lies on a 5-point scale. The six domains are memory, 
orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. 
Patients who score 0 have no cognitive decline, 0.5 indicates questionable or very mild dementia, 1 
indicates mild dementia, 2 indicates moderate dementia and 3 indicates severe dementia.  
The ADAS-Cog was designed in 1984 by Rosen and others as a rating scale to assess the severity of AD 
based on the assessment of core symptoms associated with the disease (Rosen, Mohs and Davis, 1984). 
The test is primarily used in clinical trials and consists of 11 sections which assesses memory, language, 
praxis and orientation. The test provides a score ranging from 0-70, where ≥18 indicates greater 
cognitive impairment (Rockwood et al., 2007). The test score has been shown to increase with age 
which adds complexity to the interpretation of longitudinal studies lasting several years.  
In the research environment, there is no consensus for a single “gold standard” test for cognitive 
decline, and as a result, many studies use different cognitive tests. A study compared the ADAS-cog, 
MMSE and CDR scores from the same 1709 subjects and concluded the three tests were consistent in 
identifying cognitive decline. However, CDR and ADAS-Cog were more precise in measuring the severity 
of cognitive decline than MMSE (Balsis et al., 2015).  
1.3.2 Blood-based biomarkers 
Blood-derived biomarkers offer a less-invasive, more readily accessible and potential cheaper approach 
for AD detection compared to CSF and some neuroimaging biomarkers. Since AD is a disorder of the 
brain, identifying signals in peripheral blood assumes the disease affects blood as well, or dysfunction 
of the blood-brain barrier (BBB) allows disease markers to leak from the brain to blood. The BBB is 
composed of tightly sealed endothelial cells that freely allows diffusion of oxygen and carbon dioxide. 
The specialised BBB endothelial transport system carries energy metabolites, nutrients, and regulatory 
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molecules from blood to brain, and metabolic waste products and potential neurotoxic molecules from 
brain to blood (Montagne, Zhao and Zlokovic, 2017). A breakdown of the BBB in AD has been detected 
in 20 independent human studies and has even been detected before cognitive decline is apparent 
(Montagne, Zhao and Zlokovic, 2017), suggesting biomarkers for AD may potentially exist in peripheral 
blood. Currently, there is no blood-based biomarker that is being used in the clinical setting for AD 
discovery; however, many methods have been proposed by individual studies, which are discussed 
below. 
1.3.2.1 Genetics 
As discussed earlier, there are a number of genetic mutations that can increase the risk of AD, with 
APOE genotype carrying the greatest risk. Incorporating the APOE Ɛ4 status can improve clinical 
diagnostic status from 55% to 84% (Mayeux et al., 1998). In addition, a study observed 50% of MCI 
patients who are APOE Ɛ4 carriers, progressed to AD in 3 years compared to 20% who were APOE Ɛ4 
negative (Petersen, 2004).  
Genome-Wide Association Studies (GWAS) identify genetic variants associated with a particular trait 
and have been performed between subjects with and without AD to identify genetic markers associated 
with AD. A recent study combined these AD markers into polygenic risk scores (PRS), and along with sex 
and age, were capable of predicting AD with 70% accuracy (70% sensitivity and 70% specificity) within 
a case-control dataset (3049 AD and 1554 controls) (Escott-Price et al., 2015). As AD is known to share 
genetic risk factors with other neurological disorders, such as DLB (Orme, Guerreiro and Bras, 2018), 
predicting AD using only genetic variation may not be able to distinguish AD from other disorders. In 
addition, due to the heterogeneity of the disease, which is influenced by a combination of genetic and 
environmental factors, the use of DNA characteristics and phenotypic information to predict AD may 
not capture the full spectrum of molecular-level changes influenced by environmental factors, and as 
a result, may not be able to predict the onset of the disease. Therefore, genetic information should be 
incorporated with other biomarkers to aid AD diagnostics. 
1.3.2.2 Gene expression 
Several studies have attempted to exploit blood gene expression measurements for AD biomarker 
discovery, with initial research relying on DEG as a means to distinguish AD from non-AD subjects (Rye 
et al., 2011; Han et al., 2013). However, the limited overlap and reproducibility of DEG from 
independent cohorts suggests this method alone is not reliable enough (Han et al., 2013). A solution to 
this problem would be to use information across all genes simultaneously through machine learning 
algorithms, which can capture minute gene expression changes, which collectively may be more 
informative than DEG. This technique has been demonstrated in multiple AD studies to build AD 
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classification models; (Fehlbaum-Beurdeley et al., 2010; Booij et al., 2011; Lunnon et al., 2013; Roed et 
al., 2013; Voyle et al., 2016) however, as many were underpowered due to lack of samples, validation 
was either performed in the same subjects that were used to develop the classification model, which 
is known to significantly exaggerate validation performance and is referred to as an overfit, or they split 
their existing small dependent cohort into a training set for model development and a testing set for 
validation purposes, which can inadvertently lead to learning and predicting platform technical noise 
and batch effects rather than biology. 
Previous studies have demonstrated the potential use of blood transcriptomic levels to differentiate 
between AD and cognitively healthy individuals; however, they are yet to be precise enough for clinical 
utility and are yet to be extensively evaluated on specificity by evaluating model performance in a 
heterogeneous ageing population of multiple diseases. This validation process is critical to determine 
whether the classification model is indeed disease-specific, a general indication of ill health, or an 
overfit. 
1.3.2.3 Peptides 
Peptides are short chains of amino acid monomers linked by peptide bonds. Blood Aβ peptides ratios 
Aβ1–42:Aβ1–40 have been measured by enzyme-linked immunosorbent assay (ELISA) methods, with early 
studies reporting little or no significant difference between AD and control subjects. However, recent 
studies based on ultrasensitive immunoassay techniques have reported weak significant correlations 
between CSF and plasma Aβ1–42:Aβ1–40 ratios (Hampel et al., 2018). Mass-spectrometry-based studies 
have also reported reduced plasma Aβ1–42:Aβ1–40 ratios in patients with AD when compared to controls 
(Pannee et al., 2014). In addition, immunoprecipitation coupled with mass-spectrometry identified 
APP699-711/Aβ1–42c and Aβ1–42:Aβ1–40 ratios were able to predict Aβ-positive individuals based on PET 
scans with 90% accuracy (Nakamura et al., 2018), further suggesting plasma Aβ measurements may be 
useful as biomarkers for AD. However, other disorders including cardiovascular and cerebrovascular 
have also reported altered plasma Aβ-levels (Roeben et al., 2016; Hilal et al., 2017), suggesting further 
investigations are required to determine the specificity of this biomarker. 
1.3.2.4 Proteins 
Tau protein is an obvious choice to measure as an AD biomarker, however, reported plasma levels been 
contradictory, with individual studies reporting AD subjects having no significant change, mild elevation, 
significant elevation or even reduced levels of plasma Tau protein (Mattsson et al., 2016). In addition, 
a longitudinal AD study reported increased plasma tau levels were correlated with future cognitive 
decline, increasing atrophy and hypermetabolism (Mattsson et al., 2016). However, subjects with 
Frontotemporal lobar degeneration (FTLD) have also been observed to have elevated plasma tau levels 
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(Foiani et al., 2018); therefore, plasma tau levels alone may not be able to distinguish AD from other 
disorders that have tau pathology. 
An additional 163 candidate blood-derived proteins were identified as potential AD biomarkers from 
21 separate studies (Kiddle et al., 2014). The overlap of discovered proteins between studies was 
limited, with only four biomarkers α-1-antitrypsin, α-2-macroglobulin, apolipoprotein E and 
complement C3 found to replicate in five independent cohorts. However, a follow-on study discovered 
these four biomarkers were not specific to AD and were also discovered to be associated with other 
brain disorders including Parkinson’s Disease (PD) and Schizophrenia (SCZ) (Chiam et al., 2014).  
1.3.2.5 Metabolites 
Metabolites are small intermediate products formed from the metabolic reactions caused by various 
enzymes and have been found to be perturbed in AD brains (Inoue et al., 2013). The blood consists of 
thousands of small metabolites at any given time, which may have transported from the brain through 
the BBB, providing a potential signal of the brains activity. Using ultra-performance liquid 
chromatography (UPLC) coupled with mass spectrometry (UPLC-MS), a multicentred study compared 
495 plasma metabolites to identify a 7-metabolites profile capable of differentiating AD and aMCI from 
healthy controls. The 7 metabolites included; three amino acids (glutamic acid, alanine, and aspartic 
acid), one non-esterified fatty acid (22:6n-3, DHA), one bile acid (deoxycholic acid), one 
phosphatidylethanolamine [PE(36:4)], and one sphingomyelin [SM(39:1)] (Olazarán et al., 2015). These 
metabolite biomarkers still require further validation in similar disorders. 
1.3.3 Limitations 
The current time-consuming clinical diagnosis of AD is based on cognitive tests and neuroimaging, 
which has been shown to have an estimated accuracy of 75% at autopsy (Sabbagh et al., 2017). Clearly, 
a more accurate, easily accessible, relatively cheap, and quicker method for AD diagnosis is required. 
CSF biomarkers seem the most promising; however, as a relatively intrusive method, it may not appeal 
to the broader population. Blood-based biomarkers are more appealing, with many individual studies 
consistently demonstrating the ability of various biomarkers capable of differentiating AD from healthy 
controls; however, many lack reproducibility and specificity are rarely tested. Blood-based biomarkers 
require an extensive evaluation with age-related and other similar disorders to be useful as a clinical 
screening test for the general population. 
1.4 AD treatment 
To date, no disease-modifying treatment is available for AD. The underlying cause of the disease is 
currently unknown, making it extremely difficult to develop treatments to cure, reverse or even halt 
the neuropathological process of AD. In addition, effective treatment response in animal models does 
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not necessarily reflect the outcomes in humans. The slow clinical recruitment of patients and the 
relatively long time needed to observe the effectiveness of treatment on disease progression further 
contribute to the difficulty in developing an effective treatment. 
1.4.1 Pharmacological 
Symptomatic relief is available in the form of cholinesterase antagonist’s donepezil, rivastigmine and 
galantamine, and an N-methyl-D-aspartate (NMDA) inhibitor, memantine. These drugs only provide 
temporary symptomatic relief, and do not modify the underlying disease pathology, and may not have 
the same effect on all patients (Calciano et al., 2010; Anand, Gill and Mahdi, 2014).  
The three cholinergic inhibiting compounds all have slightly different pharmacological properties, but 
all work by preventing the enzyme acetylcholinesterase breaking down acetylcholine, a 
neurotransmitter associated with memory. The three cholinesterase inhibitors are effective for mild to 
moderate AD and have been reported to temporarily improve a patients ADAS-cog score by an average 
of 2.7 points (Birks, 2006). 
In AD, damage to brain cells releases excessive neurotransmitters such as glutamate. In normal 
conditions, glutamate plays an essential role in learning and memory. However, excessive glutamate 
causes overexcitation of nerve cells, which can lead to cell damage and/or death. Memantine works by 
blocking glutamate receptors NMDA, which prevents the excessive activity of glutamate and 
temporarily stabilising cognitive decline. Memantine has been shown to be less effective than 
cholinergic inhibitors, but in combination, have proved to be more effective when compared to 
standalone treatment with each drug (Parsons et al., 2013). The side-effects associated with these 
drugs are generally mild and include gastrointestinal side-effects such as diarrhoea and nausea (Loi et 
al., 2018). 
1.4.2 Non-Pharmacological 
Non-pharmacological treatment is often used to maintain or improve cognitive function without the 
use of medication, and like pharmacological treatments, do not slow, stop or reverse the 
neuropathological characteristics of AD. These treatments typically involve computerised cognitive 
training, listening to music or physical exercise to improve overall cognitive function (‘2018 Alzheimer’s 
disease facts and figures includes a special report on the financial and personal benefits of early 
diagnosis’, 2018). Non-pharmacological treatment response in AD has been inconsistent, with very little 
evidence to support a specific treatment for AD. Nevertheless, individuals have reported improvement 
from these methods, and these methods may be more suited to be personalised per patient, although 
this may be more resource-intensive (Loi et al., 2018). 
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1.4.3 Future treatments 
Changes in AD brains occurs several years in advance before the onset of clinical symptoms, 
identification of patients at this preclinical stage may allow interventions to halt further brain damage, 
which may have later led to dementia. This may be more effective than attempting to reverse the 
pathology that already exists in AD patients. However, the major drawback here is the lack of diagnostic 
methods to identify AD early, and therefore, the majority of treatments are focusing on clinically 
diagnosed AD patients. 
Although the exact cause of the disease is unknown, clinical trials are primarily targeting specific 
processes which may reverse or prevent further accumulation of Aβ and NFT. Several clinical trials are 
currently ongoing and are primarily targeting Aβ clearance, BACE inhibition, γ-secretase inhibition, 
stabilising Tau, inhibiting Tau aggregation or P-Tau clearance, however, from 1984-2018, more than 
200 of these drugs have entered phase 2 of a clinical trial but none have made it to clinical use (Loi et 
al., 2018).  
1.4.3.1 Drug repositioning 
The typical time for an AD drug development program takes 13 years with costs estimated to be £4.4 
billion, which is considerably higher than the estimated £624.1 million for cancer treatment 
development (Cummings, Reiber and Kumar, 2018). Drug repositioning can provide an alternative 
strategy, where established drugs are repurposed for new therapeutic targets, reducing the costs and 
time associated with drug development, whilst making the process accessible to academic centres 
along with pharmaceutical and biotechnology companies.  
Drug repositioning has been successfully applied to a variety of diseases, including cancer, 
cardiovascular disease, stress incontinence, irritable bowel syndrome, obesity, erectile dysfunction, 
smoking cessation, psychosis, attention deficit disorder and Parkinson's disease (Corbett et al., 2012). 
With the wealth of open publicly available biological data, drug repositioning can be applied to identify 
possible treatments for AD as well. 
1.5 Neurological disorders 
Neurological disorders are diseases of the nervous system, which may impair the brain, spinal cord, 
peripheral nerve or neuromuscular function. There are more than 600 different neurological disorders, 
with AD accounting for just one. Many neurological disorders show similar symptoms, neuropathology 
or brain changes at a molecular level to AD. Some of these disorders are incorporated into this thesis 
to aid in identifying AD-specific brain and blood changes. Therefore, a brief overview of each disorder 




As discussed earlier, dementia is a broad term given to individuals who exhibit greater cognitive decline 
than expected in normal ageing. AD accounts for an estimated 60-80% of reported dementia cases, 
however, upon autopsy, an estimated half of these individuals have shown to involve additional 
pathology consistent with other dementias (Gaugler et al., 2016). 
1.5.1.1 Dementia with Lewy bodies 
DLB is a neurodegenerative disease accounting for 10-15% of all dementias, with an incidence rate 
estimated to be 6 in every 100,000 (Savica et al., 2013) and age of onset typically between the age of 
50 to 83 years. The exact cause of the disease is unknown, but the disease shares risk loci with AD in 
the APOE E4 allele, and with PD, in variants SNCA (chromosome 4) and GBA (chromosome 1) (Orme, 
Guerreiro and Bras, 2018).  
The neuropathological hallmark of the disease includes abnormal clumps of protein alpha-synuclein 
(Lewy bodies) in neurons, which is accompanied in most cases by Aβ deposition and occasional NFT. 
The accumulation of these proteins disrupts normal cognitive functions in brain regions such as the 
cerebral cortex, areas of the temporal lobe, such as the superior temporal gyrus, parahippocampal 
gyrus and the limbic system areas, including the hippocampus and amygdala (Armstrong, 2012). 
Disruption to these brain regions causes symptoms to initial include sleep disturbances and 
hallucinations, which can occur in the absence of memory impairment. This is typically followed by 
progressive cognitive decline and parkinsonism (a clinical syndrome characterised by tremor, 
bradykinesia, rigidity and postural instability). 
In addition to sharing the same risk loci APOE, many similarities exist between DLB and AD, from 
symptoms of progressive cognitive decline and dementia to the hallmark neuropathology, which 
includes Aβ and NFT. A study found no significant difference in cognitive decline over 12 months for  
AD and DLB subjects when baseline age, gender and CDR rating are matched (Walker et al., 2012); 
however, DLB subjects have reported lower scores in visual memory, visuoperceptive, and 
visuoconstructive tests when compared to AD (Noe et al., 2003). 
1.5.1.2 Frontotemporal lobar degeneration 
Frontotemporal lobar degeneration (FTLD) is a heterogeneous group of disorders which is characterised 
by the progressive neurodegeneration of the prefrontal and temporal cortices. FTD is the most common 
FTLD and accounts for 5-15% of dementia cases (Mohandas and Rajmohan, 2009). The prevalent 
genetic risk factors for FTD include PGRN (progranulin) and MAPT (microtubule-associated protein tau), 
both located on chromosome 17. 
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The neuropathological hallmark of the disease can be categorised into three broad groups; 
frontotemporal lobar degeneration with tau, TDP‐43 or FET protein accumulation (Mackenzie and 
Neumann, 2016). The initial symptoms include personality and behavioural changes, which is dissimilar 
to the memory issues initially observed in AD. Similar to AD, FTD can occur above the age of 65 years 
of age; however, over 60% of reported cases occur between 45-60 years of age (Gaugler et al., 2016).  
1.5.1.3 Parkinson’s Disease 
PD is a progressive disorder of the nervous system that affects several regions of the brain devoted to 
the control of balance, movement, emotions and general cognition. PD is the second most common 
neurodegenerative disorder, affecting 5 to >35 per 100,000 depending on demographics (Poewe et al., 
2017). Typically the onset of PD occurs after the age of 50, with approximately 30% developing 
dementia (Aarsland, Zaccai and Brayne, 2005). A number of genes have been associated with PD, 
including LRRK2 (chromosome 12), GBA (chromosome 1), and SNCA (chromosome 4). 
The disease is characterised by neuronal loss and abnormal aggregates of alpha-synuclein protein in 
the substantia nigra brain region. Similar to dementia with Lewy body, the alpha-synuclein contribute 
to structures called Lewy body that displaces other cell components. Lewy bodies initially occur in the 
cholinergic and monoaminergic brainstem neurons but are also found in limbic and neocortical brain 
regions with disease progression (Poewe et al., 2017).  
PD and AD are distinct disorders that share common features. Both are progressively slow 
neurodegenerative diseases that typically begin late in life, although initial symptoms differ, both 
diseases can lead to dementia. The neuronal degeneration includes intraneuronal inclusions and the 
hallmark pathology of PD, alpha-synuclein, has also been reported in AD brains, but are concentrated 
mainly in limbic brain regions (Poewe et al., 2017). 
1.5.1.4 Creutzfeldt-Jakob disease 
Creutzfeldt-Jakob disease (CJD) is an extremely rare and fatal disorder characterised by misfolding 
proteins (prion) that cause other proteins to misfold and malfunction throughout the brain. CJD 
develops in approximately 1 in every million, with the onset of symptoms around 70 years of age and 
mean survival time of only 6 months.  Over 90% of subjects died within a year from the onset of 
symptoms (Mackenzie and Will, 2017).  
There are two types of CJD; sporadic (sCJD) and variant (vCJD). sCJD is the most common form of the 
disease, where the cause of the disease is unknown. In contrast, vCJD is caused by the consumption of 
meat, where the animal was infected by bovine spongiform encephalopathy. The initial symptoms in 
both forms of the disease include problems with muscular coordination; personality changes, including 
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impaired memory, judgment, thinking; and impaired vision, and eventually lead to dementia. CJD 
subject’s cognitive decline is more rapid than AD. 
1.5.1.5 Vascular dementia 
VaD is caused by blockage or damage to blood vessels, which causes strokes or bleeding to the brain. 
The location of the brain damage determines the impact on the individual’s physical and mental 
functions, including if dementia occurs. Initial symptoms often include impaired judgement and lack of 
organisation, which contrasts memory issues associated with initial symptoms of AD.  
Diagnosis of VaD is extremely difficult, with clinical diagnosis achieving an estimated 50% sensitivity at 
autopsy (McAleese et al., 2016). Pure VaD is suggested when neuropathology vascular lesions are 
present without neurodegenerative pathologies such as AD or Lewy body pathology. However, in 40% 
of dementia cases, patients exhibit deposition of Aβ and NFT consistent with AD, which can be regarded 
as mixed dementia (Gaugler et al., 2016). 
1.5.1.6 Mixed dementia 
Mixed dementia is a term given to an individual who exhibits hallmark abnormalities associated with 
more than one cause of dementia. In most cases, AD and vascular dementia, also known as Mixed 
Vascular-Alzheimer Dementia (MVAD), are most observed to coexist, followed by AD, vascular 
dementia and DLB (Gaugler et al., 2016).  
1.5.2 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects brain nerve cells 
and the spinal cord. ALS affects approximately 2 in 100,000 (The ALS Association, no date), with the 
onset of symptoms typically occurring between the age of 50-65. The exact cause of the disease is 
unknown; however, 19 genes have been associated with the disease. Mutations in superoxide 
dismutase 1 (SOD1) located on chromosome 21, accounts for approximately 20% of the inherited 
version of ALS (Zarei et al., 2015).    
In normal motor function, messages from the brain motor neurons are transmitted to spinal cord motor 
neurons which forwards these messages to muscles. In ALS, these motor neurons degenerate, causing 
a disruption to the signalling network to muscle. The muscles are unable to function correctly, leading 
to symptoms that include muscle weakness, twitching and cramping, which eventually cause muscle 
impairment. Severe cases of ALS will develop symptoms of dyspnea and dysphagia (Zarei et al., 2015).   
The neuropathology of ALS involves an abnormal accumulation of proteins in the cytoplasm of neurons, 
which causes the neurons to dysfunction. These proteins include ubiquitinated TAR DNA-binding 
protein (TDP-43) in the frontal cortex, temporal cortex, hippocampus and striatum, which has also been 
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observed to occur in FTD (Saberi et al., 2015). Dementia in ALS is uncommon; however, degeneration 
of the frontotemporal cortex can lead to mild cognitive impairment, specifically affecting verbal praxis 
and fluency (Strong, Kesavapany and Pant, 2005). 
When dementia is absent in ALS, the clinical symptoms of AD and ALS are unique to each disorder. 
Nevertheless, studies have identified similarities in ALS and AD subjects, including the activation of 
IRE1α-XBP1 and ATF6 pathways of the unfolded protein response (Montibeller and de Belleroche, 
2018), and multiple rare reports of NFT in ALS brains (Guiroy et al., 1993; Kokubo and Kuzuhara, 2004; 
Coan and Mitchell, 2015; Takeda, 2018) 
1.5.3 Bipolar Disorder 
BD, previously known as manic depression, is a mood disorder characterised by extreme fluctuation in 
an individual’s mood and depression. The disorder affects approximately 1 in 100 people in their 
lifetime with a typical onset of disease between the age of 15-19 but can occur  at any age (Bipolar 
disorder - NHS, no date). The exact cause of the disease is unknown; however, physical, environmental 
and social factors have been suggested to contribute to the increased risk of developing the disease. 
GWAS studies have identified 18 loci associated with BD, with many replicating in independent studies 
(Vieta et al., 2018). 
The brain changes involved in the disease include dendritic spine loss in the prefrontal cortex (Vieta et 
al., 2018), alterations in neuronal interconnectivity, atrophy of the hippocampus and reduced cortical 
thickness (Harrison, Colbourne and Harrison, 2018). These brain changes lead to cognitive dysfunction, 
increased cognitive decline in older patients (Lewandowski et al., 2014), and dementia in long-term 
cases (Forlenza and Aprahamian, 2013). 
BD is usually distinguishable from AD due to the early age of onset; however, BD can occur over the age 
of 50, which can make behavioural impairment challenging to differentiate from AD.  In addition, the 
following symptoms have been reported in both disorders; agitation, euphoria, disinhibition 
overactivity without agitation, aggression, dysphoria, apathy, impaired self-regulation, and psychosis 
(Besga et al., 2015). Furthermore, a study identified altered epigenetic regulation related to 
neuroinflammation, synaptic integrity, and neuroprotection in both AD and BD (Rao et al., 2012) 
1.5.4 Huntington’s disease 
Huntington’s disease (HD) is an autosomal disease with aspects of cognitive decline, which can progress 
to dementia in severe and rare cases. Therefore, the disease is generally classed as a motor disorder 
rather than dementia. The onset of HD is typically around the age of 40, with a prevalence of 
approximately 5-10 in every 100,000 (Reiner, Dragatsis and Dietrich, 2011).  
47 
 
HD individuals have an expanded CAG repeat in the huntingtin gene located on chromosome 4. The 
resulting huntingtin protein contains excessive glutamine with additional hydrogen bonds that cause 
the proteins to be “sticky” and become entangled. The aggregated proteins accumulate and interfere 
with nerve cell functions. Protein aggregates primarily accumulate in the basal ganglia, but can also 
affect the temporal and frontal lobes (Montoya et al., 2006). Typical symptoms include movement 
issues, such as involuntary movement, cognitive issues, such as difficulty organising, and psychiatric 
issues such as insomnia. 
Similar to AD, HD involves the clumping of proteins that disrupt the neuronal network in different 
regions of the brain, impairing functions associated with the normal function. This leads to the 
manifestation of memory issues in AD, while movement is primarily affected in HD.  
1.5.5 Major Depressive Disorder 
Major depressive disorder (MDD), clinically referred to as depression, is a debilitating disease 
characterised by mood swings, diminished interest, impaired cognitive function and vegetative 
symptoms, such as disturbed sleep or appetite (Otte et al., 2016). The disease does not follow Mendel’s 
law of inheritance and is caused by a combination of many genes and environmental factors (Kiyohara 
and Yoshimasu, 2009). 
Both MDD and BD patients exhibit depressive symptoms; however, BD patients also have episodes of 
mania, which makes both disorders clinically distinguishable from one another. MDD symptoms can 
initially be difficult to distinguish from AD, and both diseases are associated with hippocampal and 
frontal atrophy. 
1.5.6 Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic autoimmune disease affecting an approximate 289 per 100,000 
individuals (Mackenzie et al., 2014). The typical onset of the disease is around 20-40 years of age, with 
diagnosis after the age of 50 rare (Polliack, Barak and Achiron, 2001). The exact cause of the disease is 
unknown; however, the literature suggests a combination of genetics and nongenetic triggers, such as 
a virus, metabolism, or environmental factor thought to initiate the disease that repeatedly attacks and 
damages the myelinated axons of the CNS (Goldenberg, 2012). This interferes with the brain 
communicating with parts of the body, resulting in symptoms such as loss of motor function, speech, 
loss of coordination, and cognitive impairment. In extremely rare cases, MS can lead to dementia, and 
therefore is generally not classed as dementia. 
The hallmark pathology of MS involves focal demyelinated plaques in the CNS, with degrees of 
inflammation, gliosis, and neurodegeneration (Popescu, Pirko and Lucchinetti, 2013). MS is very distinct 
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from AD, in that MS is an autoimmune disease with earlier symptomatic onset. Both diseases exhibit 
cognitive decline, with AD more severe. Chronic inflammation with microglia activation has been 
suggested to play a vital role in both AD and MS pathogenesis; however, hallmark pathology for both 
diseases is distinctly different (Dal Bianco et al., 2008) 
1.5.7 Schizophrenia 
Schizophrenia is a complex syndrome with many symptoms. The disease prevalence is approximately 
32 per 100,000 (Reilly et al., 2012), with a typical onset of symptoms in the early twenties (Gogtay et 
al., 2011). An estimated 15% of schizophrenia are late-onset cases where disease onset is around 40 
years of age, while a rarer 4% of cases represent a very late-onset version of the disease with onset 
around 60 years of age (Howard, 2000). 
Similar to most of the disorders discussed previously, the exact cause of the disease is unknown, with 
a combination of genetics and environmental factors suspected to be the cause. Neuropathological 
studies suggest the disease is a functional disease without organic factors. Brain abnormalities primarily 
involve volume change, reduced neurons, size of neurons and change in neuronal arrangement across 
the entire brain (Iritani, 2007). Although the exact mechanism of the disease is unknown, most theories 
revolve around the deficiency or excess of neurotransmitters (dopamine, serotine, and glutamate) and 
neurochemicals (aspartate, glycine and GABA) (Patel et al., 2014).  
Brain changes in the disease lead to cognitive decline and change the way an individual thinks and 
behaves. The symptoms of the disease can be classed as “positive”, where changes relate to behaviour 
and thought, such as hallucinations and delusions, or “negative”, where individual become withdrawn 
and express lack of rational functions, such as appear emotionless (Schizophrenia - Symptoms - NHS, 
2016). Patients with schizophrenia may not develop dementia over time, but are at greater risk (Siavelis 
et al., 2016a) 
AD and schizophrenia are distinct diseases with the typical onset and symptom distinguishable from 
one another; nevertheless, genetic variations associated with endosomal trafficking, autophagy, and 
calcium channel signalling are shared between the two diseases (DeMichele-Sweet et al., 2018). 
1.5.8 Summary 
With over 600 different neurological disorders, it’s no surprise AD shares similar genetic variation, 
neuropathology, structural brain changes and clinical symptoms with other diseases. The similarities of 
brain changes occurring in the neurological disorders discussed in this thesis are summarised in Table 
1.1. This further complicates clinical diagnosis, which is evident by a large number of misdiagnosed AD 
49 
 
patients identified at autopsy (Gaugler et al., 2016). A clear need to identify AD-specific changes are 
required, which may aid in accurate AD diagnosis and therefore improve the chances of drug trials. 
Table 1.1: Similarities of brain changes across neurological disorders 
Brain changes AD  DLD FTLD PD CJD VD MD ALS BD HD MDD MS SCZ 
Brain Atrophy              
Neurodegeneration      
  
 
   
* 
 
Cognitive Decline      * *    *   
Dementia      * * 
 
* * * * * 
Aβ   
    
* 
      
NFT  *  
   
* * 
     





      
TDP-43 protein  
 
 
    
 
     
FET protein  
 
 
          
Altered Prion  
   
 
        
Vascular Lesions  
    
 * 
      
Huntingtin Protein  
        
 
   
The table illustrates the overlap of brain changes across the neurological disorders discussed in this thesis. Brain changes with 
a star (*) occur in rare cases. Abbreviations: AD: Alzheimer’s Disease, DLD: Dementia with Lewy Bodies, FTLD: Frontotemporal 
Lobar Degeneration, PD: Parkinson’s Disease, CJD: Creutzfeldt-Jakob Disease, VD: Vascular Disease, MD: Mixed Dementia, 
ALS: Amyotrophic Lateral Sclerosis, SCZ: Schizophrenia, NFT: Neurofibrillary Tangles and TDP-43: TAR DNA-binding protein 43 
1.6 Conclusions 
The increase in life expectancy has resulted in a rise in age-related disorders, including AD. The most 
common form of dementia is AD, which was first described over a century ago, however, to date, there 
still exists a lack of understanding molecular changes specific to the disease, a clinically established 
robust blood-based biomarker for accurate diagnosis and a lack of therapeutic treatments.   
1.7 Thesis overview 
This thesis analyses novel and existing transcriptomic data to further understand the genetic and 
biological mechanisms associated with AD. The investigations are presented in four analysis chapters 
consisting of three peer-reviewed publications. The different cohorts used in this thesis are described 
within individual chapters.  
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1.7.1 Transcriptomic Analysis of Probable Asymptomatic AD and AD Brains 
The thesis begins by investigating the first human brain microarray gene expression profiling of AsymAD 
subjects who were clinically free from dementia; however, upon autopsy were discovered to be 
consistent with mild AD pathology. Standard transcriptomic analysis, coupled with a system-biology 
approach, was used to identify biological perturbations in AsymAD brains, which may reveal 
mechanisms for their AD vulnerability. Subsequently, this chapter has been peer-reviewed and 
published in the Brain, Behaviour, and Immunity Journal. 
1.7.2 A Meta-analysis of Alzheimer’s Disease Brain Transcriptomic Data 
This chapter combines existing and novel AD brain microarray gene expression studies in the largest 
known AD meta-analysis to date. In addition, non-AD neurological disorders (PD, BD, Schizophrenia, 
MDD and HD) were incorporated into the analysis to identify specific molecular changes associated 
with AD brains. Furthermore, both brain regions spared and affected by hallmark AD pathology were 
analysed to reveal transcriptomic changes and disease mechanisms most likely involved with the 
accumulation of tangles and plaques. This chapter is presented as a peer-reviewed publication in the 
Journal of Alzheimer’s Disease. 
1.7.3 Automated Drug-repositioning from a disease expression signature 
This chapter develops an automated drug repositioning pipeline to query any disease gene expression 
signature in the reprocessed connectivity map (CMap) database using novel algorithms to identify 
suitable small compounds that may potentially intervene with the disease of interest with positive 
effects. This drug repositioning pipeline was applied to the two AD expression disease profiles identified 
in the first two chapters to find compounds that may intervene with the disease during the 
asymptomatic and symptomatic stage. 
1.7.4 Working Towards a Blood-Derived Gene Expression Biomarker Specific for Alzheimer's 
Disease 
In this final analysis chapter, a machine learning approach is used to identify a blood-based gene 
expression biomarker, which could discriminate AD from cognitive healthy and age-related diseased 
subjects. The expression signature is further validated in an independent cohort.  
1.8 Details of methodologies 
Since this thesis incorporates a series of publications, an overview of methods is detailed within 
individual chapters, including any applications and programming packages used during the analysis. 
However, details of more complex methods and justification behind selecting specific data processing 
and analysis methods are provided below.  
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1.8.1 Microarray Gene Expression processing 
This thesis analysis both novel and existing microarray gene expression datasets. Various microarray 
platforms exist, with this thesis only incorporating data generated on the Illumina and Affymetrix 
platform as replication between the two has been demonstrated to be very high (Barnes et al., 2005; 
Chen et al., 2007; Consortium, 2008; Maouche et al., 2008).  No universal data processing or analysis 
pipelines exist for microarray data; therefore, a data processing pipeline was developed using literature 
recommended techniques which best suited the data in this thesis. The following is the overall 
sequence of Quality Control (QC) procedures performed on the datasets, with further details on specific 
applications used to perform the analysis provided in individual chapters. 
1.8.1.1 Affymetrix platform background correction 
Microarray’s measure fluorescence intensities, which are subject to a range of different sources of 
noise, both between and within arrays (Silver, Ritchie and Smyth, 2009). Background correction is an 
important procedure which attempts to address this variation. Affymetrix platforms consist of 
GeneChips with 25-base perfect match (PM) probes accompanied by a mismatch (MM) probe differing 
at the complimentary 13th position (Rouchka, Phatak and Singh, 2008). The probe design hypothesised 
MM probes would represent background noise, which could be subtracted from the PM intensity to 
determine the true level of gene expression. MAS5.0 is a background correcting method that exploits 
this probe design by calculating a robust average of the logged PM-MM values for all probes.  
An alternative method for background correcting Affymetrix platform generated data is gcRMA. This 
method uses estimators derived from statistical models that use probe sequence information to 
calculate background intensity (Wu et al., 2004). A study compared 9 different background correction 
methods, including MAS5.0 and gcRMA, to RT-PCR as a reference and concluded a difference in 
performance between most of the algorithms was not statistically significant and noted: “MAS5.0 
performed well in their study” (Gyorffy et al., 2009). In contrast, another study reported gcRMA 
performs significantly better than MAS5.0 (Harr and Schlötterer, 2006) as studies have observed higher 
MM values when compared to PM values, implying MM values do not accurately represent background 
noise (Rouchka, Phatak and Singh, 2008). 
The MAS5.0 background correction method was one of the first to be available to pre-process 
Affymetrix platform generated data and naturally was widely adopted. As discovered in the “A Meta-
analysis of Alzheimer’s Disease Brain Transcriptomic Data” chapter, many publicly available microarray 
datasets were available in a pre-processed form, where raw data was already MAS5.0 background 




The “Automated Drug-repositioning of Transcriptomic Disease Signature” chapter focuses on DEG. The 
gcRMA method has been suggested to best suited for the detection of DEG (Harr and Schlötterer, 2006) 
and since the CMap data was available in its raw intensity format, gcRMA was the chosen background 
correcting method for this analysis. 
1.8.1.2 Illumina platform background correction 
Illumina microarray probe sequences are typically 50 nucleotide sequences, with 30 replicates on each 
array accompanied by over a 1000 negative non-specific control sequences. These control probes do 
not correspond to any expressed genomic sequence and serve as the background noise measure. 
Similar to Affymetrix platform, numerous background correction methods have been proposed to 
account for intensity variation, with Model-Based Background Correction (MBCB) shown to be more 
precise for gene expression measurements (Allen, Chen and Xie, 2010). The MBCB uses the negative 
control expression values to develop a convolutional model to estimate the background noise and 
subsequently, expression values for each probe (Ding et al., 2008). The MBCB algorithm was applied to 
Illumina generated datasets when possible. 
1.8.1.3 Normalisation 
Data normalisation is performed to account for variation between samples and experimental batches. 
Many normalisation methods have been developed for microarray data, with Robust Spline 
Normalisation (RSN) suggested as being one of the most accurate (Schmid et al., 2010). The RSN 
algorithm combines the features of quantile and loess normalisation, and as suggested by Schmid et 
al., (2010), was applied after background correction and log2 transformation of the raw microarray 
data. 
1.8.1.4 Detection of sex markers 
Sex was predicted using the R package Microarray Sample Sex Identifier (massiR) R package, with 
discrepancies between predicted and recorded sex removed from further analysis. The massiR package 
uses the expression values of uniquely mapping Y chromosome probes from the data to calculate the 
expression variance across all samples. Samples are then partitioned into two clusters, where the 
cluster with the highest Y-chromosome probe values are classified as males and the remaining classified 
as females (Buckberry et al., 2014). 
1.8.1.5 Detection of expressed probes 
Microarray’s consists of thousands of probes, each providing a measured expression intensity. 
Biologically, many are likely to be associated with “unexpressed genes” and simply represent noise due 
to non-specific binding. Filtering  these “unexpressed genes” can eliminate noise (Lazar et al., 2013) 
and increase differential power (Hackstadt and Hess, 2009). Studies have incorporated arbitrary 
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expression cut-off values to determine whether a gene is expressed (Hackstadt and Hess, 2009); 
however, this thesis takes a more biological approach and uses the log2 expression values of nine 
literature defined quality control genes (QCg) to determine the cut-off values in individual datasets. 
Five QCg’s are Y chromosome genes (KDM5D, PRKY, RPS4Y1, USP9Y, UTY) which are only expressed in 
male tissues (Vawter et al., 2004), one QCg is an X chromosome gene (XIST) which is only expressed in 
female tissue (Vawter et al., 2004), and the remaining three QCg’s (ADIPOR1, BNIP3L, MKRN1) are 
expressed in all normal cells and tissues including multiple regions of the brain (Chang et al., 2011).  
Initially, a gene with an expression value above the 90th percentile in over 80% of samples was deemed 
as “expressed”, with the remaining “unexpressed” probes removed. An expression boxplot of the nine 
QCg’s is created by sex and used to verify each QCg is correctly classified as expressed or unexpressed 
in the correct sex groups, adjusting the filtering percentile if required.  
1.8.1.6 Correcting for unwanted variation 
Several individual processes are involved during sample preparation and during microarray gene 
expression, including, transcriptional steps, labelling, hybridisation and intensity measurement. Each of 
these steps can introduce technical variations (Richard et al., 2014). Gene expression microarrays are 
also affected by non-biological variations, such as reagent lot numbers, different technicians and even 
atmospheric ozone levels (Chen et al., 2011). In addition to measurable variables, gene expression data 
are affected by factors that are unknown, unmeasured or too complicated to capture through simple 
models (Leek and Storey, 2007). These variations are referred to as “batch effects”, and should be 
addressed during microarray data processing as they have been demonstrated to have a greater effect 
on the data than the underlying biological signal (Leek et al., 2010).  
It is impossible to measure and account for all variables that are influencing how genes are expressed, 
however, a study has demonstrated through a technique called Surrogate Variable Analysis (SVA), that 
one can predict and account for these latent effects (Leek and Storey, 2007). SVA uses expression values 
across genes to estimate the large-scale effects of all unmodelled factors. Known biological variations 
can be provided to SVA, such as diagnosis and sex, which are excluded from the model (Leek et al., 
2012). Since this thesis analysed publicly available gene expression datasets, with many lacking detailed 
phenotypic information required for robust batch effect removal, SVA was used to identify latent 
variables. Any significant variation identified by SVA was then adjusted out using an Empirical Bayes 
method referred to as “Combating Batch Effects When Combining Batches of Gene Expression 
Microarray Data” (COMBAT) (Chen et al., 2011). 
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1.8.1.7 Outlier sample detection 
A network-based approach was used to identify outlier samples as described by Oldham, Langfelder 
and Horvath (2012). Within each diagnosis and gender group, sample relationship was calculated based 
on signed weighted correlations. Sample similarity measures are calculated and used to construct a 
sample network, which includes standardised sample connectivity (Z.K), standardised sample clustering 
coefficient (Z.C) and mean inter-sample adjacency (ISA). As recommended by Oldham, Langfelder and 
Horvath (2012), samples with a Z.K value below -2 were deemed outliers, samples removed, sample 
networks reconstructed, and sample similarity measures re-examined. If necessary, this process is 
repeated until no further sample is identified as an outlier. 
1.8.1.8 Annotating platform-specific probe ID’s  
This thesis uses gene expression data generated from the Illumina and Affymetrix microarray platforms, 
both of which use unique platform-specific probe identifiers. Therefore, probe identifiers were 
converted to their corresponding unique Entrez Gene Identifiers (Entrez ID) to allow information to be 
comparable across platforms and datasets. Entrez ID represents a unique stable identifier for a specific 
gene (Maglott et al., 2011) . Multiple probes can represent a single Entrez gene ID, from which the 
probe with the highest expression across all samples was retained. 
1.8.1.9 PCA 
Principal component analysis (PCA) was performed to calculate the variation in the gene expression 
data. PCA performs linear transformations to reduce the high dimensionality of the data, whilst 
retaining as much variation as possible. This creates principal components (PC’s), which are 
uncorrelated and ordered by variance explained. PC’s were graphically visualised against one another 
in a 2-dimensional plot. Clustering samples indicated similarities between the samples, with multiple 
clusters that are not explained by known biological variation an indication of batch effects (Ringnér, 
2008). PCA plots were generated and examined throughout the QC process to ensure additional 
variation was not being introduced into the data after every data processing step. 
1.8.1.10 Dataset compatibility 
During the “A Meta-analysis of Alzheimer’s Disease Brain Transcriptomic Data” chapter, multiple 
publicly available datasets from different microarray platforms, BeadArrays/GeneChips, tissue source 
and diseases were integrated for biological interpretation. To ensure dataset compatible, the gene 
expression datasets underwent additional QC based on six quantitative measures to identify 
problematic datasets. As described by Kang et al., (2012), the six quantitative measures are: 
1. Internal Quality Control Index (IQC): This metric compares pair-wise differences between 
studies to identify outlier studies from quantified co-expression dissimilarities. The analysis only 
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uses information directly from the expression data and does not use any external information. 
A study with a small IQC indicates heterogeneous co-expression structure with other studies 
and should be considered as a candidate problematic study for exclusion. 
2. External Quality Control Index (EQC): This metric is similar to the IQC but uses external pathway 
information. A study with a small EQC value is indicated to be lowly associated with the 
remaining studies in terms of gene pairwise correlation structure and should be considered as 
a candidate problematic study.  
3. Accuracy Quality Control Gene Index (AQCg): This metric assesses the reproducibility of DEG of 
a study compared to a meta-analysis of all remaining studies. A small AQCg score indicates the 
DEG’s in a study was not reproducible when compared to DEGs detected by the meta-analysis. 
4. Accuracy Quality Control Pathway Index (AQCp) – This metric is similar to AQCG but uses 
enrichment pathways instead of DEG when assessing reproducibility across studies. 
5. Consistency Quality Control Gene Index (CQCg): This metric is similar to AQCg but uses a DE 
ranking system. The ranked DEG from individual study analysis and meta-analysis are compared 
using Spearman's rank correlation. 
6. Consistency Quality Control Pathway Index (CQCp): This metric is similar to CQCg but uses 
enrichment pathways. 
A PCA plot was generated, where the direction of each QC measure was juxtaposed on top of the two-
dimensional PC subspace using arrows. Datasets in the negative region of the arrows were classed as 
outlier studies (Kang et al., 2012). 
1.8.2 Microarray gene expression analysis  
Genes are functional units of genetic material, which have been shown to interact with other genes for 
biological functionality. Therefore, this thesis focused on the identification of DEG’s and modules of 
highly co-expressed genes in AD, which collectively may provide information on biological functions 
disrupted in the disease. The following is a detailed description of the analysis used to identify these 
genes and analyses for biological interpretation. Further details of the application used to perform the 
analysis is provided in individual chapters. 
1.8.2.1 Differential expression analysis 
Differential expression analysis is a method to identify significantly perturbed genes between two or 
more different biological conditions. The analysis was performed using the Linear Models for 
Microarray Data (Limma) R package, which fits a linear model to each gene in the data (Smyth, 2005). 
During the analysis, only sex and diagnosis were used as covariates, with the assumption SVA and 
COMBAT had removed any latent variation. 
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1.8.2.2 A meta-analysis of gene expression datasets 
Replication of DEG’s across independent transcriptomic microarray studies remains poor (Zhang et al., 
2008), with the primary cause thought to be due to a small number of samples leading to low statistical 
power (Chang et al., 2013). Combining information across studies can be an intuitive way to increase 
sensitivity and can be accomplished through a p-combining meta-analysis. Many meta-analysis 
methods exist for microarray data, with a review on 12 different methods concluding Adaptively 
Weighted (AW) as one of the best methods to identify DEG with non-zero effect sizes in one or more 
microarray studies (Chang et al., 2013). AW has additional advantages by indicating which datasets are 
contributing to the meta-analysis, is biased towards studies with concordant significant effects (Li and 
Tseng, 2011), and has been demonstrated to be robust with identified DEGs showing relevant biological 
associations (Chang et al., 2013). 
1.8.2.3 Weighted Gene Correlation Network Analysis 
Correlation networks can be used to identify clusters of highly correlated genes, which collectively may 
represent or be involved in biological functions. Weighted Gene Correlation Network Analysis (WGCNA) 
is a method to identify such clusters and was used in this thesis. First, a “soft thresholding power” based 
on the criterion of approximate scale-free topology was calculated from the data and was then used to 
calculate the “signed” gene adjacency values (Langfelder and Horvath, 2008). Then, hierarchical 
clustering of the adjacency values was performed to create a dendrogram, where densely 
interconnected branches represent highly co-expressed genes. Individual branches were assigned to 
so-called “modules” (Langfelder and Horvath, 2008). 
1.8.2.4 Protein-Protein Interaction network analysis 
Proteins are essential to cellular and molecular functions and rarely act alone. Therefore, the physical 
interactions between proteins can provide insight into cellular and molecular mechanisms in AD (Safari-
Alighiarloo et al., 2014). Protein-Protein Interactions (PPI) networks were independently created on 
DEG’s lists and on co-expressed gene modules using a web-based application called NetworkAnalyst 
(Xia, Benner and Hancock, 2014). The application annotates the input gene list to their relevant 
proteins, searches binary interactions form curated PPI databases and creates a network of these 
interactions. A topology analysis was then performed on the whole network to identify important nodes 
(hubs) which represent highly interconnected proteins that may play an important role in cellular 
signalling (Xia, Benner and Hancock, 2014). 
1.8.2.5 Gene Set Enrichment Analysis 
GSEA is an alternative method to interpret gene expression data based on functional annotation of 
DEG’s or modules of co-expressed genes. GSEA can provide an insight into biological processes or 
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molecular functions that may be altered in a disease, which has been shown to be more versatile and 
reproducible across similar studies than DEG’s alone (Subramanian et al., 2005). A number of biological 
pathway databases exist, each consisting of valuable, often manually curated, and validated functional 
interactions between genes. ConsensusPathDB is a web-based application that comprehensively 
queries up to 30 publicly available repositories using a hypergeometric test, compiles a set of results 
and corrects for multiple testing (Kamburov et al., 2009). ConsensusPathDB was used throughout this 
thesis for biological pathway and Gene Ontology (GO) interpretations. 
1.8.3 Publicly available transcriptomic data 
A vast quantity of microarray-based gene expression data is increasingly becoming publicly available 
through repositories such as ArrayExpress (https://www.ebi.ac.uk/arrayexpress/), Gene Expression 
Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) and an AD focused Accelerating Medicines 
Partnership-Alzheimer’s Disease (AMP-AD, https://www.nia.nih.gov/research/amp-ad). These 
databases have stringent procedures to store only well-annotated data in a structured manner and 
generally store data from all microarray expression platforms. These three repositories were the largest 
known resources for publicly available microarray gene expression cohorts relevant to this thesis. These 
repositories were queried for suitable datasets and are discussed within individual analysis chapters.  
1.8.4 Machine Learning 
Machine learning (ML) is the use of algorithms and statistical models by computer systems to learn, 
improve from experience and predict an outcome automatically. There are two primary ML techniques; 
supervised and unsupervised. Supervised ML is useful for regression and classification on labelled data, 
while unsupervised ML is generally applied to cluster unlabelled data. This thesis used a supervised 
approach to build a classification model for biomarker discovery. 
For classification purposes, ML is developed on one dataset and ideally validated in an independent 
dataset, which has not been seen by the ML algorithm. The dataset used for the classification model 
development is referred to as the “training set”, while the validation dataset is referred to as the 
“testing set”.  
1.8.4.1 XGBoost overview 
Decision trees are a type of ML algorithms that are best suited to solve classification problems, and as 
the name implies, are trees of decisions. Tree boosting is a series of simple decision trees, where each 
successive tree is developed from the residuals of the preceding tree. One of the most widely used tree 
boosting algorithms that have shown to give the most accurate results on many classification 
benchmarks is Extreme Gradient Boosting (XGBoost) (Chen and Guestrin, 2016). In addition, XGBoost 
supports weighted samples for unbalanced datasets, uses parallel and distributed computing for fast 
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model exploration of large datasets, and allows many hyperparameters to be tuned to reduce 
overfitting. Overall, this made XGBoost an ideal algorithm to use in this thesis. 
XGBoost converts a series of weak learners, which are slightly better than random, into a collectively 
strong learner. This is achieved by using information from the prior tree to improve prediction in the 
following predictions. The overall algorithm idea is illustrated below in Figure 1.4: 
 
Figure 1.4: The Basic idea behind the XGBoost algorithm. Four trees are represented by 4 boxes, which are trying to classify + 
and – classes to hypothetical biological samples. The blue shaded regions of each box are samples classified as the + class, 
while the red shaded region is assigned a – class. The first row of boxes misclassifies samples and can be individually regarded 
as weak learners; however, collectively (Box 4) they correctly classify all samples. Reproduced from (Manish Pathak, 2018). 
Four trees represented by 4 boxes are shown above in Figure 1.4, which are trying to classify + and – 
classes to hypothetical biological samples. The tree boosting algorithm follows the basic idea to develop 
a strong classifier from weak learners: 
Box 1: The first classifier creates a vertical line at D1 to classify samples to the left of the line as + and 
samples to the right as -. This classifier misclassifies three + samples and can be considered a weak 
classifier. 
Box 2: The next classifier attempts to correct the previous classifiers (Box1) mistakes by assigning more 
weights to the three + misclassified points (bigger size of +). The new classifier creates a vertical line at 
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D2 to classify samples to the left of the line as + and samples to the right as -. This classifier misclassifies 
three - samples and can be considered a weak classifier. 
Box 3: The next classifier continues to improve upon the previous by assigning more weight to the three 
– samples that were misclassified and creates a horizontal line at D3. This classifier misclassifies three 
samples (circled) and can be considered a weak classifier. 
Box 4: Is a weighted combination of all the weak classifiers, which performs considerably better than 
individually, and be considered a strong classifier. 
This basic concept makes XGBoost a powerful tool for developing classification models. However, due 
to the simplicity of the concept, the ML algorithm can easily create an overfitted model, which is when 
the algorithm learns random error in the data rather than relationships between variables. To control 
for overfitting, XGBoost incorporates cross-validation and allows for many hyperparameters to be finely 
tuned to reduce the chance of overfitting. 
1.8.4.2 K-fold cross-validation 
Cross-validation (CV) is an approach that can be used to estimate the performance of a classification 
model. The data is divided into a number (n) of ‘folds’, where n-1 folds are used to develop the 
classification model, and the remaining fold used for validation purposes. This process is repeated n 
times where each fold is used as a validation set only once. The average validation performance across 
all folds is used to determine classification model performance and has been shown to reduce the 
chance of developing an overfitted model (Tušar et al., 2017).  
1.8.4.3 Model tuning and Logloss 
The XGBoost algorithm allows many parameters to be adjusted to improve classification model 
performance, whilst reducing the chances of overfitting. This process is generally referred to as “tuning” 
and was performed in a sequential manner whilst performing CV. The CV process was deployed using 
the standard XGBoost xgb.cv function to identify the optimum hyperparameters, which uses the default 
k-fold CV rather than a nested-cross validation. The optimum parameter configurations were selected 
based on the logloss error obtained through the CV. Logloss error is a performance metric that 
quantifies the accuracy of a classification model by penalising errors in prediction whilst taking into 
consideration how uncertain the prediction is. Hyperparameters were adjusted until the lowest logloss 





 Chapter 2: Transcriptomic analysis of probable asymptomatic and 
symptomatic Alzheimer brains 
 
2.1 Background 
The increase in life expectancy has profoundly increased the ageing population, which, unfortunately, 
is also accompanied by a rise in age-related disorders including Alzheimer’s disease (AD) (Prince et al., 
2016). Alzheimer’s disease is a neurodegenerative disorder characterised by progressive accumulation 
of extracellular amyloid-β (Aβ) protein and intracellular hyperphosphorylated tau filaments in the brain, 
which form insoluble plaques and tangles respectively. These protein aggregates affect neuronal 
activity, which can lead to progressive loss of neurons associated with deterioration in cognition and 
development of neuropsychiatric symptoms. 
Through longitudinal studies involving autopsy, it has become evident that clinical signs of cognitive 
impairment are apparent after substantial years of neurodegeneration, which occurs decades after 
neuropathological changes (Caselli and Reiman, 2012). As the disease is progressively slow, and as 
everyone is expected to experience cognitive change during normal ageing, differentiating AD 
symptoms from normal ageing at an early stage of the disease can be difficult. Up to 20-30% of the 
ageing population with intact cognition have amyloid deposition, with these individuals at higher risk 
of progressing to AD than those without amyloid (Yvette et al., 2010). These individuals are often 
referred to as asymptomatic AD (AsymAD) (Driscoll and Troncoso, 2011) and have been shown to be 
distinguishable from normal ageing based on neuropathology, brain imaging and cerebrospinal fluid 
biomarkers (Caselli and Reiman, 2012). While some of these individuals progress to developing 
symptoms related to cognition, which deviate from normal Mild Cognitive Impairment (MCI), and then 
to AD, not all do. They are therefore a heterogeneous group, representing those with prodromal AD 
and those impervious to AD despite having the pathological hallmarks.  
Measuring genome-wide expression of transcripts as markers of gene activity has revealed that 
cognitive decline is accompanied by changes in brain gene expression from normal ageing through to 
MCI and AD. Studies have suggested that some changes in the pattern of gene expression in normal 
ageing such as synaptic function and energy metabolism (Saura, Parra-Damas and Enriquez-Barreto, 
2015), are extensively altered in MCI (Nicole C. Berchtold, Ph.D.1, Marwan N. Sabbagh, M.D.2, Thomas 
G. Beach, M.D. et al., 2015) and AD (Blalock et al., 2004, 2011; Miller, Oldham and Geschwind, 2008; 
Berchtold et al., 2013; Miller et al., 2013) Additional work has also suggested a number of other 
biological pathways are more specifically altered in AD, including inflammation (Colangelo et al., 2002; 
Blalock et al., 2004; Miller, Oldham and Geschwind, 2008), protein misfolding (Colangelo et al., 2002; 
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Blalock et al., 2004), transcription factors (Colangelo et al., 2002; Blalock et al., 2004), cell proliferation 
(Colangelo et al., 2002; Blalock et al., 2004), immune response (Lambert et al., 2010; Li et al., 2012; 
Sekar et al., 2015; Chen et al., 2016), protein transcription/translation regulation (Li et al., 2012, 2015; 
Liu et al., 2013; Godoy et al., 2014; Sekar et al., 2015; Puthiyedth et al., 2016), calcium signalling (Blalock 
et al., 2011; Ramanan et al., 2013; Sekar et al., 2015), MAPK signalling (Miller et al., 2013; Puthiyedth 
et al., 2016), and various metabolism pathways (Ishii et al., 1997; Liang et al., 2008; Oshiro, Morioka 
and Kikuchi, 2011; Li et al., 2012; Paolo and Kim, 2012; Godoy et al., 2014; Puthiyedth et al., 2016) 
which reflect the extent and type of pathology and disruption to cell activity as disease progresses. It is 
unknown how early the different types of changes occur in the brain, such as in the pre-symptomatic 
phase or specifically in AsymAD subjects who already have the pathological hallmarks of AD such as 
amyloid and neurofibrillary tangles (NFTs).  Understanding the fundamental changes in this AsymAD 
group may shed light on specific biological mechanisms that may be involved in early pathological 
hallmarks of AD, providing new therapeutic targets for early intervention.  
This study investigated transcriptomic changes in the human brain of healthy ageing, AsymAD and AD 
subjects, which have been classified based on the clinical assessment before death and AD 
neuropathology at autopsy. Typical transcriptomic analysis coupled with a systems-biology approach 
was used to identify disturbances in the underlying biological mechanisms across the entorhinal cortex, 
temporal cortex, frontal cortex and cerebellum brain regions. In addition, access of gene-level results 
to the broader research community is provided through a publicly available R SHINY web-application 
(https://phidatalab-shiny.rosalind.kcl.ac.uk/ADbrainDE), allowing researchers to quickly query the 
expression of specific genes through the progression of AD and across multiple brain regions.  
2.2 Materials and Methods 
2.2.1 Medical Research Council London Neurodegenerative Diseases Brain Bank 
A total of 112 brains were obtained from the Medical Research Council (MRC) London 
Neurodegenerative Diseases Brain Bank (from now on referred to as MRC-LBB) hosted at the Institute 
of Psychiatry, Psychology and Neuroscience, KCL. All cases were collected under informed consent, and 
the bank operates under a licence from the Human Tissue Authority, and ethical approval as a research 
tissue bank (08/MRE09/38+5). Neuropathological evaluation for neurodegenerative diseases was 
performed in accordance with standard criteria. 
2.2.2 MRC-LBB sample selection 
BRAAK staging is a measure of the spread of hallmark AD pathology across the brain and is part of the 
neuropathological assessment. In general, BRAAK stages I-II, III-IV and V-VI have been suggested to 
represent prodromal, early-moderate AD, and moderate-late AD respectively. Twenty-seven control 
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cases were used - classified as showing no clinical sign of any form of dementia and no 
neuropathological evidence of neurodegeneration. Thirty-three AsymAD cases were also analysed - 
defined as clinically dementia-free at the time of death, but neuropathological assessment at autopsy 
showed hallmark AD pathology. Finally, fifty-two AD cases, which had both a clinical diagnosis of AD at 
death and confirmation of this diagnosis through neuropathological evaluation at autopsy, were 
selected. 
2.2.3 MRC-LBB brain region selection and RNA extraction 
Frozen tissues (0.5-1cm3) from the following brain regions from each case were macrodissected into 
RNAlater RNA Stabilization Reagent (Qiagen): 1) Frontal Cortex (FC), 2) Temporal Cortex (TC), 3) 
Entorhinal Cortex (EC) and 4) Cerebellum (CB). Hallmark AD pathology was confirmed in the entorhinal 
cortex, temporal cortex and frontal cortex but absent from the cerebellum of AsymAD and AD subjects. 
RNA extraction was performed within 24 hours of dissection. Total RNA was extracted using RNeasy 
Lipid Tissue Mini Kit (Qiagen,74804) following the manufacturer’s protocol. Genomic DNA was removed 
using gDNA Eliminator Spin Columns (Qiagen). The RNA quality was evaluated with an Agilent 2100 
bioanalyzer (Agilent Technologies, Inc., Palo Alto, CA). 
2.2.4 MRC-LBB Illumina beadArray expression profiling 
Total RNA (25ng) was prepared for array expression profiling using the Ovation Pico WTA System 
(NuGEN Technologies, Inc., San Carlos, CA), as described by the manufacturer’s protocol. The Nugen 
system is optimised for the amplification of degraded RNA, where amplification is initiated at the 3’ end 
as well as randomly throughout the whole transcriptome. The samples were processed at the NIHR 
Biomedical Research Centre for Mental Health (BRC-MH), Genomics & Biomarker Core Facility at the 
Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and 
Neuroscience, King’s College London (https://www.kcl.ac.uk/ioppn/depts/sgdp-centre/research/The-
IoPPN-Genomics--Biomarker-Core-Facility.aspx) in accordance with the manufacturer’s protocol using 
the Illumina HT-12_V4 beadchips (Illumina, USA). 
2.2.5 Microarray expression data processing 
Raw gene expression data was exported from Illumina’s GenomeStudio (version 2011.1) into RStudio 
(version 0.99.467) for data processing. Using R (version 3.2.2), raw data was Maximum Likelihood 
Estimation (MLE) background corrected using R package “MBCB” (version 1.18.0) (Allen, Chen and Xie, 
2010), log2 transformed, and underwent Robust Spline Normalisation (RSN) using R package “lumi” 
(version 2.16.0) (Du, Kibbe and Lin, 2008).   
A series of quality control steps were carried out before data analysis. Duplicate samples were removed 
based on lowest RIN score. Sex was predicted for each sample using the R package “massiR” (version 
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1.0.1) (Buckberry et al., 2014), with any discrepancies in predicted and clinically recorded sex from the 
same individual across all tissues removed from further analysis. For each sample, probesets “not 
reliably detected” or “unexpressed” were removed to eliminate noise (Lazar et al., 2013) and increase 
power (Hackstadt and Hess, 2009). If the expression of a probe was below the 90th percentile of the 
log2 expression scale in over 80% of samples across all groups (based on disease status, brain region 
and sex), the probe was deemed “unexpressed” and was removed from further analysis. 
Batch effects were then explored using Principal Component Analysis (PCA) and Surrogate Variable 
Analysis (SVA) using the R package “sva” (version 3.10.0) (Leek et al., 2012). Sex and diagnosis 
information was used as covariates in sva when correcting for unknown batch effects. To ensure 
homogeneity among the biological groups, outlying samples per tissue and disease group were 
iteratively identified and removed following the fundamental network concepts described in (Oldham, 
Langfelder and Horvath, 2012). Finally, Illumina-specific probe ID’s were converted to the universal 
Entrez Gene ID using the R package “illuminaHumanv4.db” (version 1.22.1). 
2.2.6 Differential Expression and Gene Set Enrichment Analysis 
Differential Expression (DE) analysis was performed using the R package “limma” (version 3.20.9) 
(Smyth, 2005). As unwanted batch effects in the data were theoretically addressed using sva, only used 
sex in the DE model was used as a covariate. A gene was regarded as significantly differentially 
expressed if the false discovery rate (FDR) adjusted p-value ≤ 0.05. 
Gene set enrichment analysis (GSEA) was performed using an Over-Representation Analysis (ORA) 
implemented through the ConsensusPathDB (http://cpdb.molgen.mpg.de) web-based platform 
(version 32) (Kamburov et al., 2009) in October 2017. ConsensusPathDB incorporates numerous well-
known biological pathway databases including BioCarta, KEGG, Reactome and Wikipathways. It 
performs a hypergeometric test while combining a background gene list, compiles results from each 
database and corrects for multiple testing using FDR (Kamburov et al., 2009). During GSEA analysis, a 
minimum overlap of the query signature and database was set as 2. 
2.2.7 Weighted Gene Co-expression Network Analysis 
Weighted gene co-expression analysis (WGCNA) was performed using R package “WGCNA” (version 
1.51) to identify clusters (modules) of highly correlated genes, with the underlying hypothesis that such 
modules could possess a common function. The WGCNA analysis was performed as described in 
(Langfelder and Horvath, 2008). In brief, a co-expression network based on “signed” adjacency was 
independently created for all three phenotypes (control, AsymAD and AD group), topological overlap 
calculated, and hierarchical clustering used to group genes into modules. The control group module 
was assigned default colours based on module size, and the AsymAD and AD module colours 
64 
 
determined based on the control module gene overlap. Module cross-tabulations were generated 
across the three phenotypes and Fisher’s exact test used to test for enrichment between modules-gene 
assignments between the control, AsymAD and AD groups. To aid in identifying significant changes in 
the co-expression network within the same modules in the three phenotypes, additional statistics 
known as “Module preservation Zsummary” and “median rank” were calculated as described in 
(Langfelder et al., 2011). 
2.2.8 Protein-Protein Interaction network analysis 
Protein-protein interaction (PPI) networks were generated by uploading gene lists (referred to as seeds 
in network analysis) to NetworkAnalyst’s (http://www.networkanalyst.ca/faces/home.xhtml) web-
based platform in December 2017. The “zero-order network” option was incorporated to allow only 
seed proteins directly interacting with each other, preventing the well-known “hairball effect” and 
allowing for better visualisation and interpretation (Xia, Benner and Hancock, 2014). Sub-modules with 
a p-value ≤ 0.05 based on the “InfoMap” algorithm (Zaki and Mora, 2015) were deemed significant 
“hubs” and the gene(s) with the most connections within this network as the “key hub gene(s)”. 
2.2.9 Study design 
Differential and co-expression analysis was performed between the three disease groups and for each 
of the four brain regions. First, the control and AsymAD groups were compared, and from this point 
onwards is referred to as the “Early AD” analysis. Second, the AsymAD and AD groups were compared, 
and from this point onwards is referred to as the “Late AD” analysis. Finally, the control and AD groups 
were compared, and from this point onwards is referred to as the “Standard AD” analysis. An overview 
of the study design and analyses is shown in Figure 2.1. 
2.2.10 Data availability 
The microarray data have been deposited in NCBI’s GEO database under the accession number 
GSE118553. Additionally, a shiny application was written in R using the “shiny” framework (version 
0.14) to allow quick visualisation of specific gene expression in the control, AsymAD and AD subjects, 
and across the EC, TC, FC and CB brain regions. The application also displays DE results of each gene 
and can be accessed at https://phidatalab-shiny.rosalind.kcl.ac.uk/ADbrainDE. All data analysis scripts 





Figure 2.1: Overview of Study Design. Four brain regions; frontal cortex (FC), temporal cortex (TC), entorhinal cortex (EC) and 
cerebellum (CB) from the three subject groups; control (CO), Asymptomatic AD (AsymAD) and Alzheimer’s disease (AD) were 
expression profiled. The typical comparison between the CO and AD group is referred to as the “Standard AD” analysis, the 
comparison between the CO and AsymAD group is referred to as the “Early AD” analysis and the comparison between the 
AsymAD and AD group is referred to as the “Late AD” analysis.  
2.3 Results 
2.3.1 Data processing 
Of the 401 tissue samples assessed (extracted from the 112 brains) 48 samples were removed due to 
duplication, 4 samples due to outlier detection analysis and 2 samples due to sex discrepancies between 
recorded and actual sex, leaving 347 tissue samples from 111 brains for DE and co-expression analysis. 
As a result of samples not being microarray profiled due to sampling quality, and samples being 
removed during the Quality Control (QC) process, not all subjects had tissue samples extracted from all 
four brain regions. The demographics for datasets by brain region and sample group is provided in Table 
2.1. 
After further QC and annotation to determine Entrez gene identifiers, the final data represented 3518 
“reliably detected” genes across all samples. Chi-squared tests revealed no significant difference in the 
proportion of males to females across the three disease groups or brain regions. Mann-Whitney U test 
revealed no significant difference between post-mortem (PM) delay or disease duration across 
analyses; however, age was significantly (p ≤ 0.01) lower in the control groups when compared to the 
AsymAD and AD group in each tissue (see Supplementary Table 2.1).  
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2.3.2 Summary of differentially expressed genes across disease groups and tissues 
A summary of DEG’s identified in each brain tissue and analyses are illustrated in Figure 2.2, and a full 
list of DEG’s can be accessed: https://phidatalab-shiny.rosalind.kcl.ac.uk/ADbrainDE. The general trend 
of DEG’s in subjects with AD (“Late AD” and “Standard AD” analysis) decreases across brain regions in 
the order of EC (n=1904 and n=1690 respectively) > TC (n=1546 and n=1517 respectively) > FC (n=52 
and n=299 respectively) > CB (n=13 and n=176 respectively). This expression pattern corresponds to 
the route AD pathology is seen to spread through the brain. By contrast, the pattern differs in the 
AsymAD group (“Early AD” analysis), where most DEGs are detected in the FC (n=398) followed by the 
TC (n=253), EC (n=19) and CB (n=1), suggesting initial molecular changes may begin in the FC brain 
region prior to AD symptoms. 
Table 2.1: Summary of MRC-LBB sample characteristics 
Brain Region Phenotype No. Samples Sex (M/F) Age (± SD) BRAAK (± SD) PM Delay (h) Disease Duration (yrs) 
Entorhinal Cortex 
Control 16 9/7 71.9 (15.6) 0 33.8 (17.8) 0 
AsymAD 28 8/20 85.4 (9.5) 2.2 (± 1.2) 52.5 (15.9) 0 
AD 34 13/21 83.9 (9.7) 4.9 (± 1) 39.5 (21.2) 11.8 (5.2) 
Temporal Cortex 
Control 24 14/10 71.5 (16.9) 0 37.2 (19.8) 0 
AsymAD 28 9/19 86.3 (8.6) 2.5 (± 1.1) 54.2 (16.6) 0 
AD 45 20/25 82.7 (9.8) 4.9 (± 0.9) 40.4 (21.4) 9.7 (5.4) 
Frontal Cortex 
Control 21 12/9 69.8 (15.4) 0 40.4 (24.6) 0 
AsymAD 32 10/22 86 (8.9) 2.3 (± 1.2) 54.1 (16.2) 0 
AD 38 13/25 82.5 (4.7) 4.9 (± 1) 39.4 (20.5) 10.5 (5.7) 
Cerebellum 
Control 18 10/8 69.4 (16) 0 37.9 (20.7) 0 
AsymAD 27 8/19 86.3 (9.2) 2.4 (± 1.2) 56 (16.5) 0 
AD 36 17/19 82.6 (10.6) 5.1 (± 0.3) 40.2 (22.3) 9.4 (5.6) 
The table provides a summary of sample characteristics used in this study. From the Initial 401 samples expression profiled, 
48 samples were removed due to duplication, 2 samples removed due to sex discrepancies and 4 samples removed due to 
being identified as outliers. The total number of samples available after quality control was 347. BRAAK staging is a measure 
of the spread of hallmark AD pathology across the brain and does not reflect pathology within a distinct brain region. In 
general, BRAAK stages I-II, III-IV and V-VI have been suggested to represent prodromal, early-moderate AD, and moderate-
late AD respectively. BRAAK scores deviate between brain regions as not all four brain regions were available from all donors. 
Hallmark AD pathology was confirmed in the entorhinal cortex, temporal cortex and frontal cortex but absent from the 
cerebellum of AsymAD and AD subjects. The values provided in Age, BRAAK and PM Delay represent the mean ± standard 
deviation. Abbreviation: M/F: the ratio of male and female samples, PM: Post-Mortem, h: Hours, yrs: Years, SD: Standard 
deviation. 
2.3.2.1 AD tau pathology marker suggests AsymAD subjects are an Intermediate state between 
normal ageing and AD. 
A previous study identified eight genes highly correlated with AD tau pathology (Miyashita et al., 2014), 
of which two genes (RELN, TRIL) are present in the data. DE analysis results indicate the TRIL gene 
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expression gradually increases through the control, AsymAD and then the AD group. In addition, the 
expression increase is only observed in brain regions known to be affected by tau pathology (EC, TC and 
FC), and the extent of expression change within these affected brain regions shadows the route of 
disease manifestation through the brain (Figure 2.3a). The EC exhibits the most significant increase of 
TRIL expression (logFC=0.99, FDR adjusted p-value=2.77e-8), followed by the TC (logFC=0.48, FDR 
adjusted p-value=1.41e-3) and then FC brain region (logFC=0.44, FDR adjusted p-value=2.21e-2). This 
expression pattern further suggests the TRIL gene is a reliable brain marker for tau pathology, and the 
AsymAD samples are a good representation of early-intermediate state between normal ageing and 
AD. 
 
Figure 2.2: Distribution of Significant DEG (FDR adjusted p-value ≤ 0.05) across brain regions and analyses. “Control>AsymAD” 
summarises the number of DEGs between the control and AsymAD group. “AsymAD>AD” summarises the number of DEGs 
between the AsymAD and AD group. “Control>AD” summarises the number of DEGs between the control and AD group. The 
proportion of up-regulated genes is represented in green while the down-regulated genes are represented in red. The total 
number of significantly differentially expressed genes in each brain region and analysis is provided on top of each bar. More 
genes are observed to be generally perturbed when comparing the AD group to the AsymAD or healthy ageing group, with the 
general pattern of more genes perturbed in the entorhinal cortex, followed by the temporal cortex, frontal cortex and then the 
cerebellum, a pattern generally representing the spread of hallmark AD pathology. In contrast, comparing the AsymAD group 
to the healthy ageing group reveals more genes are perturbed in the frontal cortex, followed by the temporal cortex, entorhinal 
cortex and then the cerebellum, suggesting initial molecular changes in AD may begin in the frontal cortex before the 
manifestation of clinical AD symptoms. 
2.3.2.2 The most significant differentially expressed genes per analysis 
The most DEG’s from each analysis is 1) MOSPD3 (downregulated in the TC brain region in “Early AD”, 
FDR adjusted p-value = 1.18e-10, Figure 2.3b), 2) NPC2 (upregulated in the EC brain region in the “Late 
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AD” analysis, FDR adjusted p-value = 2.39e-20, available to view in the SHINY web-app ) and 3) 
NOTCH2NL (upregulated in the EC brain region in the “Standard AD” analysis, FDR adjusted p-value = 
1.29e-15, available to view in the SHINY web-app).  
 
Figure 2.3: Expression boxplots of the TRIL and MOSPD3 genes. A) Previous research identified the TRIL gene as a marker for Tau pathology. 
The TRIL gene is significantly up-regulated (before multiple correction) from control to AsymAD (EC: logFC= 0.39 & p-value=0.01, TC: logFC=0.24 
& p-value=0.04, FC: logFC=0.24 & p-value=0.04) and then further to AD (EC: logFC= 0.6 & p-value=6.57e-6, TC: logFC=0.29  & p-value=4.19e-
3, FC: logFC=0.18 & p-value=0.05), but not in the cerebellum (control to AsymAD: logFC= -0.01 & p-value=1, AsymAD to AD: logFC=-0.19 & p-
value=0.2), a region spared by hallmark AD pathology. The expression pattern of the TRIL gene further supports the assignment of AsymAD 
samples, which were based on clinical records and neuropathological assessment, as an early intermediate state between healthy ageing and 
AD. B) The MOSPD3 gene is the most Significant DE gene in the Early AD analysis and is consistently down-regulated in all brain regions of the 
AsymAD group when compared to controls (EC: logFC=-0.38 & adjusted p-value=5.6e-4, TC: logFC=-0.5 & adjusted p-value=1.18e-10, FC: 
logFC= -0.27 & adjusted p-value=6.91e-4, CB: logFC=-0.59 & adjusted p-value= 1.51e-6). As all brain regions are affected in AD, albeit not to 
the same degree, the MOSPD3 gene may represent an early brain biomarker for cell dysfunction in AD. 
2.3.2.3 Common differentially expressed genes across all brain regions 
The overlap of DE genes across brain regions is shown in Figure 2.4. MOSPD3 is the only gene 
significantly differentially expressed across all four brain regions in the “Early AD” analysis. No gene was 
significantly differentially expressed in the “Late AD” analysis across all four brain regions; however, six 
genes (NPC2, DUSP1, GPM6B, SLC38A2, ANKEF1, MOSPD3) were identified in “Standard AD” analysis. 
Three of these genes (DUSP1, SLC38A2 and MOSPD3) are consistently expressed in the same direction 
across all four brain regions. DUSP1 and SLC38A2 gene expression are upregulated during disease 
progression (Control to AsymAD to AD). MOSPD3, however, is downregulated in the disease in both the 
“Early AD” and “Standard AD” analyses, with no significant difference between the AsymAD and AD 
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subjects. The remaining three genes (NPC2, GPM6B, ANKEF1) are DE in the same direction across all 
brain regions but reversed in the CB; a brain region suggested to be spared by hallmark AD pathology.  
2.3.2.4 Differentially expressed genes in brain regions with hallmark AD pathology 
The EC, TL and FC are all affected by hallmark AD pathology (amyloid and NFT’s), while the CB is known 
to be partially spared. Gene’s DE in the EC, TC and FC brain regions and not the CB, may identify hallmark 
AD pathology specific genes.  
 
Figure 2.4: Overlap of significant DEG across brain regions in A)” Early AD” analysis, B) “Late AD” analysis and C) “Standard AD” analysis. All 
brain regions in this study are affected in AD, specifically by atrophy and neuronal loss, while only three brain regions in this study (EC, TC and 
FC) are affected by the additional accumulation of hallmark AD pathology (Aβ and NFT). Genes perturbed across all brain regions may be 
markers of cell dysfunction in AD, while genes consistently perturbed in the EC, TC and FC but not in the CB may be associated with AD 
pathology. MOSPD3 gene is the only gene DE in all brain regions of the “Early AD” analysis. No gene is DE across all brain regions in the “Late 
AD” analysis. Three (ALDH2, FBLN2, METTL7A) and nine genes (FLCN, ASPHD1, ARL5A, GPR162, HBA2, PCID2, NDRG2, BEND3, RAP1Gap) are 




Three (ALDH2, FBLN2 and METTL7A) and nine (FLCN, ASPHD1, ARL5A, GPR162, HBA2, PCID2, NDRG2, 
BEND3, RAP1Gap) genes were significantly differentially expressed across the EC, TC and FC brain 
regions and not the CB brain region in the “Early AD” and “Late AD” analysis respectively. 
2.3.2.5 Gene Set Enrichment Analysis of differentially expressed genes 
To understand the functional implications of DEG’s, GSEA was performed using the significant DEG list 
from all three analyses (“Early AD”, “Late AD” and “Standard AD”) and across all four brain regions. No 
biological pathway is significantly enriched across all four brain regions in the “Early AD”, “Late AD” or 
“Standard AD” analysis. However, when excluding the brain region often referred to spared by hallmark 
AD pathology (CB), the “glutamate glutamine metabolism” and “gluconeogenesis and glycolysis” 
pathways are the only pathways significantly enriched in the “Early AD” and “Late AD” analysis 
respectively. For the “Standard AD” analysis, excluding the CB brain region additionally identified 
“mRNA processing”, “synaptic vesicle pathway” and “TNF-alpha” pathways as significantly enriched in 
the remaining three brain regions.  
2.3.3 Summary of Weighted Co-Expression Network Analysis 
Weighted gene co-expression analysis was performed on the FC and EC brain regions. This study 
focused on these two brain regions as differential expression analysis identified an increased number 
of significant DEG’s in the FC brain region prior to AD symptoms and the EC is widely regarded as one 
of the first areas of the brain to be affected in AD. Network preservation and cross-tabulation statistics 
were calculated to identify co-expression networks that may be preserved or disrupted between the 
Control, AsymAD and AD subjects. Figure 2.5 illustrates the WGCNA module assignments and module 
preservation statistics, and Figure 2.6 shows the cross-tabulation statistics across phenotypes. 
Co-expression analysis in the FC brain region identified 13, 7, and 12 modules within the control, 
AsymAD and AD groups respectively, while the analysis in the EC identified 8, 8 and 11 modules within 
the control, AsymAD and AD groups respectively. GSEA analysis was performed for all fifty-nine modules 
to identify potential biological pathways the co-expressed genes may be involved with. A summary of 
the GSEA results on the co-expression module in the FC and EC is provided in Table 2.2 and Table 2.3 
respectively. 
2.3.3.1 Co-expression modules are weakly preserved in AsymAD and AD entorhinal cortex 
Module preservation statistics were calculated for each brain region to identify co-expression networks 
that are weakly preserved through the course of the disease. Modules below a “preservation 
Zsummary” statistic of 10 and “preservation median rank” higher than the gold module (random 100 
genes) are suggested to be weakly preserved. Module colours for the AsymAD and AD groups were 
mapped to the control module colours, allowing for changes and preservation in the co-expression 
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networks to be observed as the disease progresses. The module colours assigned in the EC brain region 
are independently assigned to modules colours assigned in the FC brain region and therefore, similar 
module colours across these two tissues bare no relation.  
 
Figure 2.5: Hierarchical clustering of genes and module preservations statistics for the frontal cortex is illustrated in A-C) and entorhinal cortex 
in D-F). In brief, a co-expression network based on “signed” adjacency was independently created for all three phenotypes (control, AsymAD 
and AD group), topological overlap calculated, and hierarchical clustering used to group genes into modules. For the Hierarchical clustering 
plots, the y-axis represents the network distance with values closer to 0 indicating greater similarity of probe expression across the control 
group. The x-axis represents the modules in the control, AsymAD and AD group. The AsymAD and AD module colours are mapped to the control 
group, with the AsymAD and AD colour panel representing how well the control modules are preserved through the disease. The red line in the 
module preservation statistics (B, C, E, F) represents the correlation between module size and preservation statistics. The gold module 
represents 100 random genes, and the grey module represents uncharacterised genes. The FC preservation plots (B and C) suggest all modules 
in the control group are relatively preserved in the AsymAD and AD group. In contrast, the EC preservation plots (E and F) suggest the green 
module is not well preserved in the AsymAD and AD group and requires further investigation. 
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The FC “preservation Zsummary” statistics (Figure 2.5b and Figure 2.5c) suggests all modules from the 
control group are relatively well-preserved in the AsymAD and AD groups. In contrast, the EC 
“preservation median rank” statistics suggest the green control module is weakly preserved in AsymAD 
group (Figure 2.5e), and both the green and brown control modules are weakly preserved in the AD 
group (Figure 2.5f). In addition, the cross-tabulation statistics are also indicative of disruption to the EC 
green control module (Figure 2.6d). GSEA reveals the EC brown module in control, AsymAD and AD 
group is most significantly enriched for “selenocysteine synthesis” (control q-value=4.71e54, AsymAD 
q-value=5.89e-90, AD= 1.35E-96), suggesting this process is not significantly disrupted in AsymAD or AD 
subjects. In contrast, the EC control green module is significantly enriched (before multiple corrections) 
for “neutrophil degranulation” (p-value = 0.5e-4), “TYROBP casual network” (p-value = 2.5e-3) and the 
“innate immune system” (p-value = 2.7e-3), none of which are present in the green module of the 
AsymAD, suggesting these pathways may be disrupted in AsymAD subjects. 
Clusters of co-expressed genes in both the FC and EC brain regions were enriched for specific cell types 
including neurons, astrocytes, oligodendrocytes and microglia (results not shown); however, a 
disturbance in any cell type in AsymAD subjects was not detected. 
2.3.3.2 Frontal Cortex Co-expression network re-wired in AsymAD 
Co-expression analysis identified 13 and 12 co-expressed modules in the control and AD subjects 
respectively. However, the AsymAD group exhibits 7 larger modules of highly co-expressed genes, 
suggesting the co-expression network is re-wired in the FC brain region in this intermediate stage of 
AD. The module preservation analysis suggested all modules within the control group are relatively 
preserved through the course of the disease, however, through cross-tabulation of the modules, subtle 
changes across individual modules can be seen to contribute to a much larger magenta module in the 
AsymAD group. The biological processes associated with the magenta module changes from being 
enriched for “glucose metabolism” (q-value 6.26e-02) in the control group to “oxidative 
phosphorylation” (q-value = 2.26e-11), Parkinson’s disease  (q-value = 5.12e-9), electron transport chain 
(q-value = 5.83e-9) and Alzheimer’s disease (q-value = 8.21e-9) in the AsymAD group. Then the large 
magenta module in the AsymAD group, branches into four new AD modules (blue, turquoise, 
midnightblue, and yellow), which are most enriched for Parkinson’s disease (q-value = 3.09e-4), 
neurotransmitter receptors and postsynaptic signal transmission (q-value = 0.01), the citric acid (TCA) 






Figure 2.6: Illustrates the “module correspondence” between A) FC control and AsymAD group, B) FC AsymAD and AD group, C) FC control and 
AD group, D) EC control and AsymAD, E) EC AsymAD and AD group, and F) EC control and AD groups. The modules represent clusters of highly 
correlated genes which were calculated independently in each brain region and diagnosis group. The module colours in the AsymAD and AD 
group were assigned based on the gene overlap of the control module. The total number of genes within each module is indicated next to the 
module colour. The numbers in each cell represent the overlap of genes between modules, with increased red intensity cells indicating increased 
significant overlap based on Fisher's exact test. This “module correspondence” plot provides a visual overview of how modules of highly 
correlated genes are preserved or disrupted between, control, AsymAD and AD groups. Module preservation statistics suggested the green 
module in the EC control group is not well preserved in the AsymAD and AD groups, indicating possible disruption to the co-expression network 
in this module. This “module correspondence” plot identifies the disrupted genes in the control green module synchronises with the genes of 
the AsymAD yellow module, identifying the yellow module for further investigation. 
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2.3.3.3 Entorhinal Cortex yellow module enriched for all “Early AD” analysis DEG’s 
The yellow module contained all genes identified as significantly DE in the “Early AD” analysis (ALDH2, 
FBLN1 and METTL7A) and contained a large number of genes disrupted from the green module, which 
was the least preserved module through disease progression. Overall, this made the yellow module a 
prime candidate for further investigation. Gene set enrichment analysis of the yellow module in the 
AsymAD group reveals enrichment in “fatty acid degradation“ (q-value=0.03), “glycerophospholipid 
metabolism” (q-value=0.008), “urea cycle and metabolism of arginine, proline, glutamate, aspartate and 
asparagine” (q-value=0.05), “astrocytic glutamate-glutamine uptake and metabolism” (q-value=0.05) 
and “neurotransmitter uptake and metabolism in glial cells” (q-value=0.05), all of which were not 
previously enriched in the matched yellow module in the control group.  
Protein-protein interaction analysis in the yellow control module generated six networks, with the 
largest containing 28 nodes and 30 edges, and identified EGFR gene as the only significant key hub gene 
(p-value=0.01). APOE was not a member of this network. Further PPI analysis in the AsymAD yellow 
module generated five networks, with the largest containing 71 nodes and 81 edges, and EGRF was still 
the key hub gene (p-value=0.007). In the equivalent AD yellow module, PPI analysis identified a single 
network generated with 284 nodes and 420 edges. This network contained far higher numbers of genes 
and now integrated the APOE gene as part of the network with UBC as the key hub (p-value=4.12e63). 
This suggests protein interactions in this yellow module increases gradually through the course of the 
disease, with up-regulated EGRF interacting with more genes in the AsymAD group when compared to 
controls, followed by significant changes occurring in the AD group where up-regulated UBC gene takes 














Black 93 Pentose phosphate pathway HumanCyc 1.90E-02 
Blue 149 Parkinson's disease  KEGG 8.32E-10 
Brown 144 Differentiation Pathway Wikipathways 2.26E-02 
Green 107 Oxidative phosphorylation KEGG 1.43E-02 
GreenYellow 46 TNFs bind their physiological receptors Reactome 1.60E-02 
Grey 2247 Processing of Capped Intron-Containing Pre-mRNA Reactome 1.47E-02 
Magenta 57 Glucose metabolism Reactome 6.26E-02 
Pink 67 Tight junction interactions Reactome 1.49E-01 
Purple 52 Selenocysteine synthesis Reactome 8.66E-53 
Red 106 
TNF receptor superfamily (TNFSF) members 
mediating non-canonical NF-kB pathway 
Reactome 3.88E-02 
Tan 42 Ovarian steroidogenesis  KEGG 4.43E-02 
Turquoise 268 Attenuation of gpcr signaling BioCarta 6.13E-02 
Yellow 140 FCERI mediated MAPK activation Reactome 5.62E-02 
      
AsymAD 
Black 269 RNA Polymerase II Transcription Reactome 5.89E-04 
Brown 350 Differentiation Pathway Wikipathways 3.17E-01 
Grey 752 mRNA Processing Wikipathways 2.03E-02 
Magenta 1593 Oxidative phosphorylation - Homo sapiens (human) KEGG 2.26E-11 
Purple 165 Peptide chain elongation Reactome 5.03E-58 
Red 191 TNFR2 non-canonical NF-kB pathway Reactome 2.71E-02 
Salmon 198 Hematopoietic cell lineage - Homo sapiens (human) KEGG 2.82E-01 
      
AD 
Black 581 RNA Polymerase II Transcription Reactome 6.61E-06 
Blue 422 Parkinson's disease KEGG 3.09E-04 
Brown 169 Differentiation Pathway Wikipathways 3.23E-02 
Cyan 215 Hematopoietic cell lineage - Homo sapiens (human) KEGG 3.54E-01 
GreenYellow 61 
Steroid hormone biosynthesis - Homo sapiens 
(human) 
KEGG 2.82E-02 
Grey 1113 Neuronal System Reactome 2.89E-01 
MidnightBlue 83 
The citric acid (TCA) cycle and respiratory electron 
transport 
Reactome 1.31E-02 
Purple 250 Eukaryotic Translation Elongation Reactome 9.36E-66 
Red 124 
TNF receptor superfamily (TNFSF) members 
mediating non-canonical NF-kB pathway 
Reactome 9.31E-02 
Salmon 281 Histidine metabolism EHMN 4.87E-04 
Turquoise 215 
Neurotransmitter receptors and postsynaptic signal 
transmission 
Reactome 1.15E-02 
Yellow 171 Fas INOH 2.94E-03 
Co-expression analysis in the frontal cortex brain region identified 13, 7, and 12 modules within the control, AsymAD and AD 
groups respectively. Gene set enrichment analysis was performed on each module, and the most significant result from 
each module is provided above.  
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Black 216 Hedgehog  INOH 7.69E-03 
Blue 599 Generic Transcription Pathway  Reactome 3.32E-05 
Brown 396 Ribosome  KEGG 4.71E-54 
Green 249 Neutrophil degranulation  Reactome 1.35E-01 
Grey 288 Pink/Parkin Mediated Mitophagy Reactome 2.97E-01 
Red 232 Leptin Insulin Overlap  Wikipathways 6.01E-02 
Turquoise 1259 Neuronal System  Reactome 1.68E-08 
Yellow 279 Histidine metabolism  EHMN 5.24E-03 
      
AsymAD 
Blue 336 Generic Transcription Pathway  Reactome 2.04E-04 
Brown 107 Eukaryotic Translation Elongation  Reactome 1.13E-93 
Green 337 Processing of Capped Intron-Containing Pre-mRNA  Reactome 2.08E-06 
Grey 1661 Antigen processing and presentation KEGG 2.10E-04 
Pink 432 Neural Crest Differentiation  Wikipathways 1.44E-01 
Red 183 Hematopoietic cell lineage KEGG 2.21E-01 
Turquoise 1661 Parkinson's disease KEGG 2.82E-10 
Yellow 363 Metallothioneins bind metals  Reactome 8.08E-03 
      
AD 
Blue 342 Generic Transcription Pathway  Reactome 6.31E-04 
Brown 106 Eukaryotic Translation Elongation  Reactome 4.46E-98 








Respiratory electron transport, ATP synthesis by 







418 Processing of Capped Intron-Containing Pre-mRNA  Reactome 7.92E-07 
Red 162 Fat digestion and absorption KEGG 2.80E-01 
Salmon 109 How progesterone initiates the oocyte maturation  BioCarta 2.08E-02 
Tan 240 Differentiation Pathway  Wikipathways 1.95E-01 
Turquoise 265 Neuronal System  Reactome 5.10E-11 
Yellow 413 Propanoate metabolism  EHMN 3.67E-03 
Co-expression analysis in the entorhinal cortex brain region identified 8, 8, and 11 modules within the control, AsymAD and 
AD groups respectively. Gee set enrichment analysis was performed on each module, and the most significant result from 





2.4.1 Transcriptomic perturbations suggest AsymAD subjects could be an intermediate stage 
between control and MCI/AD 
This study hypothesises the samples labelled as “AsymAD” subjects are an intermediate state between 
healthy ageing and MCI/AD. The assignment of these samples to the AsymAD group was based on the 
fact that these individuals had no reported clinical record of dementia prior to death as indicated in the 
MRC-LBB database; however, upon autopsy, these samples were found to have low levels of hallmark 
AD pathology, i.e. BRAAK Staging >= 2. Furthermore, an independent expression study identified the 
TRIL gene as being highly correlated with AD neuropathology, specifically tau pathology (Miyashita et 
al., 2014). This study shows that the TRIL gene expression gradually increases from the Control to 
AsymAD, and then further increases in AD subjects, and this expression pattern is only observed in brain 
regions known to be affected by hallmark AD pathology (amyloid and NFT’s), i.e. the EC, TC and FC, and 
not in the CB brain region. This observation suggests the phenotype assignments (controls, AsymAD, 
AD) are a suitable representation of three points in AD progression (assuming the AsymAD subjects are 
all prodromal AD), and as suggested by the TRIL gene expression pattern across brain regions and the 
fact the CB has been consistently reported to be partially spared from hallmark AD pathology (amyloid 
and NFT’s), even those with severe AD pathology (Convit et al., 2000), genes whose expression pattern 
differs significantly in the CB from that consistently seen in the EC, TC and FC tissues may be associated 
with hallmark AD pathology. 
2.4.2 MOSPD3 gene is perturbed in the brains of AsymAD and blood of AD subjects.  
The MOSPD3 gene was the only significant DE gene which is consistently down-regulated across all four 
brain regions in the AsymAD subjects suggesting this may be an early marker of cell dysfunction in AD. 
The MOSPD3 gene encodes for a Motile Sperm Domain Containing 3 protein [provided by RefSeq, Jul 
2008] and has been reported to be significantly down-regulated (p-value = 6.47E-05) in the blood of AD 
subjects when compared to MCI subjects (Lunnon et al., 2012). This suggests MOSPD3 gene expression 
is significantly decreased in the brain before clinical signs of AD are apparent; however, blood gene 
expression levels are only significantly decreased after clinical signs of AD are apparent. It is difficult to 
interpret the biological relevance of this gene in AD, and further investigation is required. 
2.4.3 Genes perturbed in brain regions affected explicitly by hallmark AD pathology may be 
associated with plaques and tangles, providing new therapeutic targets. 
Many molecular and cellular changes occur in AD brains including nerve cell death, atrophy, loss of 
neurons and accumulation hallmark AD pathology, specifically plaques and tangles. However, not all 
brain regions are affected to the same degree. The CB, which only accounts for 10% of the brain but 
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contains over 50% of the brains total neurons, is often regarded as being partially spared from AD as 
plaques and tangles are generally not reported (Convit et al., 2000; Jacobs et al., 2017), and in this study 
are free from hallmark AD pathology in both AsymAD and AD subjects. For subjects with hallmark AD 
pathology (BRAAK >=2, AsymAD and AD), genes significantly and consistently perturbed across the EC, 
TC and FC tissues that are not or are significantly reversed in the CB, may be associated with hallmark 
AD pathology, although, it remains unclear if these genes are causative or a response to the pathology 
itself. 
This study identified a total of 15 genes (ALDH2, FBLN2, METTL7A, FLCN, ASPHD1, ARL5A, GPR162, HBA2, 
PCID2, NDRG2, BEND3, RAP1Gap, GPM6B, ANKEF1 and NPC2) with expression patterns suggestive of an 
association with hallmark AD pathology. Previous studies have already demonstrated an increased 
expression of ALDH2 accelerated neurodegeneration and increased the accumulation of 
hyperphosphorylated tau protein (Ohsawa et al., 2008) in mice, while another demonstrated NDRG2 
might play a role in generating Aβ (Rong et al., 2017). Collectively, the 15 genes are not significantly 
enriched to be involved with any biological pathway; however, individually, these genes may play an 
essential role in the pathological aspect of AD and may provide new therapeutic targets for disease 
intervention. 
2.4.4 Individuals with milder disease (early BRAAK pathology) show increased changes in 
the frontal cortex compared to the entorhinal cortex.  
The molecular changes in AD may initially begin in the FC, a region involved in working memory, as 
there were relatively more changes in the FC of mild pathology AD cases (AsymAD) than the EC region. 
This mirrors changes described in a longitudinal study involving ageing controls, where positron 
emission tomography (PET) scans were used to detect increased activity in the medial frontal cortex 
and decrease activity in the temporal lobe brain region in subjects who subsequently acquired cognitive 
impairment (Beason-Held et al., 2013). In addition, a higher degree of atrophy has also been detected 
in the FC than the temporal lobe brain region in MCI when compared to AD (Tabatabaei-Jafari, Shaw 
and Cherbuin, 2015). This study provides further evidence to suggest that brain perturbations at the 
molecular/transcriptomic level may initially occur in the FC before the presentation of more severe 
clinical symptoms consistent with a diagnosis of probable AD. 
At the later point of the disease when clinical signs of AD are present, most substantial number of 
transcriptomic changes is detected in the EC, followed by the TC, FC and only minor changes in the CB. 
This observation matches the common route AD neuropathology is seen to spread through the brain. 
Furthermore, more DEG in the “Late AD” analysis is detected when compared to “Early AD” analysis, 
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signifying more genes are disrupted in the later stage of the disease when the clinical symptoms of 
cognitive impairment are apparent.  
2.4.5 Neutrophil, TYROBP network and the innate immune system disrupted in 
Asymptomatic AD 
Co-expression analysis of the EC brain region identified a green module of highly co-expressed genes, 
which is disrupted in the AsymAD and AD subjects according to both module preservation statistics and 
cross-tabulation analysis. This green module is significantly enriched for “neutrophil degranulation”, 
“TYROBP casual network” and the “innate immune system” processes in the control subjects, but not in 
the AsymAD or AD subjects, suggesting these pathways are most likely disrupted during the disease. 
Disturbance in TYROBP and Immune system pathways have been widely accepted in AD (Lambert et al., 
2010; Ma et al., 2015), and a previous mouse study demonstrated disruptions in neutrophil levels 
impact memory loss and neurological features of AD (Pietronigro et al., 2017). This study now suggests 
these pathways are specifically perturbed in the EC brain region early in the disease when hallmark AD 
pathology exists but clinical symptoms of AD are absent. 
2.4.6 Disruption in brain energy pathways is detectable early in the disease                                                                                                                                                        
Co-expression analysis of the FC identifies disruptions in the “glucose metabolism”, “glucogenesis” 
and“oxidative phosphorylation” processes in the AsymAD group, while DE analysis identified disruption 
in the “gluconeogenesis and glycolysis” pathway in the AD subjects. The brain critically relies on a 
constant supply of energy which is known to be generated by glycolysis followed by oxidative 
phosphorylation. Changes in the brain energy pathways have been widely accepted in AD (Shoffner, 
1997; Cunnane et al., 2011), with a general decrease in glycolysis suggested to be a result of decreased 
brain functionality. This study demonstrates disruptions in the energy pathway are detectable early in 
the disease, in subjects with low levels of AD pathology. 
2.4.7 The Glutamate-Glutamine Cycle is disturbed in AsymAD and AD subjects                                                                                                                                                                             
Gene set enrichment analysis on DEGs identified the “glutamate-glutamine cycle” as the only biological 
pathway significantly perturbed across all brain regions in the AsymAD subjects. Furthermore, co-
expression analysis of the EC brain regions was indicative of disruptions to the “urea cycle and 
metabolism of arginine, proline, glutamate, aspartate and asparagine” and “astrocytic glutamate-
glutamine uptake and metabolism” in AsymAD and AD subjects, further confirming a possible disruption 
in glutamate-related activities in the brain. 
Astrocytes are the most common form of neuroglial cells in the brain, and its primary function is to 
protect neurons against excitotoxicity by converting excess ammonia and glutamate to glutamine 
through the glutamate-glutamine cycle. Glutamate is the principal excitatory neurotransmitter in the 
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brain and plays a vital role in linking carbohydrate and amino acid metabolism via the tricarboxylic acid 
(TCA) cycle. Glutamate is also a precursor of γ-aminobutyric acid (GABA) which binds and inhibits 
neuron activity; hence, an accumulation of glutamate can cause failures in synaptic connectivity, 
leading to deficient cognition and memory (Schousboe et al., 2014). A disruption in the glutamate-
glutamine cycle would have a severe knock-on effect on many other biological pathways, including a 
disruption in amino acid metabolism which could explain the enrichment of “urea cycle and metabolism 
of arginine, proline, glutamate, aspartate and asparagine” in the results as well. In addition, glutamate 
stimulates astrocytes to derive energy from oxidative and glycolytic pathways, both of which have been 
identified as disrupted in AsymAD subjects.  
The genes enriched in this pathway were all significantly up-regulated, indicating an overactive cycle. 
This could be part of the brain defence mechanism in preventing the accumulation of brain glutamate 
levels or a broken cycle which is consistently being overactive, leading to decreased levels of brain 
glutamate, a phenomenon observed in AD subjects (Fayed et al., 2011). Targetting this pathway for AD 
treatment is extraordinarily complex and challenging as over inhibition or excitation may lead to 
increased levels of glutamate and glutamine respectively, both of which can be neurotoxic at high 
levels. Therapeutic compounds affecting the “glutamate-glutamine cycle” have already been identified, 
such as memantine, which is already a clinically established therapeutic drug used to for the 
symptomatic treatment of AD, which blocks N-methyl-d-aspartate (NMDA) receptors (Johnson and 
Kotermanski, 2006), essentially preventing excitotoxicity caused by neurotransmitters such as 
glutamate and ultimately increasing cognition temporarily.  
The glutamate-glutamine cycle has been previously suggested to be disrupted in AD (Walton and Dodd, 
2007), along with many other central nervous system disorders including Huntington’s disease and 
Amyotrophic Lateral Sclerosis (ALS) (Matthews, Henter and Zarate, 2012). This study demonstrates this 
is one of the earliest biological pathways perturbed across all brain regions in AD, before clinical 
symptoms of AD are apparent, which can have a knock-on effect on other biological pathways also 
observed to be disrupted in the disease. Clinically established drugs to relieve AD symptoms already 
interact with this pathway and could also be effective in the asymptomatic period to prolong cognitive 
impairment, although clinical identification and measuring effectiveness in AsymAD subjects would be 
a challenge in itself. 
2.4.8 Co-expression network changes indicate a shift from “cell proliferation” in AsymAD 
subjects to “removal of amyloidogenic proteins” in AD subjects. 
Protein-protein interactions identified EGFR as a key hub gene in both the control and AsymAD groups; 
however, it achieves more connections with neighbouring proteins in the AsymAD group, suggesting a 
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possible increase in the EGFR activity. The EGFR gene is up-regulated in the AsymAD group and encodes 
for a transmembrane glycoprotein that binds to epidermal growth factor, leading to cell proliferation. 
In contrast, EGFR is replaced by UBC as the key hub gene in AD subjects, indicating it may play a more 
central role in the disease once the accumulation of hallmark AD pathology is at a level where clinical 
symptoms are apparent. The UBC gene is significantly up-regulated in the EC of AD subjects and is 
considered a stress gene which encodes for polyubiquitin precursor protein, a member of the ubiquitin-
proteasome system (UPS) which removes toxic proteins and impacts on the amyloidogenic pathway of 
amyloid precursor protein (APP) processing that generates Abeta (Hong, Huang and Jiang, 2014). A 
previous AD study had also observed UBC as a novel key hub gene and demonstrated UBC knockout 
models in C. elegans accelerated age-related AB toxicity (Mukherjee et al., 2017). Effectively, a portion 
of the co-expression network may have a central role involved in cell proliferation in control subjects, 
with increased activity in AsymAD subjects, followed by a shift towards the removal of toxic proteins 
such as amyloid-beta in AD subjects.  
2.4.9 Limitations 
Several individual processes are involved during sample preparation and during microarray gene 
expression, including, transcriptional steps, labelling, hybridisation and intensity measurement. Each of 
these steps can introduce technical variations (Richard et al., 2014). Gene expression microarrays are 
also affected by non-biological variations, such as reagent lot numbers, different technicians and even 
atmospheric ozone levels (Chen et al., 2011). In addition, the quantification of gene expression in post-
mortem brains has been shown to be complicated by confounding factors such as gender, age at death 
and brain pH (Preece and Cairns, 2003). It is impossible to measure and account for all variables that 
may be influencing how genes are expressed, however, a study has demonstrated SVA can predict and 
account for these latent effects (Leek and Storey, 2007). Although SVA was incorporated to account for 
hidden batch effects, it does not guarantee that all technical variation is completely removed. 
This study cannot exclude the fact AsymAD group may represent a heterogeneous group consisting of 
cognitively normal, MCI, mixed dementia and AD subjects. It remains unclear these AsymAD subjects 
would remain free from clinical symptoms of dementia with longer survival and can be argued to be a 
possible extension to general ageing. However, the extent of BRAAK staging in AsymAD subjects was at 
a level consistently found with early cognitive impairment, and therefore, this study makes the strong 
assumption that these subjects are more likely to be prodromal AD rather than an extension of natural 
ageing. As AsymAD subjects are extremely rare, hence the low sample numbers in this study, larger 





This is the first study to explore the emergence of transcriptomic changes in the human brain from 
normal ageing through to mild AD pathology and diagnosis of AD. Using DE analysis, coupled with a 
“systems biology” approach, this study was able to detect disturbances in the energy pathways and the 
“glutamate-glutamine cycle” in the brains of subjects with mild and severe AD pathology. This study 
found that changes in the FC brain region dominate in mild pathology, but are greater in the EC in 
subjects with more severe pathology, thus mirroring the changes in the aggregate spread in AD. This 
study provides new insight into the earliest biological changes occurring in the brain prior to AD 
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Abstract. 
Background: Microarray technologies have identified imbalances in the expression of specific genes 
and biological pathways in Alzheimer’s disease (AD) brains. However, there is a lack of reproducibility 
across individual AD studies, and many related neurodegenerative and mental health disorders exhibit 
similar perturbations.  
Objective: Meta-analyse publicly available transcriptomic data from multiple brain-related disorders to 
Identify robust transcriptomic changes specific to AD brains. 
Methods: Twenty-two AD, eight Schizophrenia, five Bipolar Disorder, four Huntington's disease, two 
Major Depressive Disorder and one Parkinson's disease dataset totalling 2667 samples and mapping to 
four different brain regions (temporal lobe, frontal lobe, parietal lobe and cerebellum) were analysed. 
Differential expression analysis was performed independently in each dataset, followed by meta-
analysis using a combining p-value method known as Adaptively Weighted with One-sided Correction.  
Results: Meta-analysis identified 323, 435, 1023 and 828 differentially expressed genes specific to the 
AD temporal lobe, frontal lobe, parietal lobe and cerebellum brain regions respectively. Seven of these 
genes were consistently perturbed across all AD brain regions with SPCS1 gene expression pattern 
replicating in RNA-Seq data. A further nineteen genes were perturbed specifically in AD brain regions 
affected by both plaques and tangles, suggesting possible involvement in AD neuropathology. In 
addition, biological pathways involved in the “metabolism of proteins” and viral components were 
significantly enriched across AD brains. 
Conclusion: This study identified transcriptomic changes specific to AD brains, which could make a 
significant contribution towards the understanding of AD disease mechanisms and may also provide 
new therapeutic targets. 
KEYWORDS: Alzheimer’s disease, Mental disorders, Neurodegenerative disorders, Microarray 
analysis, Gene expression, Human, Neuropathology, Meta-analysis
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Alzheimer’s disease (AD) is the most common 
form of dementia affecting over 44 million 
individuals worldwide, and numbers are 
H. Patel et al. / Meta-analysis of AD Brain Transcriptomic Data 
85 
 
expected to triple by 2050 [1]. The hallmark of 
the disease is characterised by the abnormal 
brain accumulation of amyloid-β (Aβ) protein 
and hyperphosphorylated tau filaments, which 
forms structures known as plaques and tangles 
respectively. The accumulation of these 
proteins contributes to the loss of connections 
between neurone synapses, leading to the loss 
of brain tissue and the disruption of normal 
cognitive functions.  
As AD progresses, the spread of plaques and 
tangles in the brain usually occurs in a 
predictable pattern and can begin up to 18 
years prior to the onset of clinical symptoms 
[2]. In the earliest stages of the disease, plaques 
and tangles form in areas of the brain primarily 
involved in learning and memory, specifically 
the hippocampus and entorhinal cortex, both 
situated in the temporal lobe (TL) region [3]. 
Next, the frontal lobe (FL), a region involved in 
voluntary movement, is affected, followed by 
the parietal lobe (PL), a region involved in 
processing reading and writing. In the later 
stage of the disease, the occipital lobe, a region 
involved in processing information from the 
eyes, can become affected, followed by the 
cerebellum (CB), a region which receives 
information from the sensory systems and the 
spinal cord to regulates motor movement. 
Nerve cell death, tissue loss and atrophy occur 
throughout the brain as AD progresses, leading 
to the manifestation of clinical symptoms 
associated with loss of normal brain function. 
However, not all brain regions are 
neuropathologically affected in the same 
manner. The CB, which only accounts for 10% 
of the brain but contains over 50% of the brains 
total neurones, is often neglected in AD 
research because it is generally considered to 
be partially spared from the disease as plaques 
are only occasionally seen but tangles are 
generally not reported [4,5]. 
The histopathological spread of the disease is 
well documented, and with the advent of high 
throughput genomics approaches, we are now 
able to study the transcriptomic and biological 
pathways disrupted in AD brains. Microarrays 
can simultaneously examine thousands of 
genes, providing an opportunity to identify 
imbalances in the expression of specific genes 
and biological pathways. However, microarray 
reproducibility has always been questionable, 
with replication of differentially expressed 
genes (DEG’s) very poor [6]. For example, two 
independent microarray transcriptomic studies 
performed differential expression analysis in 
the hippocampus of AD brains. The first study 
by Miller et al. identified 600 DEG’s [7], and a 
similar study by Hokama et al. identified 1071 
DEG’s [8]. An overlap of 105 DEG’s exist 
between the two studies; however, after 
accounting for multiple testing, no gene was 
replicated between the two studies. The Miller 
study consisted of 7 AD and 10 control subject’s 
expression profiled on the Affymetrix platform 
while the Hakoma study consisted of 31 AD and 
32 control subjects expression profiled on the 
Illumina platform. Replication between the 
Illumina and Affymetrix platform has been 
shown to be generally very high [9]; therefore, 
the lack of replication between the two studies 
is probably down to a range of other factors 
including low statistical power, sampling bias 
and disease heterogeneity. 
Unlike DEG’s, replication of the molecular 
changes at a pathway level are more consistent 
and have provided insights into the biological 
processes disturbed in AD. Numerous studies 
have consistently highlighted disruptions in 
immune response [10–13] protein 
transcription/translation [10,11,14–17], 
calcium signalling [10,18,19], MAPK signalling 
[7,16] various metabolism pathways such as 
carbohydrates [16], lipids [16,20], glucose 
[17,21,22], and [11,23], chemical synapse 
[7,18,19] and neurotransmitter [11,18,19] 
However, many of these pathways have also 
been suggested to be disrupted in other brain-
related disorders. For example, disruptions in 
calcium signalling, MAPK, chemical synapse and 
various neurotransmitter pathways have also 
been implicated in Parkinson’s Disease (PD) 
[24,25] In addition, glucose metabolism, 
protein translation, and various 
neurotransmission pathways have also been 
suggested to be disrupted in Bipolar Disorder 
(BD[26–29]. Although the biological disruptions 
involved in AD are steadily being identified, 
many other neurodegenerative and mental 
disorders are showing similar perturbations. 
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We are yet to identify robust transcriptomic 
changes specific to AD brains. 
In this study, we combined publicly available 
microarray gene expression data generated 
from AD human brain tissue and matched 
cognitively healthy controls to conduct the 
most extensive AD transcriptomic microarray 
meta-analyses known to date. We generate AD 
expression profiles across the temporal lobe, 
frontal lobe, parietal lobe and cerebellum brain 
regions. We further refine each expression 
profile by removing perturbations seen in other 
neurodegenerative and mental disorders (PD, 
BD, Schizophrenia [SCZ], Major Depressive 
Disorder [MDD] and Huntington’s Disease [HD]) 
to decipher specific transcriptomic changes 
occurring in human AD brains. These AD-
specific brain changes may provide new insight 
and a better understanding of the disease 
mechanism, which in turn could provide new 
therapeutic targets for preventing and curing 
AD.  
MATERIALS AND METHODS 
Selection of publicly available microarray 
studies 
Publicly available microarray gene expression 
data was sourced from the Accelerating 






doi:10.1038/sdata.2018.185) and ArrayExpress 
(https://www.ebi.ac.uk/arrayexpress/) in June 
2016. For a study to be selected for inclusion, 
the data had to (1) be generated from a 
neurodegenerative or mental health disorder, 
(2) be sampled from human brain tissue, (3) 
have gene expression measured on either the 
Affymetrix or Illumina microarray platform, (4) 
contain both diseased and suitably matched 
healthy controls in the same experimental 
batch and (5) contain at least 10 samples from 
both the diseased and control group. 
Microarray gene expression data pre-
processing 
 
Data analysis was performed in RStudio 
(version 0.99.467) using R (version 3.2.2).  All 
data analysis scripts used in this study are 
available at 
https://doi.org/10.5281/zenodo.823256. In 
brief, raw Affymetrix microarray gene 
expression data was “mas5” background 
corrected using R package “affy” (version 
1.42.3) and raw Illumina microarray gene 
expression data Maximum Likelihood 
Estimation (MLE) background corrected using R 
package “MBCB” (version 1.18.0). Studies with 
samples extracted from multiple tissues were 
separated into tissue-specific matrices, log2 
transformed and then Robust Spline 
Normalised (RSN) using R package “lumi” 
(version 2.16.0).  
BRAAK staging is a measure of AD pathology 
and ranges from I-VI. In general, stages I-II, III-
IV and V-VI represent the “low likelihood of 
AD”, “probable AD” and “definite AD” 
respectively [30]. To maintain homogeneity 
within the sample groups and to be able to infer 
pathological related genetic changes, if BRAAK 
staging was available, clinical AD samples with 
BRAAK scores ≤ 3 or clinical control samples 
with BRAAK scores ≥ 3 were removed from 
further analysis. 
Gender was predicted using the R package 
“massiR” (version 1.0.1) and used to subset the 
data into four groups based on diagnosis 
(case/control) and gender (male/female). Next, 
probes below the 90th percentile of the log2 
expression scale in over 80% of samples were 
deemed “not reliably detected” and were 
excluded from further analysis to eliminate 
noise [31] and increase power [32]. 
Publicly available data is often accompanied by 
a lack of sample processing information, 
making it impossible to adjust for known 
systematic errors introduced when samples are 
processed in multiple batches, a term often 
known as “batch effects”. To account for both 
known and latent variation, batch effects were 
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estimated and removed using the Principal 
Component Analysis (PCA) and Surrogate 
Variable Analysis (SVA) using the R package 
“sva” (version 3.10.0). Gender and diagnosis 
information were used as covariates in sva 
when correcting for batch effects. Outlying 
samples were iteratively identified and 
removed from each gender and diagnosis 
group using fundamental network concepts 
described in [33]. Platform-specific probe ID’s 
were converted to Entrez Gene ID’s using the 





“illuminaHumanv3.db”) and differential 
expression analysis was performed within each 
dataset using the R package “limma” (version 
3.20.9). 
Finally, study compatibility analysis was 
investigated through the R package 
“MetaOmics” (version 0.1.13). This package 
uses differentially expressed genes (DEGs), co-
expression and enriched biological pathways 
analysis to generate six quantified measures 
that are used to generate a PCA plot. The 
direction of each Quality Control (QC) measure 
is juxtaposed on top of the two-dimensional PC 
subspace using arrows. Datasets in the negative 
region of the arrows were classed as outliers 
[34] and were removed from further analysis. 
Meta-analysis 
Datasets were grouped by the primary cerebral 
cortex lobes (TL, FL, PL) and the CB. Meta-
analysis was performed using a “combining p-
values” method known as “Adaptively 
Weighted with One-sided Correction” (AW.OC), 
implemented through the R package “MetaDE” 
(version 1.0.5)[34]. A combining p-value 
method was chosen to address the biases 
introduced from different platforms. AW.OC 
was chosen  as it permits missing information 
across datasets which are introduced by 
combining data generated from different 
microarray platforms and expression chips. This  
avoids the need to subset individual datasets to 
common probes, which essentially allows for 
the maximum number of genes to be analysed. 
Furthermore, the method provides additional 
information on which dataset is contributing 
towards the meta-analysis p-value, and has 
been shown to be amongst the best performing 
meta-analysis methods for combining p-values 
for biological associations [35]. The meta-
analysis method does not provide an overall 
directional change for each gene; therefore, 
the standard error (SE) was calculated from the 
DE logFC values of each gene across the AW 
assigned significant datasets and used for 
standard meta-summary estimate analysis 
using the R package “rmeta” (version 2.16). This 
served as the “meta expression” change in 
downstream analysis where positive values 
represent a gene being up-regulated in AD and 
negative values as being down-regulated in AD. 
Selecting DE genes based on an arbitrary 
expression change significantly influences the 
interpretation of DE results [36]. At least half of 
differential expression based studies 
incorporate a fold change cut-off typically 
between 2-3, however, informative RNAs and 
expressed transcripts have been shown to have 
a fold change less than 2 [37], and genes with 
low fold change have been demonstrated to 
influence biological effects in signalling 
cascades and pathways [36]. In addition, gene 
expression is heavily influenced by tissue, and 
as this study performs meta-analysis across 
multiple inter-related tissues within larger brain 
compartments, we do not employ an arbitrary 
fold change cut-off to determine if a gene is 
differentially expressed, however, we do 
require the gene to be consistently expressed 
across these tissues. if a gene was significantly 
DE according to the meta-analysis (FDR 
adjusted meta p-value ≤ 0.05), but at least one 
contributing dataset (according to AW.OC 
weights) had directional logFC discrepancy (i.e. 
up-regulated in one dataset and down-
regulated in another dataset), the gene was 
deemed to be discordant and was excluded 
from further analysis. This ensured we only 
captured robust, and consistently reproducible 
expression signatures. 
Generation of disease-specific meta-
analysis expression profiles 
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Meta-analysis was performed across all AD 
datasets, followed by a separate meta-analysis 
across the non-AD disorder datasets. Using 
these meta-analysis results we generated three 
expression profiles; (1) “AD expression profile”, 
(2) “AD-specific expression profile” and (3) 
“common neurological disorder expression 
profile”.  
The first expression profile, “AD expression 
profile”, is a direct result of the meta-analysis 
performed on AD studies, which represents the 
changes typically observed from an AD and 
cognitively healthy control study design. The 
second expression profile, deemed as the “AD-
specific expression profile”, is produced by 
subtracting significantly DEG’s found in the 
non-AD meta-analysis results from the “AD 
expression profile”. This profile represents 
transcriptomic changes specifically observed in 
AD and not in any other neurodegenerative or 
mental health disorder used in this study. The 
third expression profile, deemed as the 
“common neurological disorder expression 
profile”, represents genes which are 
significantly DE in all disorders used in this 
study, including AD. 
Replication of significant microarray genes 
in RNA-Seq data 
The genes significantly DE and deemed to be of 
biological significance in this study were 
queried in the curated web-based database 
Agora (data version 9, accessible at 
https://agora.ampadportal.org), which 
provides expression change of genes in AD 
based on RNA-Seq of 2100 human brain 
samples.  
Functional and gene set enrichment 
analysis  
Gene set enrichment analysis (GSEA), and Gene 
Ontology (GO) analysis was conducted using an 
Over-Representation Analysis (ORA) 
implemented through the ConsensusPathDB 
web platform (version 32) [38] in May 2017. 
ConsensusPathDB incorporates numerous well-
known biological pathway databases including 
BioCarta, KEGG, Reactome and Wikipathways. 
The platform performs a hypergeometric test 
while integrating a background gene list, which 
in this case is a list of all the genes that pass 
quality control in this study, compiles results 
from each database and corrects for multiple 
testing using the false discovery rate (FDR) [38]. 
A minimum overlap of the query signature and 
database was set to 2, and a result was deemed 
significant if the q-value was ≤ 0.05.  
Network analysis 
Protein-protein interaction (PPI) networks were 
created by uploading the meta-analysis DEG 
lists (referred to as seeds in network analysis) 
along with their meta logFC expression values 
to NetworkAnalyst’s web-based platform 
http://www.networkanalyst.ca/faces/home.xh
tml in June 2017. The “Zero-order Network” 
option was incorporated to allow only seed 
proteins directly interacting with each other, 
preventing the well-known “Hairball effect” 
and allowing for better visualisation and 
interpretation [39]. Sub-modules with a p-value 
≤ 0.05 (based on the “InfoMap” algorithm [40]) 
were considered significant key hubs, and the 
gene with the most connections within this hub 
was regarded as the key hub gene. 
RESULTS 
The AD microarray datasets  
We Identified and acquired nine publicly 
available AD studies from ArrayExpress and 
AMP-AD, of which seven studies contained 
samples extracted from differing regions of the 
brain. The basic characteristics of each study 
and dataset are provided in Table 1. Separating 
the nine studies by brain regions resulted in 46 
datasets. Here a “dataset” is defined by brain 
region and study origin. For example, 
ArrayExpress study E-GEOD-36980 consists of 
diseased and healthy samples extracted from 
three different tissues (temporal cortex, 
hippocampus and frontal cortex). All samples 
originating from the same tissue were classified 
as one dataset; therefore, study E-GEOD-36980 
generated three datasets, representing the 
three different tissues.  
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The 46 AD datasets contained both AD samples 
and healthy controls, were assayed using seven 
different expression chips over two different 
microarray platforms (Affymetrix and Illumina) 
and consisted of a total 2718 samples before 
QC. Briefly, the MetaOmics analysis identified 
study syn4552659 as an outlier and was 
therefore removed from further analysis (see 
supplementary text 1), resulting in 1501 
samples (746 AD, 755 controls) in the 
remaining 22 datasets after QC 
Summary of the AD meta-analysis DEG 
counts 
The AD meta-analysis was performed on the 22 
AD datasets and independently identified 
differentially expressed genes within the TL, FL, 
PL and CB brain regions. A summary of the 
number of datasets in each brain region and the 
number of significant DEG’s identified is 
provided in Table 2. The complete DE results 
are provided in Supplementary Table 1. As 
mentioned in the methods, due to gene 
expression being influenced by tissue source 
and as this study incorporates different brain 
regions, we do not employ an arbitrary cut-off 
value to determine genes that are highly or 
lowly expressed, but primarily focus on genes 
consistently perturbed. However, we provide 
the meta expression values in supplementary 
tables and advise readers to consider the 
expression distribution of all DEG’s within each 
brain region independently, if determining 
whether a gene is highly/lowly expressed. For 
instance, the cerebellum meta expression 
ranges from -0.53 to 0.54 with an interquartile 
range(Q1-Q3) of -0.1 to 0.1. In contrast, the 
parietal lobe has a larger meta expression range 
of -1.5 to 1.35, with an interquartile range(Q1-
Q3) of -0.53 to 0.29. Therefore, as gene 
expression distribution varies across brain 
regions, a sensible cut-off (if one was to be 
used) for highly and lowly expressed genes may 
lie at the 1st and 3rd quartiles respectively, with 
quartiles calculated per tissue.  
The non-AD disorder microarray datasets 
Nine non-AD studies were identified and 
acquired, of which four studies consisted of 
samples generated from multiple disorders and 
brain regions. Separating the studies by disease 
and tissue equated to 21 datasets consisting of 
8 SCZ, 6 BD, 4 HD, 2 MDD and 1 PD dataset with 
a total of 1166 samples after QC. The 
demographics of the non-AD datasets is 
provided in Table 3, and a complete list of DEG’s 
is provided in Supplementary Table 2.  SCZ and 
BD were the only disorders with expression 
data available across all four brain regions, and 
the frontal lobe brain region was the only 
region with expression data available from all 
non-AD disorders identified in this study. 
Summary of non-AD brain disorder meta-
analyses DEG counts 
A second meta-analysis was performed on all 
non-AD disorders, and similarly to the AD meta-
analysis, datasets were grouped into the TL, FL, 
PL and CB brain regions. An overview of the 
non-AD meta-analysis results are provided in 
Table 4. 
The meta-analysis expression profiles  
As described in the methods, three primary 
expression signatures were derived from the 
meta-analyses for each of the four brain 
regions: - 1) “AD expression profile”, 2) “AD-
specific expression profile” and 3) “common 
neurological disorder expression profile”. The 
numbers of significant DEG’s in each of the 
three expression signatures are provided in 
Table 5. 
The DEG’s from the “AD expression profile” in 
the TL brain region were not significantly DE in 
any other disorder included in this study. 
Hence, the “AD expression profile” and the 
“AD-specific expression profile” contained the 
same 323 genes for the TL brain region. The 
“AD-specific expression profile” for all four 
brain regions is provided in Supplementary 
Table 3. 
The “common neurological disorder expression 
profile” within the four brain regions consisted 
of very little or no DEG’s (except for the parietal 
lobe); hence, the downstream analysis did not 
yield any statistically significant results of 
biological relevance. We find little robust  
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Tissue source (as stated in the 
original study publication) 
Meta-Analysis brain region 
mapping 
Number of samples after QC  
AD (M/F) Control (M/F) 
ArrayExpress E-GEOD-118553 Illumina HumanHT-12 v4 
Entorhinal Cortex Temporal Lobe 35 (14/21) 21 (12/9) 
Cerebellum Cerebellum 38 (10/28) 19 (5/14) 
Frontal Cortex Frontal Lobe 38 (13/25) 22 (11/11) 
Temporal Cortex Temporal Lobe 51 (21/30) 29 (21/8) 
ArrayExpress E-GEOD-48350 ([41]) Affymetrix 
Human Genome U133 
Plus 2.0 
Entorhinal Cortex Temporal Lobe 11 (6/5) 38 (21/17) 
Hippocampus Temporal Lobe 15 (8/7) 41 (22/19) 
Postcentral Gyrus Parietal Lobe 19 (11/8) 33 (20/13) 
Superior Frontal Gyrus Frontal Lobe 17 (8/9) 38 (22/16) 
ArrayExpress E-GEOD-29378 ([7]) Illumina HumanHT-12 v3 
Hippocampus CA1 Temporal Lobe 16 (9/7) 16 (11/5) 
Hippocampus CA3 Temporal Lobe 15 (9/6) 16 (11/5) 
ArrayExpress E-GEOD-36980 ([8]) Affymetrix Human Gene 1.0 ST 
Frontal Cortex Frontal Lobe 14 (7/7) 17 (9/8) 
Hippocampus Temporal Lobe 7 (3/4) 10 (5/5) 
Temporal Cortex Temporal Lobe 10 (5/5) 19 (8/11) 
ArrayExpress E-GEOD-28146 ([19]) Affymetrix 
Human Genome U133 
Plus 2.0 
Hippocampus CA1 Temporal Lobe 15 (4/11) 8 (5/3) 
ArrayExpress E-GEOD-1297 ([42]) Affymetrix 
Human Genome 
U133A 
Hippocampus Temporal Lobe 19 (4/11) 9 (6/3) 
ArrayExpress E-GEOD-5281 ([21]) Affymetrix 
Human Genome U133 
Plus 2.0 
Entorhinal Cortex Temporal Lobe 10 (4/6) 13 (11/2) 
Hippocampus CA1 Temporal Lobe 10 (4/6) 13 (10/3) 
Medial Temporal Gyrus Temporal Lobe 16 (10/6) 12 (8/4) 
Posterior Cingulate Parietal Lobe 9 (4/5) 13 (10/3) 
Superior Frontal Gyrus Frontal Lobe 23 (13/10) 11 (7/4) 
AMP syn3157225 ([43]) Illumina 
Whole-Genome DASL 
HT 
Temporal Cortex Temporal Lobe 189 (93/96) 186 (116/70) 
Cerebellum Cerebellum 169 (87/82) 171 (113/58) 
AMP syn4552659 ([44]) Affymetrix 
Human Genome 
U133A 
Frontal Pole Frontal Lobe 25 (6/19) 7 (4/3) 
Precentral Gyrus Frontal Lobe 20 (5/15) 3 (1/2) 
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Nine publicly available AD studies were identified and acquired for this study. Separating the studies by tissue resulted in 46 datasets, each containing AD and healthy control samples. The brain tissue in each of the 46 
datasets was mapped to their corresponding cerebral cortex (temporal lobe, frontal lobe or parietal lobe) or the cerebellum. Due to limited phenotypic information in publicly available data, the reported gender was 
predicted from gene expression if clinical gender was unavailable. Abbreviations: M = Male, F=Female. 
  
Inferior Frontal Gyrus Frontal Lobe 19 (5/14) 4 (1/3) 
Dorsolateral Prefrontal Cortex Frontal Lobe 19 (4/15) 8 (4/4) 
Superior Parietal Lobule Parietal Lobe 11 (2/9) 5 (2/3) 
Prefrontal Cortex Frontal Lobe 23 (7/16) 4 (2/2) 
Parahippocampal Gyrus Temporal Lobe 18 (5/13) 7 (3/4) 
Hippocampus Temporal Lobe 20 (5/15) 5 (2/3) 
Inferior Temporal Gyrus Temporal Lobe 20 (5/15) 6 (3/3) 
Middle Temporal Gyrus Temporal Lobe 15 (4/11) 7 (4/3) 
Superior Temporal Gyrus Temporal Lobe 15 (3/12) 8 (4/4) 
Temporal Pole Temporal Lobe 25 (7/18) 6 (3/3) 
AMP syn4552659 ([44]) Affymetrix 
Human Genome 
U133B 
Frontal Pole Frontal Lobe 26 (8/18) 7 (4/3) 
Precentral Gyrus Frontal Lobe 18 (4/14) 3 (1/2) 
Inferior Frontal Gyrus Frontal Lobe 21 (5/16) 5 (2/3) 
Dorsolateral Prefrontal Cortex Frontal Lobe 20 (5/15) 8 (4/4) 
Superior Parietal Lobule Parietal Lobe 16 (5/11) 5 (3/2) 
Prefrontal Cortex Frontal Lobe 23 (7/16) 4 (2/2) 
Parahippocampal Gyrus Temporal Lobe 19 (7/12) 7 (3/4) 
Hippocampus Temporal Lobe 22 (6/16) 5 (2/3) 
Inferior Temporal Gyrus Temporal Lobe 21 (6/15) 7 (4/3) 
Middle Temporal Gyrus Temporal Lobe 23 (8/15) 7 (4/3) 
Superior Temporal Gyrus Temporal Lobe 23 (4/19) 8 (4/4) 
Frontal Pole Frontal Lobe 26 (8/18) 7 (4/3) 
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Twenty-two AD datasets containing a total of 1501 samples remained in this study after QC.  
The case/control numbers represent the total number of AD/healthy controls subjects across  
all datasets within a particular brain region. The number of significant genes was identified  
through a combining p-value method known as Adaptively Weighted with One-sided  
Correction (AW.OC). 
evidence of shared biology based on this data 
analysis and therefore, exclude all results 
generated from the “common neurological 
disorder expression profile” from this paper; 
however, we provide the complete list of 
significantly DEG’s within this profile in 
Supplementary Table 4. 
Common differentially expressed genes 
across multiple brain regions in AD 
AD is known to affect all brain regions through 
the course of the disease, although not to the 
same degree, similar transcriptomic changes 
across all brain regions were deemed disease-
specific, while perturbations in a single brain 
region were considered to be tissue-specific. 
We were particularly interested in disease-
specific transcriptomic changes and therefore 
decided to focus on genes that were found to 
be consistently DE across multiple brain 
regions. 
Meta-analysis of the AD datasets identified a 
total of 2495 unique genes as significantly DE. 
The distribution of these genes across the four 
brain regions is shown in Figure 1. Forty-two 
genes were found to be perturbed across all 
four brain regions and can be grouped into 
three sets (Figure 2). The first group (Gene set 
1) are expressed consistently in the same 
direction across all four brain regions and can 
be regarded as disease-specific. The second 
group (Gene set 2) are expressed in the same 
direction in the TL, FL and PL, but expression is 
reversed in the CB brain region, a region 
suggested to be spared from AD pathology 
[4,5]. This expression pattern suggests these 
genes may be involved in AD pathology. Finally, 
the third group (Gene set 3) are inconsistently 
expressed across the four brain regions are 
most likely tissue-specific or even false-
positives. 
From the forty-two genes significantly 
differentially expressed across all brain regions, 
seven genes were DE in the same direction and 
belong to the “AD-specific expression profile”, 
that is, these seven genes (down-regulated 
NDUFS5, SOD1, SPCS1 and up-regulated OGT, 
PURA, RERE, ZFP36L1) were consistently 
perturbed in all AD brain regions and not in any 
other brain region of any other  disorder used 
in this study and can be considered unique to 
AD brains. The expression of these seven genes 
across AD brains is shown in Figure 3. 
Differentially expressed genes in brain 
regions affected by AD histopathology 
In AD, the TL, FL and PL are known to be 
affected by both plaques and tangles, while the 
CB brain region is rarely reported to be 
affected. In addition to identifying genes DE 
across all brain regions and reversed in the CB 
brain region, we were also interested in genes 
perturbed in the TL, FL and PL and not the CB. 
These genes may also play a role in general AD 
histopathology and could be new therapeutic 
targets in preventing or curing AD. 
Fifty-five genes were found to be significantly 
DE in TL, FL and PL but not the CB, of which 
sixteen were expressed in the same direction 
and were not DE in the other brain disorders 
used in this study. Ten of these genes (ALDOA,  
Brain region Number of datasets  
Number of samples 
(case/control) 
AW.OC Significant DEGs  
(FDR adjusted p ≤ 0.05) 
Temporal lobe 14 850 (419/431) 323 
Frontal lobe 4 180 (92/88) 460 
Parietal lobe 2 74 (28/46) 1736 
Cerebellum 2 397 (207/190) 867 
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Sample source (as stated in 
the original study 
publication) 
Mapping to brain 
region 
Number of samples after QC  
AD (M/F) Control (M/F) 
ArrayExpress E-GEOD-12649 ([43])  Affymetrix Human Genome U133A 
Bipolar Disorder Prefrontal Cortex Frontal Lobe 33 (16/17) 34 (25/9) 
Schizophrenia Prefrontal Cortex Frontal Lobe 33 (25/8) 32 (24/8) 
ArrayExpress E-GEOD-17612 ([44]) Affymetrix Human Genome U133 Plus 2.0 Schizophrenia Prefrontal Cortex Frontal Lobe 27 (18/9) 22 (11/11) 
ArrayExpress E-GEOD-20168 ([45]) Affymetrix Human Genome U133A Parkinson's Disease Prefrontal Cortex Frontal Lobe 14 (7/7) 16 (11/5) 
ArrayExpress E-GEOD-21138 ([46]) Affymetrix Human Genome U133 Plus 2.0 Schizophrenia Prefrontal Cortex Frontal Lobe 25 (21/4) 28 (23/5) 
ArrayExpress E-GEOD-21935 ([47]) Affymetrix Human Genome U133 Plus 2.0 Schizophrenia Temporal Cortex Temporal Lobe 22 (12/10) 19 (10/9) 
ArrayExpress E-GEOD-35978 ([48])  Affymetrix Human Gene 1.0 ST 
Bipolar Disorder Cerebellum Cerebellum 32 (16/16) 46 (29/17) 
Schizophrenia Cerebellum Cerebellum 43 (31/12) 46 (29/17) 
Bipolar Disorder Parietal Lobe Parietal Lobe 40 (24/16) 45 (32/13) 
Schizophrenia Parietal Lobe Parietal Lobe 51 (37/14) 36 (26/10) 
ArrayExpress E-GEOD-3790 ([49])  Affymetrix 
Human Genome U133A 
Huntingdon’s Disease Frontal Lobe Frontal Lobe 36 (22/14) 27 (19/8) 
Huntingdon’s Disease Cerebellum Cerebellum 38 (22/16) 27 (16/11) 
Human Genome U133B 
Huntingdon’s Disease Cerebellum Cerebellum 38 (23/15) 27 (16/11) 
Huntingdon’s Disease Frontal Lobe Frontal Lobe 37 (21/16) 29 (19/10) 
ArrayExpress E-GEOD-5388 ([50]) Affymetrix Human Genome U133A Bipolar Disorder Prefrontal Cortex Frontal Lobe 30 (16/14) 29 (23/6) 
ArrayExpress E-GEOD-53987 ([51]) Affymetrix Human Genome U133 Plus 2.0 
Bipolar Disorder Prefrontal Cortex Frontal Lobe 17 (10/7) 19 (11/8) 
Major Depressive 
Disorder 
Prefrontal Cortex Frontal Lobe 16 (9/7) 18 (10/8) 
Schizophrenia Prefrontal Cortex Frontal Lobe 14 (7/7) 19 (11/8) 
Bipolar Disorder Hippocampus Temporal Lobe 18 (11/7) 17 (9/8) 
Major Depressive 
Disorder 
Hippocampus Temporal Lobe 16 (9/7) 17 (9/8) 
Schizophrenia Hippocampus Temporal Lobe 15 (9/6) 18 (10/8) 
Nine publicly available non-AD studies were identified and acquired. Separating the studies by tissue resulted in 21 datasets. Each dataset contained both diseased and complimentary healthy controls. The brain tissue in 
each of the 21 datasets was mapped to their corresponding cerebral cortex (temporal lobe, frontal lobe or parietal lobe) or the cerebellum. Due to limited phenotypic information in publicly available data, the reported 
gender was predicted from gene expression if clinical gender was unavailable. Abbreviations: M = Male, F=Female.
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Table 4: Summary of non-AD study meta-analysis DEG’s 
Brain region 
























Temporal lobe 1 (18/17) 2 (37/37) 0 1 (16/17) 0 4 (71/71) 51 
Frontal lobe 3 (80/82) 4 (99/101) 2 (73/56) 1 (16/18) 1 (14/16) 11 (282/273) 149 
Parietal lobe 1 (40/45) 1 (51/36) 0 0 0 2 (91/81) 2611 
Cerebellum 1 (32/46) 1 (43/46) 2 (76/54) 0 0 4 (151/146) 177 
The table illustrates the non-AD dataset and sample distribution across the four brain regions. Disease abbreviations are as follows: BD=Bipolar 
Disease, HD= Huntington’s Disease, MDD=Major Depressive Disorder and PD=Parkinson’s Disease. The case/control numbers represent the 
total number of diseased and healthy control subjects within a disease group and brain region. For instance, “3 (80/82)” for BD datasets in the 
Frontal lobe region indicates three BD datasets with a combined total of 80 BD and 82 complimentary healthy control subjects. The number of 
significant DEG’s was identified through a combining p-value method known as Adaptively Weighted with One-sided Correction (AW.OC). 
Table 5: Summary of DEGs in each expression signature and brain region
 
The “AD” expression profile represents genes identified as DE in the AD vs control meta-analysis. The “non-AD” expression  
profile represents genes identified as DE in the non-AD meta-analysis. The “AD-specific” expression profile is a list of genes  
DE in AD and no other disorder, and the “common” expression profile is a list of genes DE in all mental disorder used in this  
 study. Each expression profile is brain region-specific. The “Total (unique)” represents a unique list of the total number  
of genes identified as significantly DE across brain regions or expression profiles 
Figure 1: Overlap of DEG’s in the AD expression profile across 
brain regions. Forty-two genes were observed to be significantly 
differentially expressed across all four AD brain regions.  
GABBR1, TUBA1A, GAPDH, DNM3, KLC1, COX6C, 
ACTG1, CLTA, SLC25A5) were consistently 
down-regulated, and six genes (PRNP, FDFT1, 
RHOQ, B2M, SPP1, WAC) were consistently up-
regulated in AD.  
Furthermore, from the forty-two genes 
identified as significantly DE across all four AD 
brain regions, ten genes were in consensus in 
their expression across the TL, FL and PL brain 
region but expression is reversed in the 
cerebellum. Only 3 of these genes (UBA1, EIF4H 
and CLDND1) belong to the “AD-specific 
expression profile”, and all three genes were 
significantly down-regulated in the TL, FL and 
PL, but significantly up-regulated in the CB 
brain region (see Gene set 2 in Figure 2). 
 
Expression Profile Cerebellum Frontal lobe Parietal lobe Temporal lobe Total (unique) 
AD  867 460 1736 323 2494 
Non-AD  177 149 2611 51 2809 
AD-specific  828 435 1023 323 1994 
Common  39 25 713 0 755 
Total (unique) 1005 584 3642 374 - 
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Figure 2: Expression pattern of genes significantly (FDR adjusted p-value ≤0.05) differentially expressed across all four AD brain regions. The 
expression values for each gene was obtained from the meta-summary calculations. Red cells represent down-regulated genes, and green cells 
represent up-regulated genes. Forty-two genes were observed to be significantly perturbed across all four AD brain regions and can be grouped 
into three “sets”. Gene set 1 represents genes which are perturbed consistently in the same direction across all AD brain regions and can be 
considered disease-specific. Gene set 2 represents genes consistent in expression in the TL, FL and PL brain regions, but reversed in the CB brain 
region; a region often referred to be free from AD pathology. Finally, Gene set 3 represents genes which are significant DE across all four brain 
regions; however, directional change is not consistent across the brain regions and may represent tissue-specific genes or even false positive. 
The gene names highlighted in red are genes perturbed in AD and not in any other disorder used in this study and are deemed “AD-specific”.  
Microarray gene expression profiling in 
RNA-Seq data 
The 7 genes (NDUFS5, SOD1, SPCS1, OGT, PURA, 
RERE, ZFP36L1) consistently expressed across 
all brain regions and the 19 genes (ALDOA, 
GABBR1, TUBA1A, GAPDH, DNM3, KLC1, COX6C, 
ACTG1, CLTA, SLC25A5, PRNP, FDFT1, RHOQ, 
B2M, SPP1, WAC, UBA1, EIF4H, CLDND1) 
consistently expressed in the TL, FL and PL and 
not in the CB or reversed in the CB, were 
queried in the web-based platform Agora to 
compare RNA-Seq based expression profiling. 
The results are provided in Table 6. Agora failed 
to provide expression profiling for 17/26 genes, 
however, from the data available, the genes 
observed to be consistently expressed across all 
brain regions based on  
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Figure 3: Seven genes consistently significantly differentially expressed in the same direction in all regions of AD brains but not in Schizophrenia, 
Bipolar Disorder, Huntington’s disease, Major Depressive Disorder or Parkinson’s disease brains. These seven genes can be assumed to be 
unique to AD brains and may play an important role in disease mechanisms. 
microarray data are relatively mirrored in RNA-
Seq data, specifically genes SPCS1, PURA and 
ZFP36L1.  RNA-Seq data was available for only 
6/19 genes (DNM3, COX6C, ACTG1, CLTA, RHOQ 
and B2M) expressed in brain regions affected 
by hallmark AD pathology (TL, FL and PL), and 
were all relatively consistent in directional 
change across AD brain regions, including the 
CB, a characteristic undesired by genes which 
may be associated with hallmark AD pathology.  
 “AD Expression Profile” functional gene 
set enrichment and GO analysis 
Gene set enrichment analysis of the “AD 
expression profile” identified 205, 197, 98, and 
45 biological pathways significantly enriched in 
the TL, FL, PL and CB brain regions respectively 
(Supplementary Table 5). There were ten 
pathways significantly enriched in all four brain 
regions, of which eight are involved in the 
“metabolism of protein” (specifically the 
translation process, the most significant being 
in CB brain region with a q-value=1.11e-7), one 
involved in “adenosine ribonucleotides de novo 
biosynthesis” (TL q-value = 0.007, FL q-value = 
7.56e-5, PL q-value = 0.04, CB q-value = 0.03) 
and one involved in the “digestive system” (TL 
q-value = 0.02, FL q-value = 0.02, PL q-value = 
0.01, CB p-value = 0.02).  
When excluding the CB brain region, 42 
pathways were significantly enriched in the 
remaining three brain regions, of which five 
pathways obtained an FDR adjusted 
significance p-value of ≤ 0.01. The five 
pathways are “Alzheimer’s disease” (TL q-value  
6.53e-4, FL q-value = 0.02, PL q-value = 0.01), 
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Table 6: Microarray gene expression compared to RNA-Seq gene expression 
 
 
The 7 genes consistently expressed across all brain regions and the 19 genes consistently expressed in the TL, FL and PL and not/reversed in the 
CB were queried in the web-based platform Agora to compare RNA-Seq expression. Only significantly (p-value ≤ 0.05) DE genes after multiple 
correction are shown. Red cells represent down-regulated genes in AD, green cells represent up-regulated genes in AD, white cells represent 
genes not significantly DE, and grey cells are when data is not available. Abbreviations are as follows; TL = Temporal Lobe, FL = Frontal Lobe, 
PL = Parietal Lobe, CB = Cerebellum, TCX = Temporal Cortex, STG = Superior Temporal Gyrus, PHG = Parahippocampal Gyrus, IFG = Inferior 
frontal gyrus, FP = Frontal pole, DLPFC = Dorsolateral prefrontal cortex. 
“Electron Transport Chain” (TL q-value = 0.006, 
FL q-value = 2.95e-5, PL q-value = 3.69e-5), 
“Oxidative phosphorylation” (TL q-value =1.77e-
4, FL q-value = 4.99e-8, PL q-value = 4.18e-05), 
“Parkinson’s disease” (TL q-value =8.57e-4, FL 
q-value = 1.59e-6, PL q-value = 1.77e-6) and 
“Synaptic vesicle cycle” (TL q-value = 5.19e-4, FL 




TL FL PL CB 
TL FL 
CB 
TCX STG PHG IFG FP DLPFC 
                        
NDUFS5 -0.127 -0.796 -0.975 -0.087               
SOD1 -0.085 -0.104 -0.047 -0.055               
SPCS1 -0.113 -0.276 -0.251 -0.079 -0.192   -0.177     -0.124 -0.317 
OGT 0.057 0.262 0.205 0.079               
PURA 0.688 0.157 0.211 0.065           0.103 0.318 
RERE 0.337 0.270 0.373 0.114               
ZFP36L1 0.484 0.502 0.317 0.123 0.603 0.389 0.619       0.355 
                        
ALDOA -1.389 -0.090 -0.091                 
GABBR1 -0.864 -0.116 -0.162                 
TUBA1A -0.728 -0.286 -0.191                 
GAPDH -0.719 -0.095 -0.759                 
DNM3 -0.611 -0.154 -0.781   -0.361   -0.119       0.141 
KLC1 -0.530 -0.115 -0.056                 
COX6C -0.504 -0.360 -0.651     -0.140 -0.200       -0.220 
ACTG1 -0.467 -0.165 -0.326             -0.250   
CLTA -0.153 -0.097 -0.183   -0.091           -0.112 
SLC25A5 -0.147 -0.122 -0.262                 
PRNP 0.115 0.168 0.130                 
FDFT1 0.158 0.196 0.283                 
RHOQ 0.227 0.128 0.330   0.465   0.310     0.190 0.029 
B2M 0.556 0.216 0.212   0.430           0.258 
SPP1 0.935 0.557 0.316                 
WAC 1.111 0.257 0.154                 
                        
UBA1 -0.213 -0.090 -0.827 0.134               
EIF4H -0.201 -0.062 -0.093 0.063               
CLDND1 -1.100 -0.113 -0.734 0.086               
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The biological GO analysis identified 384, 417, 
216, and 72 biological components as 
significantly enriched in the TL, FL, PL and CB 
brain region respectively (Supplementary Table 
6). There were 36 pathways significantly 
enriched across all four brain regions at a p- 
value threshold of ≤ 0.05 and nine at an FDR 
adjusted significant p-value threshold of ≤ 0.01. 
These nine processes are “cellular component 
biogenesis” (TL q-value =1.38e-4, FL q-value = 
0.002, PL q-value = 5.86e-4, CB q- value = 
0.006), “cellular component organization” (TL q-
value = 1.96e-8, FL q-value 0.004), “interspecies 
interaction between organisms” (TL q-value = 
1.13e-41.85e-4, FL q-value = 8.73e-5, PL q-
value = 5.59e-5 , CB q-value = 0.002), “multi-
organism cellular process” (TL q-value = , FL q-
value = 4.72e-5, PL q-value = 8.04e-5, CB q-
value = 0.002), “nervous system development” 
(TL q-value = 1.64e-7, FL q-value = 5.90e-14, PL 
q-value = 3.82e-8, CB q-value = 0.01), 
“organonitrogen compound metabolic process” 
(TL q-value = 0.002, FL q-value = 1.56e-5, PL q-
value = 1.02e-5, CB q-value = 0.002), 
“symbiosis, encompassing, mutualism through 
parasitism” (TL q-value = 4.04e-4, FL q- value = 
1.92e-4, PL q-value = 3.18e-4, CB q-value = 
0.004), “translational initiation” (TL q-value = 
0.007, FL q-value = 0.006, PL q-value = 2.41e-4, 
CB q-value = 5.24e-6 ), and “viral process” (TL q-
value = 2.82e-4, FL q-value = 1.17e-4, PL q-value 
= 3.18e-4, CB q-value =0.002 ). Excluding the CB 
brain region resulted in 84 common biological 
components being significantly enriched across 
the remaining three brain regions.  
“AD-Specific Expression Profile” functional 
gene set enrichment and GO analysis 
Analysis of the “AD-specific expression profile” 
identified 205, 196, 40 and 42 pathways as 
significantly enriched in the TL, FL, PL and CB 
brain region respectively in the GSEA analysis 
(Supplementary Table 7). The analysis identified 
six significantly enriched pathways across all 
four brain regions, and all are involved in 
“metabolism of protein” (specifically the 
translation process, with the most significant 
pathway being in the PL brain region with a q-
value = 8.92e-7). The same six pathways were 
identified when the CB region was excluded. 
The GO analysis identified 384, 344, 36 and 72 
significantly enriched biological components 
for the TL, FL, PL and CB brain region 
respectively. Only four common biological 
components were significantly enriched across 
all four brain regions, and all are indicative of 
interspecies interactions including viral. 
Excluding the CB identifies only “neural nucleus 
development” (TL q-value = 5.35e-5, FL q-value 
= 0.007, PL q-value = 0.003) as an additional 
component being enriched. The complete 
biological GO analysis results are provided in 
Supplementary Table 8. 
Network analysis hub gene identification 
PPI networks were generated for each 
expression profile and in each of the four brain 
regions (TL, FL, PL and CB) to identify genes 
whose protein product interacts with other 
protein products from the same expression 
profile. Genes with more interactions than 
expected are referred to as hub genes and may 
be of biological significance. 
Temporal lobe hub genes 
PPI network analysis was performed on the 
expression profiles of the TL brain region to 
identify key hub genes. The “AD expression 
profile” and the “AD-specific expression 
profile” both consisted of the same 323 DEG’s 
which represented 282 seed proteins with 716 
edges (interactions between proteins). Two 
significant key hub genes were identified; the 
down-regulated Polyubiquitin-C (UBC, p-value 
= 1.57e-30) and the up-regulated Small 
Ubiquitin-related Modifier 2 (SUMO2, p-value = 
3.7e-4).  
Frontal lobe hub genes 
The FL “AD expression profile” consisted of 460 
DEG’s which represented 272 seed proteins 
and 620 edges. Two significant key hub genes 
were identified; up-regulated Amyloid 
Precursor Protein (APP, p-value = 1.98e-08) and 
down-regulated Heat Shock Protein 90-alpha 
(HSP90AA1, p-value = 0.003). Using the “AD-
specific expression profile” identified the same 
two key hub genes, with APP reaching a 
significant p-value of 2.11e-09. 
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Parietal lobe hub genes 
The PL “AD expression profile” consisted of 
1736 DEG’s which represented 1437 seed 
proteins and 5720 edges. Similar to the TL and 
FL, two significant key hub genes were 
identified; down-regulated Cullin-3 (CUL3, p-
value = 1.84e-10) and down-regulated UBC (p-
value = 1.84e-10). Using the “AD-specific 
expression profile” (1023 DEGs, 810 seed 
proteins and 2351 edges) identified UBC as the 
only key hub gene, with a more significant p-
value of 1.84e-10. The CUL3 gene is no longer a 
significant key hub gene in the network. 
Cerebellum hub genes 
The CB “AD expression profile” consisted of 867 
DEG’s which represented 548 seed proteins 
and 1419 edges. Four significant key hub genes 
were identified; up-regulated APP (p-value 
=4.24e-26), down-regulated Ribosomal Protein 
2 (RPS2, p-value = 4.24e-26), down-regulated 
SUMO2 (p-value = 4e-05), and up-regulated 
Glycyl-TRNA Synthetase (GARS, p-value = 
0.0207). Using the “AD-specific expression 
profile” for the same brain region identified APP 
(p-value = 3.44e-26), RPS2 (p value= 6.61e-06), 
and SUMO2 (p-value = 3.78e-06) as the key hub 
genes only. The GARS gene is no longer a key 
hub gene in the network. 
DISCUSSION 
In this study, we acquired eighteen publicly 
available microarray gene expression studies 
covering six neurological and mental health 
disorders; AD, BD, HD, MDD, PD and SCZ. Data 
was generated on seven different expression 
BeadArrays and across two different 
microarray technologies (Affymetrix and 
Illumina). The eighteen studies consisted of 
3984 samples extracted from 22 unique brain 
regions which equated to 67 unique datasets 
when separating by disorder and tissue. 
However, due to study and sample outlier 
analysis, only 43 datasets (22 AD, 6 BD, 4 HD, 2 
MDD, 1 PD and 8 SCZ) totalling 2,667 samples 
passed QC. We grouped the AD datasets by 
tissue, into the TL, FL, PL and CB brain regions 
to perform the largest microarray AD meta-
analysis known to date to our knowledge, 
which identified 323, 460, 1736 and 867 
significant DEG’s respectively. Furthermore, we 
incorporated transcriptomic information from 
other neurological and mental health disorders 
to subset the initial findings to 323, 435, 1023, 
and 828 significant DEG’s that were specifically 
perturbed in the TL, FL, PL and CB brain regions 
respectively of AD subjects. 
Genes specifically perturbed across AD 
brain regions 
Seven genes (down-regulated NDUFS5, SOD1, 
SPCS1 and up-regulated OGT, PURA, RERE, 
ZFP36L1) were DE in AD brains and not DE in the 
other disorders used in this study. We deemed 
these seven protein-coding genes as “AD-
specific”. The expression patterns of three 
genes (SPCS1, PURA and ZFP36L1) were 
relatively mirrored in RNA-Seq data; however, 
it is important to note the RNA-Seq data does 
not contain expression profiling for the PL 
region, and it also contains three specific brain 
regions within the TL (temporal cortex, superior 
temporal gyrus, Parahippocampal gyrus) and FL 
(Inferior frontal gyrus, frontal pole and 
dorsolateral prefrontal cortex). Nevertheless, 
the SPCS1 gene was observed to be consistently 
down-regulated across all hierarchical AD brain 
regions available in both the microarray and 
RNA-Seq data. In addition, based on a network 
of genomics and epigenomic elements in the 
region of this gene, in combination with 
phenotypes, the AMP-AD consortia have 
nominated SPCS1 as a druggable target for AD 
treatment.  
Three of the “AD-specific” genes (NDUFS5, 
SOD1 and OGT) have been previously 
associated with AD. Down-regulated NADH 
Dehydrogenase Ubiquinone Fe-S Protein 5 
(NDUFS5) gene is part of the human 
mitochondrial respiratory chain complex; a 
process suggested to be disrupted in AD in 
multiple studies [45]. A study investigating 
blood-based AD biomarkers identified 13 
genes, including NDUFS5, which was capable of 
predicting AD with 66% accuracy (67% 
sensitivity and 75% specificity) in an 
independent cohort of 118 AD and 118 control 
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subjects [46]. The perturbation in NDUFS5 
expression in the blood and brains of AD 
subjects suggests this gene may have potential 
as an AD biomarker and warrants further 
investigation. 
Down-regulated Superoxide Dismutase 1 
(SOD1) gene encodes for copper and zinc ion 
binding proteins which contribute to the 
destruction of free superoxide radicals in the 
body and is also involved in the function of 
motor neurons [provided by RefSeq, Jul 2008]. 
Mutations in this gene have been heavily 
implicated as causes of familial amyotrophic 
lateral sclerosis (ALS) [47] and have also been 
associated with AD risk [48]. A recent study 
discovered SOD1 deficiency in an amyloid 
precursor protein-overexpressing mouse 
model accelerated Aβ oligomerisation and also 
caused Tau phosphorylation [49]. They also 
stated SOD1 isozymes were significantly 
decreased in human AD patients, and we can 
now confirm SOD1 is significantly under-
expressed at the mRNA level in human AD 
brains as well. 
The up-regulated O-Linked N-Acetyl 
Glucosamine Transferase (OGT) gene encodes 
for a glycosyltransferase that links N-
acetylglucosamine to serine and threonine 
residues (O-GlcNAc). O-GlcNAcylation is the 
post-translational modification of O-GlcNAc 
and occurs on both neuronal tau and APP. 
Increased brain O-GlcNAcylation has been 
observed to protect against tau and amyloid-β 
peptide toxicity [50]. A mouse study has 
demonstrated a deletion of the encoding OGT 
gene causes an increase in tau phosphorylation 
[51]. In this study, we observe a significant 
increase in OGT gene expression throughout 
human AD brains, including the cerebellum 
where tangles are rarely reported, suggesting 
OGT gene is most likely not solely responsible 
for the formation of tangles.  
OGT and O-GlcNAcase (OGA) enzymes facilitate 
O-GlcNAc cycling, and levels of GlcNAc have 
also been observed to be increased in the 
parietal lobe of AD brains [52]. Appropriately, 
OGA inhibitors have been tested for treating AD 
with promising preliminary results [53], 
prompting further investigation into targeting 
OGT for AD treatment.  
Genes involved in AD histopathology 
The CB brain region is known to be free from 
tau pathology and occasionally free from 
plaques. We exploited the CB brain region as a 
secondary control to identify sixteen genes 
(ALDOA, GABBR1, TUBA1A, GAPDH, DNM3, 
KLC1, COX6C, ACTG1, CLTA, SLC25A5, PRNP, 
FDFT1, RHOQ, B2M, SPP1, WAC) DE specifically 
in TL, FL and PL and not the CB brain region of 
AD subjects. RNA-Seq data was available for 6 
of these genes (DNM3, COX6C, ACTG1, CLTA, 
RHOQ and B2M) and all 6 genes failed to 
replicate expression patterns observed with 
microarray data. Nevertheless, DNM3 gene has 
been previously associated with AD pathology 
based on proteomic data DNM3 gene encodes 
a member of a family of guanosine 
triphosphate (GTP)-binding proteins that 
associate with microtubules and are involved in 
vesicular transport. A proteomic study 
identified a module of co-expressed proteins, 
which included DNM3, as negatively correlated 
with BRAAK staging [54]. Although DNM3 gene 
expression based on microarray and RNA-Seq 
data are in disagreement in the CB brain region, 
a region used in this study to aid in determining 
whether a gene may be involved with AD 
pathology, an independent proteomic study 
demonstrated DNM3 might indeed be 
association with AD pathology. This suggests all 
6 genes which failed replication in RNA-Seq 
data may still be associated with AD pathology 
and require further confirmation. 
An additional 9 genes (GABBR1, GAPDH, PRPN, 
FDFT1, KLC1, TUBA1A, CLTA, COX6C, SLC25A5), 
where expression profiling based on RNA-Seq 
data was unavailable, have also been previously 
associated with AD, of which four genes 
(GABBR1, GAPDH, PRPN and FDFT1) have 
individually been suggested to be involved with 
the pathogenesis of the disease. GABBR1 gene 
encodes a receptor for gamma-aminobutyric 
acid (GABA), which is the primary inhibitory 
neurotransmitter in the human central nervous 
system. As observed in this study, the GABBR1 
gene has been previously reported to be down- 
regulated in AD brains [16]. GABBR1 receptors 
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are prominent in neuronal soma, where NFT 
formation is known to accumulate. A study 
examined the immunohistochemical 
localisation and distribution of GABABR1 
protein in the hippocampus of AD subjects and 
observed a negative correlation with NFT 
formation and suggested an increase or stable 
expression of GBBR1 could contribute to 
neuronal resistance to the disease process [55]. 
GAPDH gene encodes for a member of the 
glyceraldehyde-3-phosphate dehydrogenase 
protein family, which catalyses an essential step 
in the carbohydrate metabolism. GAPDH has 
been shown to interact with Aβ precursor 
protein but not cleaved Aβ and has been 
proposed to be directly involved in tau 
aggregation and NFT formation in AD [56–58]. 
The PRNP gene encodes for the prion protein, a 
membrane glycosylphosphatidylinositol-
anchored glycoprotein that tends to aggregate 
into rod-like structures. Mutations in the PRNP 
gene has been associated with AD and prion 
protein has also been suggested to be involved 
in the pathogenesis of AD [59]. FDFT1 gene 
encodes a membrane-associated enzyme 
located at a branch point in the mevalonate 
pathway, which generates isoprenoids that 
have been found to be positively correlated 
with tau pathology [60]. KLC1 gene encodes for 
Kinesin Light Chain 1 which transports various 
cargos such as vesicles, mitochondria, and the 
Golgi complex along microtubules. An 
immunoblotting study observed decrease 
expression of kinesin light chains (KLCs) in the 
frontal cortex of AD subjects but not in the 
cerebellum of the same subjects [61]. TUBA1A 
gene encodes for Tublin Alpha 1a, which has 
been observed to be perturbed in AD [62], and 
CLTA gene encodes for clathrin Light Chain A, 
which has been observed to be perturbed in AD 
as well [63]. COX6C and SLC25A5 gene encodes 
for products which interact with mitochondria 
and mitochondrial dysfunction in AD has been 
suggested on numerous occasions [45,64,65]. 
We identified an additional three AD-specific 
genes (UBA1, EIF4H and CLDND1) which were 
significant DE in all four brain regions. However, 
the genes were down-regulated in the TL FL and 
PL but up-regulated in the CB brain region. 
Ubiquitin-Like Modifier Activating Enzyme 1 
(UBA1) encodes for a protein that catalyses the 
first step in ubiquitin conjugation to mark 
cellular proteins for degradation. Eukaryotic 
Translation Initiation Factor 4H (EIF4H) encodes 
for a translation initiation factors, which 
functions to stimulate the initiation of protein 
synthesis at the level of mRNA utilisation and 
Claudin Domain Containing 1 (CLDND1) is a 
transmembrane protein of tight junctions 
found on endothelial cells [66]. As the 
cerebellum is the only brain region spared from 
tangle formation and occasionally from plaque, 
we suggest these 19 genes (ALDOA, GABBR1, 
TUBA1A, GAPDH, DNM3, KLC1, COX6C, ACTG1, 
CLTA, SLC25A5, PRNP, FDFT1, RHOQ, B2M, 
SPP1, WAC, UBA1, EIF4H and CLDND1)) could 
potentially be associated with AD 
histopathology.  
Translation of proteins perturbed 
specifically in AD brains 
Functional gene set enrichment analysis of the 
“AD expression profile” revealed more 
pathways were significantly perturbed in the 
TL, followed by the FL, PL and CB, which is the 
general route AD pathology is known to spread 
through the brain. We originally observed ten 
biological pathways being enriched across all 
AD brain regions, which included biological 
pathways likely to be irrelevant such as the 
“digestive system”. However, when 
incorporating transcriptomic information from 
non-AD disorders, we were able to refine the 
AD expression signature to specific genes 
perturbed in AD only. This resulted in the 
enrichment of pathways only involved in the 
“metabolism of proteins”, specifically the 
translation process which has been previously 
suggested in be associated with AD on 
numerous occasions [10,11,14–17] We now 
suggest this may be a biological process 
specifically disrupted in AD brains, and not BD, 
HD, MDD, PD or SCZ brains. 
Previous biological perturbations observed 
in AD are only associated with the 
temporal lobe brain region. 
Previous AD studies have consistently 
suggested the immune response [10–13] 
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protein transcription/translation regulation 
[10,11,14–17], calcium signalling [10,18,19], 
MAPK signalling [7,16] chemical synapse 
[7,18,19], neurotransmitter [11,18,19] various 
metabolism pathways [11,16,17,20–23] are 
disrupted in AD. We observe the same 
pathways enriched in our meta-analysis; 
however, only in the TL brain region, a brain 
region often heavily investigated in AD. Except 
for “metabolism of proteins”, we did not 
observe any of these pathways significantly 
enriched across all of the four brain regions, 
suggesting these pathways observed to be 
perturbed in previous studies may be tissue-
specific rather than disease-specific. 
Interspecies interactions possibly involved 
in AD 
Gene Ontology analysis on the “AD expression 
profile” identified nine different biological 
components enriched across all four brain 
regions. However, when we remove genes 
perturbed in other neurological or mental 
health disorders, we only observe four 
biological components as significantly enriched, 
and all four were indicative of interspecies 
interactions. AD brains have a prominent 
inflammatory component which is 
characteristic of infection, and many microbes 
have been implicated in AD, notably herpes 
simplex virus type 1 (HSV1), Chlamydia 
pneumonia, and several types of spirochaete 
[67]. A very recent study also identified 
common viral species in normal and ageing 
brains, with an increased human herpesvirus 
6A and human herpesvirus 7 in AD brains [68]. 
Furthermore, Aβ has been suggested to be an 
antimicrobial peptide and has been shown to 
protect against fungal and bacterial infections 
[69]. Thus, the accumulation of Aβ may be part 
of the brains defence mechanism against 
infections. Although a controversial theory, we 
also observe a viral component in AD brains, 
and as a result of this meta-analysis, further 
suggest this maybe AD-specific and warrants 
further investigation. 
Network analysis identifies AD-specific APP 
UBC and SUMO2 hub genes 
Network analysis identified five (APP, 
HSP90AA1, UBC, SUMO2 and RPS2) significant 
hub genes specific to AD brain regions. APP, 
UBC and SUMO2 gene appear as hub genes in 
multiple brain regions. The APP gene encodes 
for a cell surface receptor transmembrane 
amyloid precursor protein (APP) that is cleaved 
by secretases to form a number of peptides. 
Some of these peptides are secreted and can 
bind to the acetyltransferase complex 
APBB1/TIP60 to promote transcriptional 
activation, while others form the protein basis 
of the amyloid plaques in AD brains. In addition, 
two of the peptides are antimicrobial peptides, 
having been shown to have bactericidal and 
antifungal activities [provided by RefSeq, Aug 
2014]. Changes in APP functions have been 
suggested to play an essential role in the lack of 
AB clearance, ultimately leading to the 
formation of plaques [70]. 
UBC (ubiquitin-C) gene encodes for a 
Polyubiquitin-C protein which is part of the 
ubiquitin-proteasome system (UPS), the 
primary intracellular protein quality control 
system in eukaryotic cells. UPS has an immense 
impact on the amyloidogenic pathway of APP 
processing that generates Abeta [71]. A recent 
GWAS study identified UBC as a novel LOAD 
gene, and through network analysis also 
identified UBC as a key hub gene. The study 
validated their findings in a UBC C. elegans 
model to discover UBC knockout accelerated 
age-related AB toxicity [72]. We also observe 
the UBC gene being down-regulated and as a 
key hub gene in multiple regions of human AD 
brains, further providing evidence of its key role 
in AD. 
Small Ubiquitin-Like Modifier 2 (SUMO2) gene 
encodes for a protein that binds to target 
proteins as part of a post-translational 
modification system, a process referred to as 
SUMOylation [73]. However, unlike ubiquitin, 
which targets proteins for degradation, this 
protein is involved in a variety of cellular 
processes, such as nuclear transport, 
transcriptional regulation, apoptosis, and 
protein stability [provided by RefSeq, Jul 2008]. 
Early studies have indicated that the SUMO 
system is likely altered with AD-type pathology, 
which may impact Aβ levels and tau 
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aggregation [73]. Genetic studies have 
supported this theory with a GWAS study 
linking SUMO-related genes to LOAD [74], with 
further studies showing that the two natively 
unfolded proteins, tau and α-synuclein, are 
sumoylated in vitro [75]. We identified SUMO2 
as a significant key hub gene in both the human 
TL and the CB brain region. However, what 
makes this discovery interesting is that SUMO2 
is significantly up-regulated in the TL, a region 
where both plaques and tangles can be 
observed, but significantly down-regulated in 
the CB, where only plaques have been 
occasionally observed, but tangles never 
reported. The up-regulation of SUMO2 gene 
may play a vital role in the formation of tangles, 
and further investigation into this gene is 
warranted. 
Limitations 
Although this study presents novel insights to 
AD-specific transcriptomic changes in the 
human brain, limitations to this study must be 
addressed. Firstly, we meta-analysed a total of 
22 AD and 21 non-AD datasets, and many of 
these datasets lacked necessary experimental 
processing or basic phenotypic information 
such as technical batches, RNA integrity 
numbers (RIN), age, NFT’s, clinical gender, or 
ethnicity, all of which can have confounding 
effects. To address this, we incorporated 
recommended best practices to estimate and 
correct for both known and hidden batch 
effects using SVA and COMBAT to ensure data 
is comparable between experiments and 
studies. However, this does not guarantee that 
all technical variation is completely removed. 
Secondly, the terminology used to label brain 
tissue varied across studies, with some 
reporting a broad region such as the 
“hippocampus” used in study E-GEOD-48350, 
while others were particular to the tissue layer, 
such as “hippocampus CA3” in study E-GEOD-
29378. We, therefore, decided to map all brain 
tissue as mentioned in each dataset publication 
to their hierarchical cerebral cortex lobe (TL, FL 
and PL) and the CB. The mapping procedure 
was completed using publicly available 
literature defined knowledge, and we assume 
tissues within these brain regions are relatively 
comparable to infer AD-associated 
histopathological changes.  
Thirdly, this study relied on publicly available 
transcriptomic data, and as previous research 
has heavily investigated brain regions known to 
be at the forefront of disease manifestation, 
this led to unbalanced datasets per brain region 
in both the AD and non-AD meta-analysis. 
Subsequently, the AD meta-analysis consisted 
of 14, 4, 2, and 2 datasets for the TL, FL, PL and 
CB brain regions respectively, with the PL brain 
region consisting of only 74 samples (28 AD and 
46 controls) in total. In addition, the non-AD 
meta-analysis lacked expression signatures 
form all non-AD diseases across all brain 
regions (except for FL). Nevertheless, the brain 
regions most affected by each disorder was 
captured in this study, suggesting we most 
likely were able to capture key brain 
transcriptomic changes relating to each 
disorder. Furthermore, as AD is known to affect 
all brain regions, albeit not to the same extent, 
we focus on transcriptomic changes observed 
across all brain regions that are also not 
observed in any brain region of the non-AD 
subjects, ensuring we capture transcriptomic 
signatures unique to AD brains.  
Fourthly, the advances in next sequencing 
technologies (RNA-Seq) which are capable of 
profiling the whole transcriptome, thus not 
limited by the pre-defined probes based on 
known sequencing, would be ideal for disease 
discoveries. However, AD and mental health 
studies profiled through RNA-Seq is somewhat 
limited in the public domain, and those that 
have published DE results are based on small 
sample numbers, which would fail our selection 
criteria, such as [76–79]. In addition, these 
studies lack the same brain regions and mental 
health disorders covered in this meta-analysis. 
Nevertheless, we were able to query our genes 
of interest in the largest known AD RNA-Seq 
web-based database (Agora) which contains DE 
results from over 2100 human brain samples; 
however, expression profiling was unavailable 
for 17/26 genes, and DE on the parietal lobe 
was unavailable. Therefore, this study was 
unable to validate all findings in RNA-Seq data 
and additional experimental validation, such as 
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RT-PCR is still required to support this study’s 
results. 
Finally, we assume the non-AD datasets are 
comparable through meta-analysis, and by 
identifying common expression signatures that 
are not associated with individual disease 
mechanisms may represent false positives or 
even a general signature for “brain disorder”. 
Removing this signature from the AD meta-
analysis expression profile may result in 
transcriptomic changes specific to AD brains, 
revealing more relevant changes to the 
underlying disease mechanism rather than 
general diseases. Under this assumption, we 
observe more relevant and refined biological 
enrichment results. For example, we originally 
observed ten biological pathways enriched 
across all AD brain regions, including biological 
pathways such as the “digestive system”. 
However, by refining the AD expression 
signature by removing genes perturbed in non-
AD disorders, only pathways involved in the 
“metabolism of proteins” remain, which has 
been previously suggested in be associated 
with AD on numerous occasions [10,11,14–17] 
This observation provides strong evidence of 
our assumption of incorporating non-AD 
diseases in this study to infer AD-specific 
changes as valid. 
Conclusion 
We present the most extensive human AD brain 
microarray transcriptomic meta-analysis study 
to date, incorporating, brain regions both 
affected and partially spared by AD pathology, 
and utilise related non-AD disorders to infer 
AD-specific brain changes. This led to the 
identification of seven genes specifically 
perturbed across all AD brain regions and are 
considered disease-specific, nineteen genes 
specifically perturbed in AD brains which could 
play a role in AD neuropathology, and the 
refinement of GSEA and GO analysis results to 
identify specific biological pathways and 
components specific to AD. These AD-specific 
changes may provide new insights into the 
disease mechanisms, thus making a significant 
contribution towards understanding the 
disease.  
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The supplementary material is available in the 
electronic version of this article: 
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3.1 Additional limitations: risks of biases 
Chapter 3: Analysis of Alzheimer's Disease brain transcriptomic data, is an article which was published 
in the Journal of Alzheimer’s Disease. The following is a discussion of the risks and biases associated 
with the study that was not included in the original publication. Bias in research is the systematic error 
or deviation from the truth in data collection, data analysis and result interpretation that leads to a false 
conclusion (Šimundić, 2013). This study combined novel and existing AD and non-AD (PD, BD, 
Schizophrenia, MDD and HD) brain microarray gene expression studies to infer AD specific changes. The 
complexity of this study leaves it open to the introduction of unintentional biases.  
The first step in this study was data collection. The data used in this study was already expression 
profiled, with no direct input into the population selection or gene expression profiling process. The 
AD, PD, BD, Schizophrenia and HD samples are assumed to be a good representation of their respective 
population, however, without the appropriate information on data collection and associated 
phenotypic information, it cannot be ruled out these samples are a misrepresentation of their 
respective population, which would inadvertently introduce biases into the data collection and 
interpretation. For instance, sample collection, admission, and misclassification biases can be 
introduced if AD patients were diagnosed across different studies using different cognitive tests or 
varying test cut-off points (Storandt and Morris, 2010). Furthermore, without detailed phenotypic 
information on diagnosis date, it is unknown if survivor bias exists in the data. For instance, AD samples 
were only retained if BRAAK staging was ≥ 3, however, it is unknown how long the subjects were 
diagnosed with AD prior to death. Therefore, newly diagnosed AD subjects at BRAAK stage 6 may be 
analysed with long term AD subjects who are slow progressors or stable AD subjects with only BRAAK 
stage 3 pathology. This would inadvertently introduce disease heterogeneity into the mix. 
Dataset selection criteria were in place to ensure only comparable datasets were acquired, reducing 
dataset biases. These criteria were (1) data must be generated from a neurodegenerative or mental 
health disorder, which would restrict to diseases that affect the brain. (2) be sampled from human brain 
tissue, restricting to tissues known to be affected by the disease. (3) have gene expression measured 
on either the Affymetrix or Illumina microarray platform, restricting to platforms that are comparable 
(Barnes et al., 2005; Chen et al., 2007; Consortium, 2008; Maouche et al., 2008). (4) contain both 
diseased and suitably matched healthy controls in the same experimental batch, avoiding the 
introduction of batch effects (Chen et al., 2011; Taminau et al., 2012; Lazar et al., 2013) and (5) contain 





Another source of potential bias is the tissue source itself. This study relied on publicly available data, 
with many studies heavily investigating brain regions known to be at the forefront of disease 
manifestation, leading to unbalanced datasets per brain region in both the AD and non-AD disorders. 
This led to the AD meta-analysis consisting of 14, 4, 2, and 2 datasets for the TL, FL, PL and CB brain 
regions respectively. In addition, the non-AD meta-analysis lacked expression signatures across all brain 
regions (except FL) in the non-AD disorders. This introduces a tissue source bias where different 
diseases affect different tissues, hence, comparing similar tissue sources for different diseases may not 
reflect disease pathologies. However, the brain regions most affected by each disorder was captured 
in this study, and as AD is known to affect all brain regions, albeit not to the same extent, the focus on 
transcriptomic changes observed across all brain regions that are also not observed in any single brain 
region of the non-AD subjects, potentially addresses the tissue source bias. 
Data analysis can be a common source of bias. For instance, when numerous methods are applied to 
the same data until a preferred result and/or statistically significant result is obtained  (Šimundić, 2013). 
To avoid this type of bias, this study performed a literature review before data acquisition, to identify 
the most appropriate data processing and meta-analysis approaches to apply to the data. The methods 
applied in this study are discussed in section 1.8. Confounding variables are also a common source of 
biases during data analysis. Known variation in the data such as demographics (age and gender) can be 
accounted for during data analysis, however, the effect of unmeasured or unknown confounders can 
only be controlled by true study randomization (Pannucci and Wilkins, 2010). Due to the nature of the 
data, detailed information on each study including demographics and technical variations were 
somewhat limited. Therefore, to address unwanted variation, SVA and COMBAT were incorporated into 
the data processing procedure to estimate and eliminate variation not associated with diagnosis and 
gender. However, this does not guarantee that all technical variation is completely removed, and 
confounding biases may still remain in the data. 
To avoid data interpretation biases, a fixed significant threshold (adjusted p-value ≤ 0.05) was used 
throughout this study to identify significant results. Genes identified as significantly and specifically 
perturbed in AD were further investigated in an independent dataset that was sequenced with superior 
sequencing technologies (RNA-Seq). This validation process adds a layer of certainty that results 
identified as significant by both technologies may not be by chance. 
There are numerous sources of bias that can be introduced in research. This study took the relevant 
steps in order to reduce or eliminate the possibility of biases; nevertheless, unintentional biases may 
still exist, particularly within the data collection process, where no input or detailed phenotypic 




dataset sequenced using next-generation technologies; however, like many research output, further 





 Chapter 4: Automated drug-repositioning from a disease 
expression signature  
 
4.1 Background 
To date, no disease-modifying treatment is clinically available for AD. However, symptomatic relief is 
available in the form of three cholinesterase antagonists (donepezil, rivastigmine and galantamine), and 
an N-methyl-D-aspartate (NMDA) inhibitor known as memantine. These drugs only provide temporary 
symptomatic relief, do not modify the underlying disease pathology, and do not have the same effect 
in all patients (Calciano et al., 2010; Anand, Gill and Mahdi, 2014).  
4.1.1 AD drug discovery 
There is a high failure rate for AD drug discovery, with more than 99% of clinical trials showing no 
difference between the compound of interest and the placebo, while disease-modifying therapies have 
a 100% failure rate (Cummings, Feldman and Scheltens, 2019). Drugs require specific characteristics to 
be viable as scalable treatment option for diseases, such as its toxicity, absorption, distribution, 
metabolism and excretion. However, for AD, an additional property is required which enables the 
compound to penetrate the BBB. This can complicate preclinical trials as the human BBB and its 
properties may not be present in animal AD model’s, and therefore a compounds effect in animal 
models may not be reflected in human clinical trials (Cummings, Feldman and Scheltens, 2019). 
One of the major challenges in AD drug discovery has been to identify the right druggable target. The 
current successful treatments for AD have all targeted the cholinergic system. However, since the 
underlying cause of the disease is currently unknown, it’s been extremely difficult to develop 
treatments to reverse or even halt the neuropathological process of AD. The central causal hypothesis 
for AD involves the amyloid and tau cascade, which naturally became therapeutic targets. However, 
drugs targeting these systems have so far failed. Identifying the right participants in AD clinical trials is 
an additional important process and has most likely contributed to the lack of suitable compounds 
identified for AD treatment. Studies have shown many AD diagnosed patients lack Aβ deposition, with 
one study showing 25% of subjects diagnosed with mild AD lacked evidence of Aβ plaques when 
investigated with amyloid PET (Sevigny et al., 2016). Therefore, these patients may not respond to 
compounds targeting AD pathology. 
The development of new compounds targeting AD remains an important health goal. The current 
failures in AD clinical trials have been suggested to be caused by (1) wrong drug, (2) wrong dose, (3) 




wrong stage of disease (i.e., “too late” or “too early”), (8) problems with recruitment and retention, (9) 
unacceptable tolerability, (10) wrong conceptual model of the disease, (11) wrong patients, and/or (12) 
poor study conduct (Khachaturian et al., 2018). 
4.1.2 Drug repositioning 
The primary strategy for drug development was to screen multiple molecules for a single therapeutic 
target. However, the ratio of successful drugs identified against the total number of drugs has declined 
dramatically through the years (Iorio et al., 2013). The typical time for an AD drug development program 
takes 13 years and costs an estimated £4.4 billion (Cummings, Reiber and Kumar, 2018). Drug 
repositioning (also referred to as drug repurposing) can provide an alternative strategy, where Food 
and Drug Administration (FDA) approved drugs are repurposed for new therapeutic targets, reducing 
the costs and time associated with drug development, whilst making the process accessible to academic 
centres along with pharmaceutical and biotechnology companies. Drug repositioning has been 
successfully applied to a variety of diseases, including cancer, cardiovascular disease, stress 
incontinence, irritable bowel syndrome, obesity, erectile dysfunction, smoking cessation, psychosis, 
attention deficit disorder and Parkinson's disease (Corbett et al., 2012).  
Typically, there are three types of drug repositioning strategies; computational approaches, biological 
experiments, and mixed approaches (Xue et al., 2018). Computational approaches can be further 
subcategorised into knowledge-based and signature-based drug repositioning. Knowledge-based drug 
repositioning uses predetermined information such as drug-target, chemical structures, adverse effects 
and pathways to predict unknown mechanisms, targets or biomarkers for diseases (Yella et al., 2018). 
In contrast, signature-based drug repositioning compares gene expression profiles from drugs directly 
to the target diseases to identify candidate compounds, which is the focus of this chapter.  
Publicly available gene expression repositories such as GEO (Barrett et al., 2013) and ArrayExpress 
(Brazma et al., 2003) provide a wealth of disease expression profiles, while the Connectivity Map 
(CMap) (Lamb et al., 2006) and Library of Integrated Network-based Cellular Signatures (LINCS) 
(Subramanian et al., 2017) databases provide the most extensive publicly available drug-induced gene 
expression profiles. The CMap and LINCS databases contain transcriptomic profiles of dozens of cell 
lines treated with thousands of chemical compounds and can serve as “reference” databases. These 
databases provide a computational opportunity for gene-expression-based drug repositioning for many 
disorders, including AD.  
4.1.2.1 The Connectivity Map 
The CMap was first introduced in 2006 (Lamb et al., 2006), with the idea to become a web-based 




profiling which can be queried using a disease-specific gene expression signature. The initial database 
consisted of 164 small molecules (referred to as compounds in this thesis) and was named CMap build 
01. The updated build 02 consists of 1309 compounds. All experiments were performed on the 
Affymetrix microarray platform using the HT_HG_U133A (22,283 probesets), HG_U133A (22,277 
probesets) or HT_HG_U133A_EA (21,607 probesets) GeneChips. The experiments were performed on 
five different cell lines which included; MCF7, ssMCF7, HL60, PC3 and SKMEL5. The MCF7 cell line is 
human breast epithelial adenocarcinoma, ssMCF7 is MCF7 cell lines cultured in phenol red-free DMEM, 
HL60 is a human promyelocytic cell line, PC3 is epithelial cell line from human prostate 
adenocarcinoma, and SKMEL5 is a human malignant melanoma cell line. The experiments were 
performed multiple times (batches), occasionally using the same compound at different 
concentrations, resulting in over 6000 instances (compound expression profiles). Each batch consisted 
of at least one calibrator compound that was referred to as the “vehicle control”. Following 
standardised pre-processing of the raw data using MAS 5.0, gene fold change in each instance was 
calculated using the “vehicle control” as a comparison, genes were then ordered by decreasing fold 
change and assigned a rank. Thus, for a single instance expression profiled on the HT_HG_U133A 
GeneChip, the gene ranked one will be the most up-regulated gene while the gene ranked 22,283 would 
be the most down-regulated gene. 
A disease-gene signature is calculated using the standard differential expression analysis, with the 
DEG’s split into two lists; one containing up-regulated genes while the second contains down-regulated 
genes. Only the top 500 genes in each list can be queried in the current CMap database using a rank-
ordered Kolmogorov–Smirnov (KS) test to calculate a connectivity score, which is further normalised 
using random permutations. The refined connectivity score ranges from -1 to +1 where positive 
connectivity results indicate the corresponding instance induced a similar expression profile to the 
disease, while a negative connectivity score indicates the corresponding instance repressed the 
expression profile of the disease. The degree of positive/negative connectivity scores also reflects how 
strongly related the disease and drug has been calculated according to the KS algorithm, while the 
permutation test assigns a statistical significance (Musa et al., 2018). 
Several studies have used the CMap to identify candidate compounds to treat several disorders  (Musa 
et al., 2018), including AD (Williams, 2012; F. Chen et al., 2013; Fowler et al., 2015; Siavelis et al., 2016b), 
with a few experimentally validating the candidate compound to show association with the target 
disease. For instance, a study queried a gastric cancer gene expression signature in the CMap, resulting 
in histone deacetylase inhibitors vorinostat and trichostatin A being identified as candidate compounds. 
The authors experimentally validated vorinostat in vitro using cancer cell lines to demonstrate the 




2014). However, to date, no literature has been found to demonstrate drug repositioning using the 
CMap has resulted in candidate compounds being clinically used to treat diseases. 
4.1.2.1.1 The CMap Limitations 
The CMap has many limitations, with a significant drawback being the processing of the raw data. The 
CMap data were initially processed using MAS 5.0 background correction, which removes the Mismatch 
(MM) probe intensity from the multiple Perfect-Match (PM) intensity for each transcript to calculate 
an expression value for each probe independently. However, this has been reported to increase 
variation at low signal strengths, which has been suggested to be a result of non-specific binding of the 
MM probes (Irizarry et al., 2003). Alternative methods, such as RMA can result in more accurate 
expression values and have been suggested to be superior to MAS5.0 during DE analysis (Jiang et al., 
2008), which is the foundation of drug repositioning the CMap. In addition, the use of a single “vehicle 
control” within each instance batch cannot account for technical and biological variation, which can be 
addressed by grouping replicated instances and performing differential expression analysis against the 
average change observed from a group of controls. 
Furthermore, the CMap restricts users to query only 500 genes which can only consist of genes 
perturbed in the same direction, i.e. be either up or down-regulated. The current method of querying 
two separate gene lists will identify two separate lists of candidate compounds and will not take into 
consideration all the genes further perturbed by a drug or disease. For instance, querying a disease 
signature where gene A is up-regulated, and gene B is down-regulated in the current CMap database, 
may suggest candidate compound X which down-regulates the gene A. However, the current method 
does not take into consideration if compound X also further down-regulates gene B, which may further 
exacerbate the disease. Therefore, it is vital to consider all genes perturbed in a disease when 
identifying suitable candidate compounds, thus, using a single disease expression signature to query 
the CMap may be more effective in identifying relevant candidate compounds. 
4.1.2.2 The Library of Integrated Network-based Cellular Signatures 
The Library of Integrated Network-based Cellular Signatures (LINCS) database expands on the CMap 
database by providing approximately one million gene expression profiles generated from 22,412 
different perturbations applied to 56 different cellular contexts, including 5806 genetic perturbations 
such as single-gene knockdowns or overexpression (Duan et al., 2014). The LINCS data was generated 
using the L1000 technology, which is a high-throughput method to estimate genome-wide mRNA 
expression by measuring only 1000 genes and imputing the remaining 22,000 genes based on 
expression patterns observed in GEO. This makes the LINCS approach a cost-effective method for 




4.1.2.2.1 The LINCS Limitations 
The database relies on technology which directly measures the expression of a relatively small number 
of genes, which is then imputed approximately 22-fold using both internal and external information. 
Gene expression reproducibility has always been questionable, with studies reporting low 
reproducibility at gene level across studies with identical samples (Zhang et al., 2008). Relying on low 
reproducible expression data to infer expression of unknown genes can inevitably lead to poor 
imputation. A systematic review on the LINCS data observed 80% correlation between the L1000 and 
Affymetrix platform generated data prior to LINCS data imputation, however, once L1000 was imputed, 
the overlap of differentially expressed genes was only 30% (Musa et al., 2018). The study concluded 
that a robust QC pipeline is required to process the LINCS data prior to addressing biological questions, 
and therefore, due to the issues surrounding the reliability of the LINCS database, this chapter only 
incorporates the CMap. 
4.1.3 Alternative approaches to drug reposition the CMap 
The potential capability and pitfalls of the CMap have been widely recognised, leading many studies to 
reprocess the CMap data and query using alternative algorithms. Some of the more common 
approaches are briefly discussed below. 
4.1.3.1 ssCMap: Statistically significant connectivity map  
Zhang et al. developed a method named statistically significant connectivity map (ssCMap) that 
implemented additional permutation to decrease the number of false positives. They assigned a new 
ranking system based on gene expression change between the compound and the control vehicle, 
where all genes are ranked including both up and down-regulated genes into one list. Unlike the current 
CMap method, this would allow the query expression signature to contain both up and down-regulated 
genes during the matching process. Following a connection scoring process, compounds are assigned 
values of -1 to +1 in relation to the input query signature, where +1 indicates similar expression profiles 
and -1 indicates inversely correlated expression profiles.  
The method was validated using a random 25 probe gene expression signature in both the CMap and 
ssCMap database. The hypothesis here is that this expression signature is random and should not find 
any significantly relevant compounds. The CMap database identified 113 candidate compounds with 
positive connectivity scores and 83 with negative connectivity scores. In contrast, the ssCMap database 
identified no significant candidate compounds, suggesting the ssCMap reduces false positives (Zhang 
and Gant, 2008). Further validation for sensitivity was performed using an independent gene expression 
signature of HDAC inhibitors, estrogens and immunosuppressive drugs, with results indicating ssCMap 




4.1.3.2 CMapBatch: A meta-analysis of drug response 
Fortney et al. adapted an established meta-analysis framework to analyse multiple gene expression 
signatures of disease in parallel. The method, named CMapBatch, attempts to address the 
heterogeneity issue of gene expression data where different gene signatures from the same disease 
often show poor reproducibility across studies (Fortney et al., 2015). The method applies multiple gene 
expression signatures obtained from independent studies to the web-based CMap portal, resulting in 
multiple lists of candidate compounds which are combined and ranked based on how highly the 
compound was ranked in individual results. The authors validated their framework using 21 previously 
published lung cancer studies, which identified 247 candidate compounds. The authors used 
independent growth inhibitor data to demonstrated that compounds identified through CMapBatch 
were significantly better at inhibiting growth than other CMap compounds. 
4.1.3.3 ProbCMap: Probabilistic drug connectivity mapping 
Pakkinen and Kaski focused on common and distinct gene expression changes of the same compound 
on multiple different cell lines to create a probabilistic connectivity map (ProbCMap) (Parkkinen and 
Kaski, 2014). The ProbCMap is based on correlations of compounds across tissues, with the ultimate 
goal to identify functional and chemically similar compounds. The method was evaluated on 718 
compounds in CMap that were profiled across three different cell lines. Compounds were compared to 
one another using the probabilistic score, with the external Anatomic Therapeutic Chemical (ATC) 
classification codes used to validate connectivity, where an ATC code of four indicates compounds share 
similar functionality (Parkkinen and Kaski, 2014). 
4.1.3.4 cudaMap: a GPU accelerated program for gene expression connectivity mapping 
The current and extended methods to query the CMap have failed to address the computational load 
for analysis, particularly with the repeated permutation tests. This issue is addressed by a study which 
harnessed the computational power of NVIDIA Graphics Processing Units (GPUs) to reduce the 
processing times for data analysis (McArt et al., 2013) and presented their high-performance computing 
(HPC) models as a software platform called the cudaMAP. The authors further demonstrated that the 
ssCMap approach on this platform was capable of analysing multiple gene expression signatures in a 
matter of minutes rather than days. Although the cudaMAP is not a new method to query the CMap 
database, it addresses one of the significant issues surrounding computational drug repositioning, the 
computational demand. 
4.1.3.5 SPIED: a searchable platform-independent expression database  
The searchable platform-independent expression database (SPIED) compiles expression profiles from 




compounds (Williams, 2012). The database contains over 100,000 samples and includes experiments 
that lack controls. The author addresses the no control reference issue by generating fold change 
profiles using the experimental series average as a reference and uses a simple regression scoring 
scheme to match diseases to candidate compounds. The method essentially searches for anti-
correlated disease signatures to candidate compounds in the CMap. 
The authors initially validated their method by illustrating estrogen transcriptional response was anti-
correlated to estrogen antagonists fulvestrant (R2=-0.76), tamoxifen (R2=-0.46) and raloxifene (R2=-
0.63). Further validation was performed by combining AD disease signatures from human and rodent 
brains, which identified 24 genes that were conserved in the disease. Using this small AD expression 
profile in the SPIED identified galantamine (R2 = -0.34) as the 19th most significant result, a compound 
that is clinically prescribed to AD patients. However, the correlation of -0.34 can be interpreted as a 
weak-moderate negative correlation (Rumsey, 2011), and as the 19th most significant result from drug 
repositioning, may ordinarily be overlooked when querying a disease with unknown treatment. 
Furthermore, the published peer-reviewed portion of this thesis has identified hundreds of genes 
perturbed in AD (Patel, Dobson and Newhouse, 2019) and a simple 24 gene expression marker cannot 
account for all perturbations in AD and therefore would be inadequate for validation purposes. 
4.1.4 Summary 
Drug repositioning using the CMap database is potentially a useful approach to identify candidate 
compounds for disease intervention. However, many new methods focus on developing new, quicker 
and sophisticated techniques to query the CMap database, rather than addressing the quality of the 
initial data. The CMap has potential pitfalls in data quality, particularly the outdated processing 
methods used to QC the data, which needs to be addressed prior to developing algorithms to query the 
data. Furthermore, many methods lack robust computational validation, which can be evaluated by 
both drug-drug and disease-drug relations (Musa et al., 2018). In drug-drug validation, a drug signature 
is queried through CMap to determine if the method retrieves compounds with similar chemical 
structure, while in disease-drug relations, a disease gene expression signature with treatment available 
in the CMap is queried to determine whether the method can identify candidate compounds that are 
already being clinically used to treat the disease in question. 
This chapter attempts to address the current issues surrounding drug repositioning the CMap. First, the 
raw CMap data is re-processed using up-to-date robust pre-processing techniques. Next, inspired by 
previous research, different algorithms are developed to incorporate both up and down-regulated 
genes to search the reprocessed CMap database for candidate compound identification. The methods 




the best-equipped method for drug repositioning the CMap. Finally, two AD brain disease signatures 
identified in this thesis; one from AsymAD brains and the second from AD brains will be queried in the 
CMap to identify candidate compounds that may potentially intervene at both the asymptomatic and 
symptomatic stage of the disease. The work undertaken in this chapter is purely exploratory with all 
candidate compounds requiring further experimental investigations. 
4.2 Method 
4.2.1 The CMap data processing 
The raw CMap intensity data (build 02) was manually downloaded from 
https://portals.broadinstitute.org/cmap/ in August 2016. The data consisted of small compounds 
expression profiled across five different cell lines and on three different Affymetrix expression chips 
(see background section “The Connectivity Map” for additional details).  
Each cell line and expression chip was processed independently in RStudio (version 1.1.447) using R 
(version 3.4.4). The raw gene expression data were first pre-processed using the R package “gcrma” 
(version 2.50.0), which Robust Multi-Array (gcRMA) background corrects, log2 transforms, and then 
quantile normalises the data. Next, to account for technical and latent variation between batches due 
to the CMap experimental design consisting of small batches of 2-5 samples, batch effects were 
explored and adjusted by SVA using the R package “sva” (version 3.10.0). Drug-repositioning in this 
thesis was based on DE results, which is performed between two experimental groups. Therefore, 
compounds that lacked multiple expression profiles repeated at the same concentration were removed 
from further analysis. 
Next, to ensure homogeneity within the control group, outlying samples were iteratively identified and 
removed using the fundamental network concepts described in (Oldham, Langfelder and Horvath, 
2012). Then, to enable cross-platform probes to be comparable, Affymetrix platform-specific probe 
identifiers were annotated to their corresponding universal Entrez gene identifiers using the 
“hgu133a.db” R annotation file. Finally, DE analysis was performed using the R package “limma” 
(version 3.20.9) (Smyth, 2005). 
4.2.2 Drug-Disease mapping 
The Therapeutic Targets Database (TTD) is enriched with information on drug-disease relations, 
including compounds that are FDA approved to treat specific diseases (Yang et al., 2016). The TTD was 
acquired in June 2017 and contained drug-disease mappings for 31,614 compounds. The compounds 
in the CMap database were annotated to the TTD to identify the diseases that the CMap compounds 




4.2.3 Method development to query the CMap database 
Four methods were developed to query the re-processed CMap database. Each method requires the 
disease gene expression signature in the format output from differential expression analysis. The 
general idea behind each method was to identify compounds that may “neutralise” the disease 
expression signature queried. Unlike the original CMap algorithm, the developed methods are not 
limited by 500 genes and allow all genes perturbed in the disease signature, including up and down-
regulated genes, to be simultaneously queried in the CMap database to identify candidate compounds. 
A “candidate compound” is a compound deemed as a significant result by any method used to query 
the CMap. The four methods developed are “bi-directional enrichment”, “anti-correlation”, “ranked 
genes”, and a “pathway-based” approach. 
4.2.3.1 Method 1: Bi-directional enrichment method development 
This method was inspired by the typical GSEA approach. It uses an enrichment test to assess the overlap 
between the DEG’s in a disease signature and DEG’s in every CMap compound, with the added 
modification of identifying inverse relation, i.e. matching compounds where the gene is significantly 
perturbed in the opposite direction to that from the disease. 
First, the CMap reference database was prepared. For each compound, an “UP” was appended to the 
gene name if the gene’s logFC was positive and a “DOWN” was appended to the gene name if the 
gene’s logFC was negative. For instance, if gene “A” was up-regulated, and gene “B” was down-
regulated than the gene names would be changed to “A_UP” and “B_DOWN” respectively. Then, the 
gene list for all CMap compounds was filtered to only those that were significantly differentially 
expressed (FDR adjusted p-value ≤ 0.05).  
Next, the disease signature was prepared. The disease-gene list is first subset to only significant DEG’s 
(FDR adjusted p-value ≤ 0.05) to create the disease signature profile. Next, similar to the CMap 
reference database, an “UP” and “DOWN” was appended to the gene names; however, as an anti-
relation between disease and drug was required, the criteria was reversed. Thus, an “UP” was 
appended to a gene when the logFC was negative, and a “DOWN” was appended when the logFC was 
positive. For instance, if gene “A” was up-regulated, and gene “B” was down-regulated than the gene 
names would be changed to “A_DOWN” and “B_UP” respectively.  
An enrichment test was performed on the two gene lists using the WGCNA (version 1.51) 
“userListEnrichment” function. This function requires three arguments (“geneR”, “labelR” and “fnIn”). 
The “geneR” argument was a vector of all gene identifiers in the analyses, which includes both the 
DEG’s and background genes that are not perturbed by the drug. Essentially, this was a list of all genes 




“flIn” argument was the DEG’s in the disease signature. The enrichment test was repeated for each 
compound in the CMap using the R packages “foreach” (version 1.4.4) and “doParallel” (version 1.0.11) 
for parallel processing, and results were corrected for multiple testing using FDR.  
4.2.3.2 Method 2: Anti-correlation method development 
This method was inspired by SPIED. It used a simple anti-correlation approach to identify compounds 
where the expression signature is anti-correlated with the disease expression signature. First, the CMap 
reference database was created. The logFC for all genes were converted to +1 if the logFC value was 
positive, or -1 if the logFC value was negative. Next, the disease query signature was prepared. The 
disease genes are first subset to those that are differentially expressed (FDR adjusted p-value ≤ 0.05). 
Then, the logFC values are converted to +1 or -1 using a reversed criteria to that used in the CMap 
database, i.e. the logFC was converted to +1 if the logFC value was negative, or -1 if the logFC value was 
positive. 
Then, using the R “cor.test” function, a Spearman's correlation test was then iteratively performed 
between the disease signature and every compound expression signature in the CMap database. This 
method was repeated for each compound in the CMap database and results were corrected for 
multiple testing using FDR.  
4.2.3.3 Method 3: Ranked gene-based method development 
This method was inspired by the ssCMap algorithm. It incorporates the extent of statistical perturbation 
(p-value) in combination with the magnitude of differential expression (logFC) of the disease gene 
expression signature when identifying candidate compounds. First, the reference CMap database was 
created. The genes for each CMap compound were ordered from the most significantly up-regulated 
gene to the most significantly down-regulated gene. Next, the disease gene expression signature was 
created. The significant DEG’s (FDR adjusted p-value ≤ 0.05) from the disease gene expression signature 
was ordered using a reverse criteria to that used in the CMap reference database so that the most 
significantly down-regulated gene is at the top of the list and the most significantly up-regulated gene 
is at the bottom of the list. 
The Rank-Rank Hypergeometric Overlap (RRHO) test was then used through the R package “RHHO” 
(version 1.18.0) to assess the significant overlap between the disease gene expression signature and 
the CMap reference database. The RRHO algorithm steps through the two gene lists and measures the 
statistical significance of the number of overlapping genes through a hypergeometric enrichment of k 
overlapping genes calculated for all possible threshold pairs (Plaisier et al., 2010). The “RRHO” function 




each compound using the R packages “foreach” (version 1.4.4) and “doParallel” (version 1.0.11) for 
parallel processing the CMap database. 
4.2.3.4 Method 4: Pathway-based method development 
This method uses a system-biology approach to first asses the biological pathways perturbed in the 
disease gene expression signature, then attempts to identify candidate compounds that may intervene 
with the same biological pathways with a reversed effect. For instance, if a disease gene expression 
signature is found to “activate” the “glutamate-glutamine cycle”, then a compound that inhibits the 
same biological pathway is sought after. Therefore, this method is not limited by individual gene overlap 
and looks at the bigger picture of how interactions between different genes may influence biological 
processes and uses this information to create disease-drug relations. 
The method uses the signalling pathway impact analysis (SPIA) to identify biological pathways 
perturbed by each compound. The SPIA method was implemented through the R package “SPIA” 
(version 2.30.0) and uses the human signalling pathways from KEGG (Ogata et al., 1999), which contains 
pathway activation and repression information that was derived from gene and protein signalling and 
interactions (Tarca et al., 2009). The SPIA method combines the evidence obtained from the classical 
enrichment analysis with a novel topology type of evidence to infer actual perturbation of a given 
pathway (Tarca et al., 2009).  
The pathway-based drug repositioning approach begins by creating a reference CMap database. First, 
the SPIA method is iteratively performed on the DEG’s of every compound in the CMap database to 
generate a list of significant (p≤0.05) biological pathways “activated” and “inhibited” by each 
compound. Next, the disease gene expression signature was analysed with SPIA to identify significant 
(p≤0.05) biological pathways “activated” and “inhibited” in the disease. The biological pathway 
perturbations are reversed in the disease signature so “activated” pathways are changed to “inhibited” 
and vice-versa. A standard hypergeometric test using the R function “phyper” was performed on 
pathways labels, which essentially assess the overlap of the number of same pathways being perturbed 
in the disease and by the compound. The resulting p-value is corrected for multiple testing using FDR. 
The output of this method specifies the number of biological pathways perturbed in the disease and a 
list of compounds with respective biological pathways it may correct with a corresponding p-value.  
4.2.4 CMap database query algorithm validations 
The four methods developed to query the CMap database were validated through two recommended 
techniques; drug-drug relations and disease-drug relations (Musa et al., 2018). The drug-drug relation 




queries a known disease gene expression signature to identify compounds known to interact with the 
disease in question. The drug-rug approach was adapted for this thesis and both are described below. 
4.2.4.1 Drug-drug relation 
Five compounds were randomly selected from the CMap database using the “sample” function in R. 
The five compounds had their gene expression signatures reversed by inverting the logFC signs for all 
genes. The compounds were thereafter treated as “dummy” disease gene expression signatures and 
queried in the CMap database using the four developed methods (“bi-directional enrichment”, “anti-
correlation”, “ranked genes”, and “pathway-based). The underlying hypothesis behind this strategy 
expects the “dummy” disease expression signatures, which have originated from compounds in the 
CMap, should be a perfect match to the same compound in the CMap database, and each method 
should identify this compound as the most statistically significant result, followed by compounds with 
similar properties. This process can be used to validate that the methods are capable of identifying 
compounds where the gene expression signature is a “reverse” match to queried disease gene 
expression signature.  
4.2.4.2 Disease-drug relation 
Disease datasets where the FDA approved treatment was available in the CMap database were sought 
from public repositories ArrayExpress and GEO. The criteria used to identify potential datasets were: 1) 
data must be generated from the Affymetrix or Illumina microarray expression platform, 2) data must 
be generated from a human cell line, 3) dataset must include both diseased and complimentary healthy 
controls in the same experimental match, allowing for differential expression analysis to be performed, 
4) dataset must contain at least 10 cases and 10 controls and 5) dataset description or associated 
publication must explicitly mention the patients were not on any disease-modifying treatment prior to 
sample extraction. 
Microarray gene expression studies were acquired from public repositories using the R package 
“ArrayExpress” (version 1.38.0). Raw gene expression data generated on the Affymetrix platform were 
“gcRMA” background corrected using R package “gcRMA” (version 2.50.0), log2 transformed and then 
quantile normalised. Datasets generated on the Illumina platform were “normexp” background 
corrected, log2 transformed, and quantile normalised using the “limma” R package (version 3.20.9).  
Sex was then predicted using the R package “massiR” (version 1.0.1) and subjects with discrepancies 
between predicted and recorded sex removed from further analysis. Next, within each gender and 
disease diagnosis group, probes above the “X” percentile of the log2 expression scale in over 80% of 
the samples were deemed “reliably detected”. To account for the variation of redundant probes across 




literature defined house-keeping genes were correctly defined as expressed or unexpressed in their 
corresponding gender groups (Chang et al., 2011). Any probe labelled as “reliably detected” in any 
group (based on gender and diagnosis) was taken forward for further analysis from all samples within 
that dataset. This essentially eliminates noise (Lazar et al., 2013) and ensures disease and gender-
specific signals are captured within each dataset.  
Publicly available data is often accompanied by a lack of sample processing information, making it 
impossible to adjust for systematic errors introduced when samples are processed in multiple batches, 
a term often known as “batch effects”. To account for both known and possible latent variation, batch 
effects were estimated and removed by SVA using R package “sva” (version 3.10.0). Next, to ensure 
homogeneity within biological groups, outlying samples were iteratively identified and removed using 
the fundamental network concepts described in (Oldham, Langfelder and Horvath, 2012), followed by 
annotating platform-specific probe ID’s to their corresponding universal Entrez gene identifiers using 
the appropriate R annotation files; “hgu133plus2.db”, “hugene10sttranscriptcluster.db” and 
“illuminaHumanv4.db”. Finally, differential expression analysis was performed using the R package 
“limma” (version 3.20.9) to create the expression signature for each disease, which was queried in the 
CMap database using the four developed methods (“bi-directional enrichment”, “anti-correlation”, 
“ranked genes”, and “pathway-based”).  
The underlying hypothesis behind this validation strategy assumes querying known disease gene 
expression signatures should identify the CMap compounds that are clinically used to treat the disease. 
4.2.5 Identifying candidate compounds for AD 
This thesis explored transcriptomic changes in probable AsymAD brains and identified significant brain 
changes in the FC of AsymAD subjects when compared to healthy controls, suggesting this may be the 
first brain region affected in AD. Further analysis identified a gene expression signature consisting of 
398 genes, which was deemed to represent early changes in AD, prior to clinical symptoms. In addition, 
this thesis identified a gene expression signature in the TC of AD subjects through the largest AD meta-
analysis known to date. This gene expression signature consisted of 323 genes and represented robust 
changes in AD brains.  
The AsymAD and AD disease gene expression signatures were independently queried through the re-
processed CMap database to identify candidate compounds that may intervene with AD in the 
asymptomatic and symptomatic phase of the disease. The compounds identified are merely candidate 




4.2.6 Predicting BBB permeability 
Compounds of interest were queried in the web-based database “admetSAR2.0” which is available at 
http://lmmd.ecust.edu.cn/admetsar2/. The application uses 210,000 experimental data for 96000 
compounds and 27 computational models to predict chemical and biological properties of 
compounds, including BBB permeability (Yang et al., 2019). Compounds of interest identified by the 
drug repositioning pipelines were manually analysed in the ametSAR2.0 application to assess the 
compounds BBB permeability likelihood. 
4.2.7 Data availability 
All data processing scripts are available at https://doi.org/10.5281/zenodo.3518008 
4.3 Results 
4.3.1 Summary of processing the CMap data 
The CMap data consisted of 7056 raw intensity files, of which 6100 were generated from compounds 
and 956 generated from “control vehicles”. A summary of sample numbers by cell line and expression 
chip is provided in Table 4.1. 
Table 4.1: Summary of CMap sample numbers by cell line and expression chip 
Expression GeneChip HG U133A Total 
Cell Line HL60 MCF7 PC3 SKMEL5 ssMCF7   
Compounds 344 171 124 17 18 674 
Control vehicle 52 47 24 5 5 133 
  
Expression GeneChip HT-HG U133A   
Cell Line HL60 MCF7 PC3 SKMEL5 ssMCF7   
Compounds 885 2740 1617 0 0 5242 
Control vehicle 125 409 253 0 0 787 
  
Expression GeneChip HT-HG U133A EA   
Cell Line HL60 MCF7 PC3 SKMEL5 ssMCF7   
Compounds 0 184 0 0 0 184 
Control vehicle 0 36 0 0 0 36 
  
Total 1406 3587 2018 22 23 7056 
The CMap data was generated across three expression chips (HG-U133A, HT-HG U133A, HT-HG U133A EA), five cell lines 
(HL60, MCF7, PC3, SKMEL5, ssMCF7) and consisted of expression profiles from 6100 compounds and 956 control vehicles. The 
MCF7 cell line that was expression profiled on the HT-HG U133A expression chip contained the largest number of samples. 
The cell lines are MCF7 (human breast epithelial adenocarcinoma cell line), ssMCF7 (MCF7 cell lines cultured in phenol red-
free DMEM), HL60 (human promyelocytic cell line), PC3 (epithelial cell line from human prostate adenocarcinoma) and 




DE analysis calculates the average expression difference between two experimental groups, where 
each group must contain at least two samples. Therefore, prior to DE analysis, a summary of 
compounds that were repeated in each cell line and expression chip was compiled and is presented in 
Table 4.2. Compounds with multiple expression profiles were discovered to have been experimentally 
repeated 2-16, 17, 19, 22, 36, or 64 times. Multiple samples were also discovered to have been 
experimentally repeated at different concentrations on the same cell line and expression chip, each 
generating different expression profiles for the same compound. These expression profiles were 
treated as unique instances, and the compound names were modified to include concentration details 
to aid in differentiation. For instance, compound trichostatin was expression profiled at two different 
concentrations; 1e-06 and 1e-07, therefore the names of the two compounds have been converted to 
trichostatin_1e-06 and trichostatin_1e-07 respectively. 
The MCF7 cell line from the HT HG U133A expression chip contained the highest number of unique 
compounds and control vehicles that were experimentally repeated multiple times. Therefore, only this 
cell line and expression chip were used for further analysis.  
Table 4.2: Summary of the number of repeated compounds by cell line and expression chip 




HL60 351 3 
MCF7 78 40 
PC3 109 7 
SKMEL5 17 0 
ssMCF7 14 2 
HT HG U133A 
HL60 741 34 
MCF7 95 1146 
PC3 853 337 
SKMEL5 0 0 
ssMCF7 0 0 
HT HG U133A EA 
HL60 0 0 
MCF7 42 54 
PC3 0 0 
SKMEL5 0 0 
ssMCF7 0 0 
This table summarises the number of compounds that were experimentally repeated in each cell line and expression chip. The 
cell lines are MCF7 (human breast epithelial adenocarcinoma cell line), ssMCF7 (MCF7 cell lines cultured in phenol red-free 
DMEM), HL60 (human promyelocytic cell line), PC3 (epithelial cell line from human prostate adenocarcinoma) and SKMEL5 
(human malignant melanoma cell line). The CMap compounds may have been experimentally repeated 2-16, 17, 19, 22, 36, 
or 64 times. The MCF7 cell line from the HT HG U133A expression chip has the greatest number of unique compounds and 




4.3.2 Summary of differential expression analysis 
Following QC, the MCF7 cell line from the HT-HG U133A expression chip contained 12,501 annotated 
probes and 1146 unique compound expression profiles. Differential expression analysis was performed 
using each compound repeated at the same concentration against the pooled control vehicles. 
Differential expression analysis on the CMap compounds identified a range of 26-9167, a mean of 
1157.5 and an interquartile range (IQR) of 312-1576.5 (Q1-Q3) DEG’s across the 1146 compounds.  
4.3.3 Drug-disease mapping identifies 768 unique drug-disease relations 
The TTD contained information on 31,614 drug-disease relations and were used to identify diseases 
which can be treated by any of the 1146 CMap compounds. The CMap database contains 1121 unique 
compounds, with some compounds experimentally repeated at different concentrations and therefore, 
accounts for 1146 expression profiles. Only 612 CMap compounds annotated to 299 different diseases; 
however, due to multiple drug-disease combinations, 768 CMap drug-disease relations were identified 
and are provided in Supplementary Table 4.1. The top ten diseases targeted by multiple CMap 
compounds are illustrated in Figure 4.1 
 
Figure 4.1: Top 10 most treatable diseases by multiple CMap compounds. The compounds in the CMap database were 
annotated to the disease for which, according to TTD, are FDA approved to treat. A total of 768 Drug-Disease relations were 
identified in the CMap database. The CMap database contains the most number of compounds to treat bacterial infection. 





















4.3.4 Drug-drug validation results 
The Five random compounds identified from the CMap database were iopanoic acid, atractyloside, 
ursolic acid, methoxamine and 6-azathymine. These compounds had their DE logFC signals reversed, 
were then treated as “dummy” disease signatures and queried in the CMap database using the four 
different methods developed in this thesis. The five most significant results from each method are 




Table 4.3: Top five significant results from Drug-Drug validation analysis 
Compound (DEG's) 
Method 1 Method 2 Method 3 Method 4 
CMap compound p-value CMap compound p-value CMap compound p-value CMap compound p-value 
Iopanoic acid (263) 
iopanoic acid_7e-06 0.00E+00 iopanoic acid_7e-06 0.00E+00 iopanoic acid_7e-06 0.00E+00 iopanoic acid_7e-06 4.11E-09 
procarbazine_1.56e-05 4.35E-52 10-methoxyharmalan_1.86e-05 7.21E-04 10-methoxyharmalan_1.86e-05 0.00E+00 noscapine_9.6e-06 1.33E-04 
piribedil_1.2e-05 1.62E-50 scopolamine N-oxide_1e-05 3.24E-03 acemetacin_9.6e-06 0.00E+00 lisinopril_9e-06 2.75E-03 
S-propranolol_1.36e-05 2.13E-49 naproxen_1.74e-05 4.08E-03 alfaxalone_1.2e-05 0.00E+00 albendazole_1.5e-05 3.09E-03 
tribenoside_8.4e-06 1.11E-40 talampicillin_7.8e-06 1.07E-02 amitriptyline_1.28e-05 0.00E+00 bufexamac_1.8e-05 3.45E-03 
  
Atractyloside (293) 
atractyloside_5e-06 0.00E+00 atractyloside_5e-06 0.00E+00 atractyloside_5e-06 0.00E+00 atractyloside_5e-06 5.42E-11 
guanadrel_7.6e-06 7.32E-49 calcium folinate_7.8e-06 1.64E-03 AG-013608_1e-05 0.00E+00 cefazolin_8.4e-06 3.41E-05 
merbromin_5e-06 9.50E-49 ethoxyquin_1.84e-05 5.81E-03 alpha-ergocryptine_7e-06 0.00E+00 vitexin_9.2e-06 6.05E-05 
sulfadimethoxine_1.28e-05 5.88E-40 alpha-ergocryptine_7e-06 7.35E-03 atractyloside_5e-06 0.00E+00 remoxipride_9.8e-06 9.94E-05 
glycopyrronium bromide_1e-05 1.81E-37 bendroflumethiazide_9.4e-06 1.13E-02 calcium folinate_7.8e-06 0.00E+00 flufenamic acid_1.42e-05 4.46E-04 
  
Ursolic acid (792) 
ursolic acid_8.8e-06 0.00E+00 ursolic acid_8.8e-06 0.00E+00 ursolic acid_8.8e-06 0.00E+00 ursolic acid_8.8e-06 4.77E-37 
diazoxide_1.74e-05 6.91E-177 iopamidol_5.2e-06 6.07E-21 0179445-0000_1e-05 0.00E+00 mephentermine_9.4e-06 7.52E-12 
cefotaxime_8.4e-06 8.39E-173 tetrandrine_6.4e-06 1.94E-10 0179445-0000_1e-06 0.00E+00 prochlorperazine_6.6e-06 4.34E-09 
clindamycin_8.6e-06 2.61E-167 podophyllotoxin_9.6e-06 3.76E-09 0297417-0002B_1e-05 0.00E+00 hydrocortisone_1.1e-05 7.90E-09 






methoxamine_1.62e-05 0.00E+00 methoxamine_1.62e-05 0.00E+00 methoxamine_1.62e-05 0.00E+00 methoxamine_1.62e-05 3.60E-03 
cefaclor_1.04e-05 3.17E-43 phenacetin_2.24e-05 4.46E-08 6-azathymine_3.14e-05 0.00E+00 amitriptyline_1.28e-05 1.08E-02 
pyrazinamide_3.24e-05 4.09E-40 L-methionine sulfoximine_2.22e-05 1.39E-04 acebutolol_1.08e-05 0.00E+00 oxamniquine_1.44e-05 1.08E-02 
lovastatin_9.8e-06 3.66E-36 liothyronine_6.2e-06 1.78E-04 apramycin_7.4e-06 0.00E+00 atropine oxide_1.18e-05 1.44E-02 
betahistine_1.72e-05 6.82E-29 cefaclor_1.04e-05 4.51E-04 arcaine_1.48e-05 0.00E+00 metoprolol_5.8e-06 1.44E-02 
  
6-azathymine (324) 
6-azathymine_3.14e-05 0.00E+00 6-azathymine_3.14e-05 0.00E+00 6-azathymine_3.14e-05 0.00E+00 6-azathymine_3.14e-05 1.55E-18 
phenacetin_2.24e-05 3.69E-20 amiprilose_1.18e-05 8.84E-06 0179445-0000_1e-06 0.00E+00 flumequine_1.54e-05 1.54E-06 
molsidomine_1.66e-05 1.73E-16 phenacetin_2.24e-05 2.10E-05 0317956-0000_1e-05 0.00E+00 (+)-isoprenaline_1.1e-05 1.33E-04 
omeprazole_1.16e-05 3.68E-15 proglumide_1.2e-05 2.78E-05 0317956-0000_1e-06 0.00E+00 ethaverine_9.2e-06 7.22E-04 
cinchocaine_1.16e-05 1.71E-14 dicoumarol_1.18e-05 2.60E-04 6-azathymine_3.14e-05 0.00E+00 idoxuridine_1.12e-05 1.10E-03 
Five random compounds were identified from the CMap database; iopanoic acid, atractyloside, ursolic acid, methoxamine and 6-azathymine. These compounds had their differential logFC signals 
reversed and were then queried in the CMap database using four different methods. Some CMap compounds were experimentally used multiple times at different concentration, generating 
different expression profiles for the same compound. Therefore, each compound has the concentration at which it was used appended to the end of the compound name. Method 1 represents 
the Bi-directional enrichment approach. Method 2 represents the anti-correlation approach. Method 3 represents the ranked genes approach, and method 4 represents the pathway-based 
approach. All four methods successfully identify the same queried compound as the most significant result, suggesting the methods are all capable of identifying compounds where the gene 




significant result, suggesting all four methods can identify compounds where the gene expression 
signature is a “reverse” match to queried disease gene expression signature. However, as shown in  
Table 4.4, the processing time and the number of additional candidate compounds identified by each 
method varies, with method 3 taking considerably much longer than the remaining methods. In 
addition, a positive correlation between the number of DEG’s in the query signature and the number 
of candidate compounds identified, and the execution time for the method is observed. On average, 
the bi-directional enrichment method identifies the greatest number of candidate compounds, 
followed by the ranked genes, anti-correlation and then the pathway-based method.   

























iopanoic acid 263 863 35.71 12 0.62 223 1055.94 39 198.01 
atractyloside 293 891 44.76 18 0.70 177 1195.95 122 207.49 
ursolic acid 792 1035 42.80 392 0.91 833 4185.68 252 213.57 
methoxamine 222 750 37.77 36 0.55 232 945.00 44 205.80 
6-azathymine 324 830 41.44 81 0.51 198 1432.68 40 211.87 
Average 379 874 40.50 108 0.66 333 1763.05 99 207.35 
Correlation 
Coefficient 
  0.90 0.44 0.99 0.88 0.97 1.00 0.93 0.64 
Five random compounds were identified from the CMap database; iopanoic acid, atractyloside, ursolic acid, methoxamine 
and 6-azathymine. These compounds had their differential expression logFC signals reversed and were then queried in the 
CMap database using the four different methods. Method 1 represents the Bi-directional enrichment approach; method 2 
represents the anti-correlation approach, method 3 represents the ranked genes approach and method 4 represents the 
pathway-based approach. The number of significant results and the execution time from each method is provided above. A 
positive correlation of the number of DEG’s in the query signature and the number of significant compounds is observed. 
4.3.5 Disease-drug validation results 
Three disease datasets were identified in the public domain where corresponding FDA approved 
treatment was available in the CMap database. The diseases were tuberculosis, breast cancer and 
prostate cancer. Each dataset was independently processed, and an overview of the dataset 
demographics after processing is provided in Table 4.5. Differential expression analysis was 
independently performed in each dataset to identify DEG’s, which represented the diseases gene 
expression signature that was queried in the CMap database. The five most significant candidate 
compounds identified from this analysis is provided in Table 4.6, and a summary of all candidate 






Table 4.5: Demographics of the datasets used in the disease-drug validation analysis 
  Tuberculosis Breast cancer Prostate cancer 
Accession number E-GEOD-34151 E-GEOD-54002 E-GEOD-29079 
Platform Illumina Affymetrix Affymetrix 
Expression chip HT-12 v4.0 U133 plus 2.0 Exon 1.0 ST 
Tissue source Primary dendritic cells Mammary gland Prostate epithelium 
N.o. cases 124 405 46 
N.o. controls 112 15 47 
N.o. DEG's identified 2947 5628 6674 
Three disease datasets (tuberculosis, prostate cancer and breast cancer) were identified from the public repository 
ArrayExpress where treatment was available in the CMap database. Each dataset was independently processed to identify 
DEG’s, which represent the diseases gene expression signature. Sample numbers are provided after QC. 
The bi-directional enrichment approach (method1) correctly identified FDA approved drugs to treat the 
cancer gene expression signatures, with two cancer drugs being the two most significant result when 
querying the breast cancer disease gene expression signature. However, this method failed to identify 
any FDA approved drugs for tuberculosis and prostate cancer. 
The anti-correlation approach (method 2) was the only method to consistently identify FDA approved 
drugs to treat all three diseases queried, although they were never ranked in the top ten most 
significant results. This method also identified the highest number of candidate compounds when 
compared to the remaining three methods, particularly when querying the prostate and breast cancer 
disease gene expression signatures where 886 and 762 candidate compounds were identified 
respectively. This is more than 66% of the total number of compounds available in the CMap database 
(total = 1146 compounds), and therefore statistically, it is highly likely an FDA approved compound used 
to treat the disease would be identified by chance.  
In contrast, the rank gene-based approach was more reserved and identified 1, 3 and 4 candidate 
compounds when querying tuberculosis, prostate cancer and breast cancer disease gene expression 
signatures respectively. However, none of the candidate compounds is FDA approved to treat any of 
the diseases, although the single drug identified for tuberculosis, a bacterial infection, is an anti-
bacterial compound. However, no relation between the candidate compound and tuberculosis is 
mentioned in the TTD, and it cannot be ignored anti-bacterial compounds are the most abundant in the 
CMap database. Nevertheless, if this anti-bacterial compound can be used to treat tuberculosis, 




Table 4.6: Top five significant results from the disease-drug validation analysis 
Disease 































cephaeline 9.36E-40 <NA> GW-8510 6.75E-10 <NA> cefsulodin 9.00E-03 
Bacterial 
infection 














mitoxantrone 4.84E-09 Cancers    liothyronine 4.65E-04 Hypothyroidism 
tanespimycin 7.06E-17 
Breast cancer;  
Multiple 
myeloma 
doxorubicin 1.80E-07 Cancers    tracazolate 4.97E-04 <NA> 













































chlortalidone 7.74E-04 Hypertension 
tretinoin 3.17E-23 







   labetalol 2.15E-03 Hypertension 
nocodazole 2.45E-22 <NA> procyclidine 1.64E-43 
Parkinson's 
disease 





































trichostatin A 0.00E+00 anti-fungal isotretinoin 7.62E-04 Acne vulgaris 












5.66E-36 <NA> Prestwick-984 3.60E-38 <NA>    naftidrofuryl 3.29E-03 Vascular disorder 
Three disease datasets (tuberculosis, prostate cancer and breast cancer) were identified from the public repository ArrayExpress where treatment was available in the CMap database and where 
the human samples were not on any disease-modifying treatment. Each dataset was independently processed and analysed to identify the DEG’s, which represented the diseases gene expression 
signature. These disease gene expression signatures were queried in the CMap database using the four different methods developed. “N.o. prescribed drugs identified” represents candidate 
compounds identified by the method that has been FDA approved to treat the queried disease according to the TTD. “<NA>” represents a drug that is not FDA approved to treat diseases according 
to TTD. Method 1 represents the Bi-directional enrichment approach; method 2 represents the anti-correlation approach, method 3 represents the ranked genes approach and method 4 




Table 4.7: Summary of disease-drug validation 
Disease 

































Tuberculosis 66 0 171 6 1 0 106 2 
Prostate cancer 73 1 886 4 3 0 99 0 
Breast cancer 74 5 762 3 4 0 67 0 
Average 71.00 2.00 606.33 4.33 2.67 0.00 90.67 0.67 
Three disease datasets (tuberculosis, prostate cancer and breast cancer) were identified from the public repository 
ArrayExpress where treatment was available in the CMap database and where the human samples were not on any disease-
modifying treatment. Each dataset was independently processed and analysed to identify the DEG’s, which represented the 
diseases gene expression signature. These disease gene expression signatures were queried in the CMap database using the 
four different methods developed. “N.o. prescribed drugs identified” represents candidate compounds identified by the 
method that has been FDA approved to treat the queried disease according to the TTD. Method 1 represents the Bi-directional 
enrichment approach, method 2 represents the anti-correlation approach, method 3 represents the ranked genes approach, 
and method 4 represents the pathway-based approach 
The final method to identify candidate compounds was a pathway-based approach (method 4), which 
correctly identified FDA approved drugs for tuberculosis but failed to identify FDA approved drugs for 
the cancer datasets correctly. The current results from this disease-drug analysis are inconclusive to 
suggest which method is best suited for identifying candidate compounds from a disease gene 
expression signature. However, method 2 can be regarded as the worst performing method based on 
the high number of candidate compounds identified in each analysis, indicating increased false 
positives. Therefore, this method was dropped from further use.  
4.3.6 Candidate compounds identified for AsymAD treatment 
The AsymAD gene expression disease signature was queried in the CMap database. The five most 
significant results from each method are provided in Table 4.8.  Querying the AsymAD disease signature 
identified 3, 2 and 15 candidate compounds using methods 1, 3, and 4 respectively. No overlap of 
candidate compounds was identified across the four methods. The bi-directional enrichment approach 
(method 1) identified three candidate compounds with anisomycin, an antibiotic, being the most 
significant candidate compound. The ranked-gene based approach identified only two candidate 
compounds; tacrine (FDR adjusted p-value=0.03), an FDA approved drug to treat AD, and epirizole (FDR 
adjusted p-value=0.04), an anti-inflammatory drug. In addition, galantamine, another FDA approved 
compound to treat AD, identified as the 6th most significant compound, although it did not pass multiple 




The pathway-based approach identified 15 candidate compounds based on perturbation of biological 
pathways. Similar to the bi-enrichment based approach, the most significant candidate compound was 
an antibiotic (bacampicillin, FDR adjusted p-value=0.001). This method also identified thioperamide as 
the 5th most significant candidate compound (FDR adjusted p-value=0.02), which is an FDA approved 
drug to treat cognitive impairment. 
4.3.7 Candidate compounds identified for AD treatment 
Similar to the AsymAD, the AD gene expression disease signature was queried in the CMap database to 
identify candidate compounds. The five most significant results are also provided in Table 4.8.  Only 
method 3 (ranked gene-based) and method 4 (pathway-based) identified candidate compounds for AD. 
The ranked gene-based approach identified 63 candidate compounds, with paromomycin, an antibiotic, 
being the most significant result (FDR adjusted p-value=0). This method also identified memantine; an 
FDA approved compound to treat AD, as the 62nd most significant compound (FDR adjusted p-
value=0.04). 
The pathway-based approach identified the activation of “bacterial invasion of epithelial cells” pathway 
in AD. This biological pathway was the only pathway identified as significantly perturbed in AD. Twelve 
candidate compounds were identified to inhibit this pathway with kawain; an FDA approved compound 
to treat cardiovascular disease, identified as the most significant (FDR adjusted p-value=0.02) candidate 
compound. However, according to the results, this compound significantly perturbs an additional three 
biological pathways (salmonella infection, focal adhesion, neuroactive ligand-receptor interaction) that 
are not affected in AD. The 5th most significant candidate compound identified by this pathway-based 




Table 4.8: Top five most significant candidate compounds identified for Alzheimer's disease 
Disease 

















anisomycin 3.32E-02 Antibiotic tacrine 3.10E-02 Alzheimer's disease bacampicillin 1.54E-03 Bacterial infection 
SR-95531 
(Gabazine) 
3.32E-02 <NA> epirizole 3.50E-02 Anti-inflammatory cinchocaine 6.96E-03 <NA> 
cephaeline 3.57E-02 <NA>   <NA> estropipate 6.96E-03 Hypogonadism 
      metamizole 
sodium 
8.88E-03 <NA> 






   paromomycin 
0.00E+0
0 
Acute and chronic intestinal 
amebiasis 
kawain 1.44E-02 Cardiovascular disease 
   bendroflumethiazide 1.00E-03 High blood pressure budesonide 2.16E-02 
Asthma; Non-infectious 
rhinitis 




   ethoxyquin 2.00E-03 <NA> phenelzine 2.16E-02 Depression; Anxiety disorder 
   oxprenolol 4.00E-03 Angina; Hypertension clomipramine 2.52E-02 Depression 
   *memantine 4.40E-02 Alzheimer's disease **velnacrine 3.00E-02 Cognitive impairment 
This thesis explored transcriptomic changes in probable AsymAD brains and identified significant brain changes in the FC of AsymAD subjects when compared to healthy controls, suggesting this 
may be the first brain region affected in AD. The 398 gene expression signature identified in the FC of AsymAD subjects represented early changes in the disease and was queried through the 
reprocessed CMap database to identify candidate compounds that may intervene with AD in the early stage of the disease, prior to clinical symptoms. In addition, this thesis identified a 323 
gene expression signature in the TC of AD subjects through the largest AD meta-analysis known to date. This gene expression signature represented robust changes in AD brains and was queried 
through the reprocessed CMap database to identify candidate compounds that may intervene with AD once clinical signs of AD are present. The top five most significant candidate compounds 
identified by each query method is provided in the above table. Method 1 represents the Bi-directional enrichment approach, method 3 represents the ranked genes approach, and method 4 
represents the pathway-based approach. *Two compounds galantamine and memantine are FDA approved to treat Alzheimer’s disease and were identified as significant results prior to multiple 
corrections. **velnacrine is an FDA approved drug for cognitive impairment and was identified as the 8th most significant result when querying the AD gene expression signature in the CMap 





This chapter re-processed the raw CMap data using appropriate up-to-date data processing techniques 
and developed four different methods to query the reprocessed CMap database for drug repositioning 
based on gene expression profiling. The four methods go beyond the constraints of the current CMap 
algorithm by not limiting the input gene expression signature by 500 genes and by considering both the 
up-regulated and down-regulated genes in a disease signature to identify more relevant candidate 
compounds. The four methods are bi-directional enrichment (method 1), anti-correlation (method 2), 
ranked genes-based (method 3) and a pathway-based approach (method 4).  
4.4.1 The drug-drug validation suggests all four drug repositioning methods are valid 
The drug-drug validation analysis used five random compounds from the CMap database, reversed their 
expression profile and used them as “dummy” disease gene expression signatures. All four methods 
successfully identified all five compounds in the CMap database as the most significant candidate 
compound, suggesting each method can identify candidate compounds which has a reverse gene 
expression profile to the input query signature. However, the number of significant candidate 
compounds identified by each method varied, with no apparent relation between the remaining 
candidate compounds across methods. In addition, a positive correlation was observed between the 
input DEG length and the number of candidate compounds identified by each method, suggesting 
disease signatures with more DEG’s may identify more candidate compounds. However, during the 
disease-drug validation process, this phenomenon was not observed, suggesting many compounds 
within the CMap database may have similar expression profiles. 
4.4.2 Method validation fails to identify the most effective drug repositioning technique 
To evaluate the effectiveness of each method’s capability of identifying relevant candidate compounds 
in relation to the input profile, three disease gene expression signatures were queried in the CMap 
database. The three disease gene expression profiles represented tuberculosis, breast cancer and 
prostate cancer. Samples were acquired prior to treatment, and current FDA approved treatment for 
these diseases were available in the CMap database. The underlying hypothesis of this approach 
assumed the gene expression profile of each disease dataset, after processing, would primarily be the 
result of the disease. Therefore, the best drug-repositioning method would correctly and consistently 
identify FDA approved compounds that are routinely used to treat each of the three diseases. 
The only method to correctly identify at least one candidate compounds for all three diseases was the 
anti-correlation approach, however, on average across the three diseases, this method identified 606 
candidate compounds of which four were FDA approved to treat the disease. When compared to the 




CMap database as a significant result, this method has the lowest specificity, and as such, can be 
deemed the worst approach from the four methods for drug repositioning. Therefore, this method was 
discarded from further use. 
The bi-directional enrichment approach correctly identified the treatments for prostate cancer and 
breast cancer but failed to identify the correct candidate compounds for tuberculosis. In contrast, the 
pathway-based approach identified the correct treatment option for tuberculosis but failed for the 
cancer datasets. This may suggest, different methods may be suitable for different diseases and/or 
tissue sources.  
The ranked gene-based method was very reserved in comparison to the remaining three methods, 
identifying a total of 7 candidate compounds for all three diseases, none of which were in the TTD as a 
treatment option for the three diseases. The number of candidate compounds identified by this method 
contradicted the drug-drug validation results, where a positive correlation was observed between the 
number of candidate compounds identified and the number of DEG’s in the disease signature. This can 
suggest that this method may possibly be less prone to false positives. When querying the tuberculosis 
disease signature, only one significant result was identified; cefsulodin – an FDA approved treatment 
for bacterial infection. There is no relation of cefsulodin and tuberculosis in the TTD database; however, 
further literature investigation identifies this compound to be associated with tuberculosis (He et al., 
2015), although it is unknown if it can be used to treat the disease. If this compound is indeed a 
treatment option for tuberculosis, this ranked gene-based method would be the most sensitive method 
for drug repositioning. However, it cannot be disregarded that antibiotics are the most abundant drugs 
in the CMap database, and the result obtained is by chance. 
The CMap experiments were performed on various cell lines; however, only the MCF7 cell line was 
analysed due to containing the highest number of instance expression profiles. Gene expression is 
tissue-specific (Aguet et al., 2017) and drug-gene expression signatures observed in the MCF7 cell line 
may not reflect gene expression signatures of different tissues, such as those in the disease-drug 
validation (primary dendritic cells for tuberculosis, mammary gland for breast cancer and prostate 
epithelium for prostate cancer). Different methods were observed to work well with different disorders, 
which can be the consequence of different methods compensating for tissue-specific expression 
effects. However, it cannot be disregarded that significant results obtained from each method could be 
potential compounds to treat the disease or are false positives. The current results cannot conclude 
which approach is the best-suited method for drug repositioning the CMap based on gene expression 
profiling. Additional disease datasets for disease-drug validation that satisfy the inclusion criteria and 




4.4.3 Candidate compound gabazine identified to treat AsymAD 
Drug repositioning the AsymAD brain gene expression signature identified a number of candidate 
compounds. The Bi-directional enrichment method identified compound SR-95531, which according to 
TTD was not approved to treat any disease; however, additional literature investigation discovered SR-
95531 is also referred to as gabazine (Behrens, van den Boom and Heinemann, 2007), which although 
is not FDA approved to treat any disease, is a GABAA-receptor antagonist. Gamma-aminobutyric acid 
(GABA) is the principal inhibitory neurotransmitter in human CNS and most aspects of the GABA 
signalling system including the expression levels and functional characteristics of GABA receptors and 
transporters, are affected in AD (Kwakowsky et al., 2018). The activity of GABA can be inhibited through 
three receptor families; GABAA, GABAB and GABAC receptors (Li et al., 2016). Reduced long-term 
potentiation (LTP) has been suggested to be linked to enhanced GABAA receptor-mediated inhibition, 
and several independent rodent studies have observed improved cognitive functions by long term 
GABAA antagonists (Yoshiike et al., 2008). Gabazine also has a BBB permeability probability of 0.97 
according to admetSAR, suggesting it is highly likely to penetrate the BBB, making it an ideal candidate 
compound for AD. To date, no literature was found to assess the effects of gabazine in AD, and further 
experimental investigation is warranted.  
4.4.4 FDA approved treatments for AD and cognitive impairment may be effective in 
AsymAD 
The ranked gene-based approach identified tacrine as the most significant candidate compound when 
repositioning the AsymAD gene expression disease signature in the CMap database. Tacrine is a 
cholinesterase inhibitor, and the first-ever FDA approved drug to treat AD which has been shown to 
improve cognition in mild to moderately impaired patients, although the treatment does not affect the 
course of the disease (Crismon, 1994). However, the drug was not widely adopted as periodic blood 
tests were required to monitor hepatotoxicity and many side-effects were reported including nausea, 
vomiting, dizziness, diarrhoea, seizures and loss of consciousness (Mehta, Adem and Sabbagh, 2012). 
Subsequently, tacrine has been replaced in many countries by safer alternative cholinesterase 
inhibitors galantamine, rivastigmine and donepezil to treat AD. Galantamine was also identified as a 
candidate compound (6th most significant) with the ranked genes-based method; however, it did not 
pass multiple corrections. This suggests the discontinued AD treatment tacrine may be statistically and 
computationally more effective in reversing the gene expression signature of AsymAD patients than the 
current FDA-approved AD treatment galantamine. 
A different drug repurposing approach based on biological pathway perturbations (method 4) identified 




impairment. A deficit in cholinergic neurotransmitters has been suggested to be the primary cause of 
cognitive decline in AD, with other neurotransmitter systems such as neuronal histamine suggested to 
further contribute to the development of AD. Therefore, targeting the histamine system for AD 
treatment is an obvious choice, although it has been largely neglected  (Zlomuzica et al., 2016). Drugs 
targeting the histamine system have been suggested to enhance the degradation of Aβ and NFT by 
promoting brain autophagy whilst stimulating neurogenesis to counteract memory-related cell loss 
(Zlomuzica et al., 2016). However, human clinical trials in mild-to-moderate AD have failed to show 
specific histamine antagonists can improve cognition (Grove et al., 2014), with future studies 
recommended to investigate novel histamine-related drugs (Zlomuzica et al., 2016). Thioperamide 
(identified as a candidate compound for AsymAD) is a histamine antagonist and has not been previously 
associated with AD, and therefore is a prime candidate for further experimental investigations. 
The candidate compounds discussed above (tacrine and thioperamide) have been identified in this 
thesis to treat AsymAD, which coincidently have already been FDA approved to treat AD and cognitive 
impairment respectively. It is important to note the FDA approved compounds available in the CMap 
database to treat AD (tacrine, galantamine and memantine) and cognitive impairment (thioperamide 
and velnacrine) were not identified as significant candidate compounds during the drug-drug or 
disease-drug validation processes (excluding the anti-correlation approach which was discarded due to 
increase of false positives), and therefore provides confidence the results obtained from repurposing 
the AsymAD disease signature may be biologically relevant. As these compounds were not identified by 
repurposing the AD gene expression signature as well, these compounds may be more effective in the 
asymptomatic stage of the disease. Nevertheless, it is important to remember these compounds are 
prescribed for AD symptomatic relief and do not modify the underlying pathology of the disease. 
4.4.5 Anti-inflammatory drug epirizole identified to treat AsymAD 
Inflammation response has been suggested to contribute to neurodegeneration in AD patients and has 
been suggested to be induced by Aβ and NFT interfering with a neuronal activity which activates 
inflammatory activities of microglia (Bolós, Perea and Avila, 2017). The potential of a nonsteroidal anti-
inflammatory drug (NSAID)  to treat AD was postulated when rheumatoid arthritis patients who were 
on NSAID were discovered to be at a lower risk of dementia (Martyn, 2003). Mouse models have also 
demonstrated NSAID such as ibuprofen have been found to reduce the production of β42 peptides 
(Weiner and Selkoe, 2002); however, AD clinical trials involving anti-inflammatory drugs have had 
contradictory results, with discrepancies across studies possibly explained due to different trials using 
different anti-inflammatory drugs. In addition, it has been suggested NSAID may be ineffective in AD 
once the disease has been established but may be beneficial in the presymptomatic phase of the 




in symptomatic AD, however, treating AsymAD patients reduced the incidence of AD, but only after 2-
3 years of continuous administration (Breitner et al., 2011).  
Epirizole is an FDA approved NSAID and the second most significant candidate compound identified 
when repurposing the AsymAD gene expression signature using the ranked gene-based method in the 
CMap database. According to admetSAR, epirizole is highly predicted to penetrate the BBB, which is 
further supported by experimental evidence that demonstrated epirizole is able to pass the BBB and 
possess CNS activity (Dileep et al., 2013). However, to date, no clinical trial has attempted to assess the 
effects of this compound in AD. The current results combined with literature review suggests epirizole 
may potentially have therapeutic effects in AsymAD, and further investigation is required. 
4.4.6 An anti-bacterial compound identified to treat AsymAD and AD 
Anisomycin was identified as the most significant compound to treat AsymAD subjects according to 
drug repositioning method 1. Anisomycin is an antibiotic that inhibits bacterial protein and DNA 
synthesis, and is predicted (probability 0.8) by admetSAR to be able to penetrate the BBB. A study 
investigated the effects of administration of anisomycin in an animal model of posttraumatic stress 
disorder and observed reduced anxiety-like and avoidant behaviour (Cohen et al., 2006). These extreme 
behaviour responses are involved in memory consolidation; therefore, the study concluded the results 
suggests that anisomycin disrupts traumatic memory consolidation in rats. Although no literature 
association has been found between anisomycin and AD, the drug repositioning method in this study 
has identified a compound that has been suggested to be involved affecting memory, which is the 
hallmark symptom of AD, thus, warranting further investigation. 32 
The most significant candidate compound identified for AD patients was paromomycin, an antibiotic 
used for the treatment of acute and chronic intestinal amebiasis. Although the CMap database contains 
the most anti-bacterial compounds (66/1146) and the fact anti-bacterial compounds were identified as 
candidate compounds during the disease-drug validation suggesting these compounds may represent 
false positives, the p-value associated with paromomycin result (p-value = 0) cannot be ignored. The 
literature on paromomycin is limited, with no known association with AD. Pathogenic components have 
been long suspected of playing an essential role in the onset and progression of AD. A recent study 
identified porphyromonas gingivalis (p.gingivalis), a pathogenic bacterium, in human AD brains and 
demonstrated mice infected with the same bacterium resulted in the release of toxic proteases known 
as gingipains which increased the production of Aβ1–42, a component of amyloid plaques (Dominy et al., 
2019). Subsequently, the authors demonstrated a broad spectrum of antibiotics (did not test 




inhibitor reduced the bacterial brain load, blocked Aβ1–42 productions, reduced neuroinflammation, and 
rescued neurons in the hippocampus.  
Amyloid-β peptides have also been shown to protect against microbial infections in mice (Kumar et al., 
2016), providing further evidence of bacterial involvement in AD. Therefore, the antibiotic 
paromomycin that was identified when repurposing the AD gene expression signature may be of 
therapeutic benefit and as admetSAR predicts (probability = 0.87) the compound to be able to 
penetrate the BBB, paromomycin also requires further investigation. 
4.4.7 Limitations 
The four-drug repositioning methods developed to query the CMap database all have their strengths 
and weaknesses. The first method was the bi-directional enrichment approach which uses a 
hypergeometric test to assess the overlap of genes in the disease signature and every CMap compound. 
This method is a simple, quick and practical approach that is commonly used to associate gene lists to 
biological pathways through GSEA. However, this method ignores the magnitude of gene expression 
fold change and may, therefore, suggest candidate compounds for diseases based on “weak” relations. 
For instance, if gene A in a disease is significantly up-regulated 10-fold, and compound X significantly 
down-regulates gene A, but only by 0.1-fold, the bi-directional approach would match this compound 
to the disease signature, however, the compound may not be as effective at countering the effects of 
gene A. This issue could be addressed merely by adjusting the concentration of compound X to increase 
its effect on gene A, although this gets extremely complex and may not be effective when many genes 
are perturbed.  
The second method was a simple anti-correlation approach where DEG’s in the disease gene expression 
profile is correlated to the same genes in a CMap compound. This method assumes each compound in 
the CMap database can affect the gene expression of all genes, and it’s the directional change of the 
gene that is important. Therefore, all genes in both the disease and compound expression profiles are 
assigned a fold change of either +1 or -1. However, the basis of this method is also a limitation as the 
method fails to consider if a gene is significantly affected by a compound (does not use p-values). Similar 
to method 1, the method ignores the magnitude of gene expression fold change and may, therefore, 
suggest candidate compounds for diseases based on “weak” relations.  
The third approach used a ranked gene-based method, which incorporated the magnitude of fold 
change and the statistical significance of a gene being perturbed. This method addressed the flaws of 
the first two methods but is more computationally intensive. The fourth method used information 
across the perturbed genes to identify disrupted biological pathways. This method is free from gene-




does not need to directly counteract against the same genes affected in the disease gene expression, 
but instead the candidate compound needs to counteract against the biological effects of the DEG’s in 
the disease. This pathway-based method uses SPIA to identify biological pathways as perturbed from a 
gene list; however, the SPIA method is limited to the number of biological pathways it queries. The SPIA 
method only contains information on 139 biological pathways when other biological pathway databases 
such as the ConsensusPathDB contains information on over 4000 biological features (Kamburov et al., 
2009). However, the SPIA incorporates topological information, including PPI to determine if a 
biological pathway is likely to be “inhibited” or “activated”, which is vital to identify candidate 
compounds. This information is missing in other publicly available databases such as ConsensusPathDB. 
The largest repository identified with this information is the KEGG database (Ogata et al., 1999), which 
contains information on over 300 biological pathways; however, this version of the database is only 
available at a commercial cost, which could not be financially supported by this thesis. 
 The CMap experiments were performed on various cell lines. However, only the MCF7 cell line was 
analysed as it contained the greatest number of unique compound expression profiles. Gene expression 
is tissue-specific (Aguet et al., 2017) and drug-gene expression signatures observed in the MCF7 cell 
line may not reflect gene expression signatures of different tissues, such as the brain tissue. Therefore, 
this work purely identifies candidate compounds that need further experimental validation. 
Finally, clinical phenotypes were somewhat limited for the AsymAD or AD subjects, including 
medication. Therefore, it is unknown if these subjects were on any medication that may have influenced 
gene expression signatures. However, as the AsymAD group had no clinical mention of dementia and 
were assumed to be clinically healthy until an autopsy, they would have been highly unlikely to be on 
medication relating to AD, and therefore the AsymAD gene expression profile most likely represented 
the disease alone. However, the AD group were all clinically and autopsy-confirmed AD and would have 
most likely been on AD medication, and therefore the AD gene expression profile obtained in this thesis 
most likely represented the combination of disease and effect of any medication. Nevertheless, as there 
is currently no pathological modifying treatment for AD, the AD gene expression signature may have 
captured gene expression representing hallmark AD pathology and the candidate compounds identified 
by repurposing the AD gene expression signature may still be of therapeutic value. 
4.5 Conclusion 
Drug repositioning has been demonstrated to be an effective and quick method for repurposing FDA 
approved compounds for new therapeutic targets. In this chapter, the CMap database was reprocessed 
using appropriate up-to-date processing techniques, and new sophisticated drug repositioning 




compounds to treat AD, and cognitive impairment was identified as candidate compounds for AsymAD, 
but not AD, suggesting these approved treatments may be more effective in the asymptomatic stage 
of the disease. Additional candidate compounds epirizole (anti-inflammatory compound) and 
paromomycin (antibiotic) were identified for AsymAD and AD respectively. These compounds warrant 







 Chapter 5: Working Towards a Blood-Derived Gene Expression 
Biomarker Specific for Alzheimer's Disease 
 
5.1 Background 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting an estimated one in nine 
people over the age of 65 years of age, making it the most common form of dementia worldwide (‘2018 
Alzheimer’s disease facts and figures includes a special report on the financial and personal benefits of 
early diagnosis’, 2018). Current clinical diagnosis of the disease is primarily based on a time-consuming 
combination of physical, mental and neuropsychological examinations. With the rapid increase in the 
prevalence of the disease, there is a growing need for a more accessible, cost-effective and time-
effective approach for early diagnosis and monitoring AD. 
For research purposes, brain positron emission tomography (PET) scans and cerebral spinal fluid (CSF) 
have been used for disease identification. In particular, decreased Aβ and increased tau levels in CSF 
have been successfully used to distinguishing between AD, mild cognitive impairment (MCI) and 
cognitively healthy individuals with high accuracy. However, as a relatively invasive and costly 
procedure, it may not appeal to the majority of patients or be practical on a large-scale trial basis for 
screening the population (Han et al., 2013; Lunnon et al., 2013; Henriksen et al., 2014). Peripheral 
blood-derived biomarkers could potentially be a solution to this problem.  
Blood is a complex mixture of fluid and multiple cellular compartments that are consistently changing 
in protein, lipid, RNA and other biochemical entity concentrations (Thambisetty and Lovestone, 2010), 
which may be useful for AD diagnosis. Nakamura et al. successfully used APP669–711/ Aβ1–42 and Aβ1–
40/Aβ1–42 ratios, and their composites, to predict individual brain Aβ load when compared to Aβ-PET 
imaging (Nakamura et al., 2018). However, the test predicts Aβ, which is also found in other brain 
disorders such as FTD and therefore, the test requires AD specificity evaluation. Another study reviewed 
163 candidate blood-derived proteins as potential AD biomarkers from 21 separate studies (Kiddle et 
al., 2014). The overlap of biomarkers between studies was limited, with only four biomarkers α-1-
antitrypsin, α-2-macroglobulin, apolipoprotein E and complement C3 found to replicate in five 
independent cohorts. However, a follow-on study discovered these biomarkers were not specific to AD, 
and were also discovered to be associated with other brain disorders including Parkinson’s Disease (PD) 
and Schizophrenia (SCZ) (Chiam et al., 2014), suggesting the need to consider other neurological and 
related disorders in study designs to enable the discovery of biomarkers specific to AD. 
Similarly, several studies have attempted to exploit blood transcriptomic measurements for AD 




(DEG) as a means to distinguish AD from cognitively healthy individuals (Rye et al., 2011; Han et al., 
2013). However, the limited overlap and reproducibility of DEG from independent cohorts suggests this 
method alone is not reliable enough (Han et al., 2013). A solution to this problem would be to use 
information across all genes simultaneously through machine learning algorithms to identify 
combinations of gene expression changes that may represent a biomarker for AD. This technique has 
been employed in multiple studies, which have demonstrated the ability to differentiate AD from non-
AD subjects (Fehlbaum-Beurdeley et al., 2010; Booij et al., 2011; Lunnon et al., 2013; Roed et al., 2013; 
Voyle et al., 2016). However, small sample size and lack of independent validation datasets most likely 
led to overfitting. The decrease in costs associated with microarray technologies led a study developing 
an AD classification model based on a larger training set of 110 AD and 107 controls and validating in a 
larger independent cohort of 118 AD and 118 controls. The model achieved 56% sensitivity, 74.6% 
specificity, and an accuracy of 66%, which equated to 69.1% Positive Predictive Power (PPV) and 63% 
Negative Predictive Power (NPV) (Voyle et al., 2016). This was one of the first studies to demonstrate 
validation in an independent cohort; however, the classification model still lacked the 90% predictive 
power desired from a clinical diagnostic test (Huynh and Mohan, 2017). 
Previous studies have demonstrated the potential use of blood transcriptomic levels to differentiate 
between AD and cognitively healthy individuals; however, they are yet to be precise enough for clinical 
utility and/or are yet to be extensively evaluated on specificity by assessing model performance in a 
heterogeneous ageing population of multiple diseases. This validation process is critical to determine 
whether the classification model is indeed disease-specific, a general indication of ill health, or an 
overfit.  
This study developed a novel XGBoost classification model trained on blood transcriptomic profiling 
from AD, related mental disorders (Parkinson’s disease [PD], Multiple Sclerosis [MS], Amyotrophic 
Lateral Sclerosis [ALS], Bipolar Disorder [BD], Schizophrenia [SCZ]), age-related disorders (Coronary 
Artery Disease [CD], Rheumatoid Arthritis [RA], Chronic Obstructive Pulmonary Disease [COPD]), and 
cognitively healthy subjects to differentiate AD from diseased and otherwise normal subjects. The 
classification model was developed with clinical utility in mind, with each dataset processed and 
transformed independently and evaluated in an independent ageing heterogeneous population 
(testing set) consisting of similar diseases as the training set. 
5.2 Methods 
5.2.1 Data acquisition 
Microarray gene expression studies were sourced from publicly available repositories GEO 




2018. Study inclusion criteria were; 1) microarray gene expression profiling must be performed on an 
age-related or neurological disorder, 2) RNA was extracted from whole blood or a component of blood, 
3) study must contain at least ten subjects, and 4) data was generated on either the Illumina or 
Affymetrix microarray platform using a BeadArray containing at least 20,000 probes. The microarray 
platform was restricted to Affymetrix and Illumina only, as replication between the two platforms is 
generally very high (Barnes et al., 2005), and BeadArrays restricted to a minimum of 20,000 probes to 
maximise the overlap of genes across studies, while also optimising the number studies available for 
inclusion. 
5.2.2 Data processing  
The data processing pipeline was designed with reproducibility and clinical utility in mind. New subjects 
could be independently processed and predicted through the same classification model without using 
any prior knowledge on gene expression variation of the data used to develop the classification model 
and without making any alteration to the classification model itself. All data processing was undertaken 
in RStudio (version 1.1.447) using R (version 3.4.4). Microarray gene expression studies were acquired 
from public repositories using the R packages “GEOquery” (version 2.46.15) and “ArrayExpress” 
(version 1.38.0). For longitudinal studies involving treatment effect, placebo subjects or initial gene 
expression profiling from baseline subjects before treatment were used. Studies consisting of multiple 
disorders were separated by disease into datasets consisting of diseased subjects and corresponding 
healthy controls if available.  
Raw gene expression data generated on the Affymetrix platform were “mas5” background corrected 
using R package “affy” (version 1.42.3), log2 transformed and then Robust Spline Normalised (RSN) 
using R package “lumi” (version 2.16.0). Datasets generated on the Illumina platform were available in 
either a “raw format” containing summary probes and control intensities with corresponding p-values 
or a “processed format” where data had already been processed and consisted of a subset of probes 
and samples deemed suitable by corresponding study authors. When acquiring studies, preference was 
given to “raw format” data where possible, and when available, was “normexp” background corrected, 
log2 transformed, and quantile normalised using the “limma” R package (version 3.20.9).  
Sex was then predicted using the R package “massiR” (version 1.0.1) and subjects with discrepancies 
between predicted and recorded sex removed from further analysis. Next, within each gender and 
disease diagnosis group of a dataset, probes above the “X” percentile of the log2 expression scale in 
over 80% of the samples were deemed “reliably detected”. To account for the variation of redundant 
probes across different BeadArrays, the “X” percentile threshold value was manually adjusted until a 




unexpressed in their corresponding gender groups (Chang et al., 2011). Any probe labelled as “reliably 
detected” in any group (based on gender and diagnosis) was taken forward for further analysis from all 
samples within that dataset. This substantially eliminates noise (Lazar et al., 2013) and ensures disease 
and gender-specific signatures are captured within each dataset. 
Next, to ensure homogeneity within biological groups, outlying samples were iteratively identified and 
removed using the fundamental network concepts described in (Oldham, Langfelder and Horvath, 
2012). Finally, to enable cross-platform probes to be comparable, platform-specific probe identifiers 
were annotated to their corresponding universal Entrez gene identifiers using the appropriate 
BeadArray R annotation files; “hgu133plus2.db”, “hgu133a.db”, “hugene10sttranscriptcluster.db”, 
“illuminaHumanv4.db” and “illuminaHumanv3.db”.  
5.2.3 Cross-platform normalisation 
To enable transcriptomic information between datasets to be directly comparable, a rescaling 
technique, the YuGene transform, was applied to each dataset independently. YuGene assigns modified 
cumulative proportion value to each measurement, without losing essential underlying information on 
data distributions and allows the transformation of independent studies and individual samples (Lê Cao 
et al., 2014). This allows new data to be added without global renormalisation and enables the training 
and testing data to be independently rescaled. Common probes across all processed datasets that 
contained both female and male subjects were extracted from each dataset and independently 
rescaled using the R package YuGene (version 1.1.5). YuGene transformation assigns a value between 
0 and 1 to each gene, where 1 is highly expressed. As samples originated from publicly available 
datasets, potential duplicate samples may exist in this study. To address this issue, correlation analysis 
was performed on all samples using the common probes. Any sample with a Pearson’s correlation 
coefficient equal to 1 was suggested to be a duplicate sample and would be removed from further 
analysis. 
5.2.4 Training Set and Testing Set assignment  
Multiple datasets from the same disease were available, allowing entire datasets to be assigned to 
either the “Training Set” for classification model development or “Testing Set” for independent external 
validation purposes. Larger datasets from the same disease were prioritised to the training set, allowing 
the machine learning algorithm to learn in a larger discovery set.  
Individual subjects within the training and testing set were assigned a “0” class if the individual was AD 
or “1” if the individual was non-AD (includes healthy controls and non-AD diseased subjects). Grouping 




where subjects may have a related mental disorder, neurodegenerative disease, age-related disease or 
are considered relatively healthy.  
5.2.5 Classification model development 
Two classification models were created. (i) The first was developed using only the AD and associated 
control datasets available in the training set and is referred to as the “AD vs healthy control” 
classification model. (ii) The second classification model was developed using all datasets and diseases 
available in the training set (AD, non-AD disease and all controls) and is referred to as the “AD vs mixed 
control” classification model. The second approach aimed to develop a classification model that may 
be more specific in identifying AD than the typical “AD vs healthy control” classification model. 
Classification models were built using a powerful tree boosting algorithm, XGBoost, which in 2015 was 
used in every winning team in the top 10 of the Data Mining and Knowledge Discovery competition for 
a wide range of machine learning problems (Chen and Guestrin, 2016) and was suggested to be one of 
the most sophisticated methods at the time of this work (Patil, Aghav and Sareen, no date; Dhaliwal et 
al., 2018). Furthermore, the tree learning algorithm uses parallel and distributed computing and is 
approximately 10 times faster than existing methods and allows many hyperparameters to be tuned to 
reduce the chance of overfitting (Dhaliwal et al., 2018). 
First, the training sets were balanced by up-sampling the minority class with replacement to match the 
number of samples in the majority class. As the second classification model (“AD vs mixed control”) 
consisted of multiple diseases and complementary controls in the training set, all the control samples 
were assumed to be healthy and were therefore pooled. Then, within each disease classes of the mixed 
control group were up-sampled to match the total number of samples in the pooled control group. The 
AD samples were then up-sampled to match the total number of samples in the mixed control group. 
This process would ensure that all diseases in the mixed control group had the same probability to be 
used during the model development process. 
Next, the R package “xgboost” (version 0.6.4.1) was used to create optimised models. Default tuning 
parameters were set to eta=0.3, max_depth=6, gamma=0, min_child_weight=1, subsample=1, 
colsample_bytree=1, objective=“binary:logistic”,  nrounds=5000, early_stopping_rounds 
parameters=20 and eval_metric=”logloss”. The “seed” was randomly assigned “222” throughout the 
model developmental stages for reproducibility purposes. The initial model was built and internally 
evaluated using 10-fold cross-validation with stratification which calculates a test logloss mean at each 
nrounds iteration, stopping if an improvement to the test logloss means is achieved in the last 20 
iterations. The nrounds iteration that achieved the optimal test logloss mean was used to build the 




During the internal cross-validation process, each feature (gene) was assigned an importance value 
(“variable importance feature”) based on how well it contributed to the correct prediction of individuals 
in the training set. The higher the variable importance value for a gene, the more useful that gene was 
in distinguishing AD subjects from non-AD individuals. The genes contributing to the initial XGBoost 
model were each assigned a variable importance value. The least two variable important features were 
then iteratively removed, classification models re-built, and logloss performance measures re-
evaluated. This process was repeated through all available baseline features, with the minimum logloss 
from all iterations used to determine the most predictive genes. This process is referred to as “recursive 
feature elimination” and has been shown to improve classification model performance and reduce 
model complexity by removing weak and non-predictive features (Guyon et al., 2013). 
Following identification of the most predictive genes, the classification model was further refined by 
iteratively tuning through the following hyperparameter values: max_depth (2:20, 1), min_child_weight 
(1:10, 1), gamma (0:10, 1), subsample (0.5:1, 0.1), colsample_bytree (0.5:1, 0.1), alpha (0:1, 0.1), ), 
lambda (0:1, 0.1), and eta (0.01:0.2, 0.01), whilst performing a 10-fold cross-validation with 
stratification and evaluating the test logloss mean to select the optimum hyperparameters.   
5.2.6 Classification model evaluation  
The classification models were validated on the independent unseen testing set, predicting the 
diagnosis of all subjects as a probability ranging from 0 to 1, where AD ≤ 0.5 > non-AD. The prediction 
accuracy, sensitivity, specificity, PPV and NPV were calculated to evaluate the overall classification 
model’s performance. To assess the sensitivity and specificity of the classifiers, ROC curves and AUC 
scores were generated using the R package “ROCR” (version 1.07) with the following recommended 
diagnostic interpretations used: “excellent” (AUC = 0.9-1.0), “very good” (AUC = 0.8-0.9), “good” (AUC 
= 0.7-0.8), “sufficient“ (AUC = 0.6-0.7), “bad” (AUC = 0.5-0.6) , and “test not useful” when AUC value is 
<0.5 (Šimundić, 2009). 
The clinical utility metrics were calculated to evaluate the clinical utility of the classification models. The 
positive Clinical Utility Index (CUI +) was calculated as PPV * (sensitivity/100) and the negative Clinical 
Utility Index (CUI -) calculated as NPV * (sensitivity/100). The Clinical Utility Index (CUI) essentially 
corrects the PPV and NPV values for the occurrence of that test in each respective population and 
scores can be converted into qualitative grades as recommended: “excellent utility” (CUI >= 0.81), 
“good utility” (CUI >=0.64) and “satisfactory utility” (CUI >=0.49) and “poor utility” (CUI < 0.49) 
(Mitchell, 2012). An overview of the classification model development and evaluation process is 




5.2.7 The biological importance of predictive features 
The final classification model taken forward for external validation contains a list of ranked genes which 
collectively differentiate AD from non-AD subjects. These genes have been derived from multiple 
disorders and may be involved with biological processes, which was therefore assessed through Gene 
Set Enrichment Analysis (GSEA). The predictive genes were analysed using an Over-Representation 
Analysis (ORA) implemented through the ConsensusPathDB (http://cpdb.molgen.mpg.de) web-based 
platform (version 33) (Kamburov et al., 2009) in November 2018. For GSEA analysis, a minimum overlap 
of the query signature and database was set as 2. 
5.2.8 Data availability 
The data used in this study were all publicly available with accession details provided in Table 5.1. All 






Figure 5.1: Overview of Study Design. “Logloss” metric was used throughout the model developmental stage to identify 






5.3.1 Summary of data processing 
Twenty-one publicly available studies were identified, acquired and processed. Separating studies by 
disease status resulted in 22 datasets, which consisted of 3 AD, 3 MS, 3 SCZ, 3 CD, 3 RA, 2 COPD, 2 BD, 
2 PD and 1 ALS orientated dataset. Only 15 datasets contained both diseased and complementary 
control subjects, while the remaining 7 contained only diseased subjects. An overview of the 
demographics of each dataset is illustrated in Table 5.1 
Independently processing the 22 datasets resulted in a total of 2740 samples after Quality Control (QC), 
of which 287 samples were AD. Since 11 different BeadArrays had been used to expression profile the 
9 different diseases, and as 7 datasets were only available in a “processed format” (GSE63060, 
GSE63061, E-GEOD-41890, GSE23848, E-GEOD74143, E-GEOD-54629 and E-GEOD-42296), each 
dataset varied in the number of “reliably detected” genes after QC (detailed in Table 5.1). Initially, an 
overlap of the common measurable probes across all 22 datasets which were also deemed “reliably 
detected” in any one of the datasets was compiled, resulting in 7452 genes. However, following the 
independent transformation of each dataset, platform and BeadArray-specific batch effects were 
observed (Figure 5.2a-b). This can be largely explained by different platforms having different probe 
designs to target different transcripts of the same gene, leading to significant discrepancies and even 
absence in the measurement of the same gene by different platforms (Barnes et al., 2005). Therefore, 
to address this platform and BeadArray-specific batch effect, 1681 common “reliably detected” genes 
across all datasets that contained both male and female subjects (20 datasets) were extracted from 
each dataset and independently YuGene transformed. Essentially, these 1681 genes are expressed at a 
level deemed “reliably detected” in all 11 different BeadArrays. The distribution of the 1681 genes in 
each subject is shown in Figure 5.2c-d and can be seen to be more evenly distributed across the 2740 
subjects than Figure 5.2a-b, a characteristic desired for the machine learning algorithms. Correlation 
analysis was then performed on all samples, which suggested all samples were highly correlated, with 
the maximum per sample correlation coefficients ranging from 0.86-0.99. No sample was deemed to 





Figure 5.2: Shows the distribution of gene expression across all subjects. The distribution of gene expression across all 
individuals is expected to be similar when no batch effects exist. a) and c) are density plots, where each line represents the 
expression density of an individual while b) and d) represent the same data as boxplots respectively. a) and b) demonstrates 
batch effects caused by specific platform and BeadArrays when extracting 7452 unique genes deemed “reliably detected” in 
any of the 22 datasets. The shallow “n” curve in density plot a) are dominantly Illumina generated data, suggesting Illumina 
generated data have less lowly expressed genes in comparison to Affymetrix generated data. In contrast, c) and d) reveals a 
more evenly distributed gene expression profile across all subjects when extracting the 1681 common “reliably detected” genes,  
















































GSE63060 (Sood et al., 
2015) 
I HT-12 v3.0 WB 38323 46/99 42/62 249 2 10 5364 45/93 40/59 237 Training 
GSE63061 (Sood et al., 
2015) 
I HT-12 v4.0 WB 32049 51/81 55/87 274 5 4 5241 48/79 54/84 265 Testing 
E-GEOD-6613 
(Scherzer et al., 2006) 




(Scherzer et al., 2006) 
A HG U133A WB 22283 38/12 0/0 50 0 0 3674 38/12 0/0 50 Training 
E-GEOD-72267 
(Calligaris et al., 2015) 




et al., 2010) 
A HG U133A  WB 22283 9/16 0/0 25 0 0 6633 9/16 0/0 25 Testing 
E-GEOD-16214 (De 
Jager et al., 2009) 
A HG U133 plus 2.0 PBMC 54675 11/71 0/0 82 0 3 8098 11/68 0/0 79 Training 
E-GEOD-41890 (Irizar 
et al., 2014) 
A Exon 1.0 ST PBMC 33297 20/24 12/12 68 0 1 8157 19/24 12/12 67 Training 
Schizophrenia 
GSE38484 (de Jong et 
al., 2012) 
I HT-12 v3.0 WB 48743 76/30 42/54 202 9 5 6700 69/28 39/52 188 Training 
E-GEOD-27383 (van 
Beveren et al., 2012) 
A HG U133 plus 2.0 WB 54675 43/0 29/0 72 0 1 11297 42/0 29/0 71 Testing 
GSE38481 (de Jong et 
al., 2012) 
I Human-6 v3 WB 24526 4/11 16/6 37 2 1 8106 11/3 15/5 34 Testing 
Bipolar Disorder 
E-GEOD-46449 
(Clelland et al., 2013) 
A HG U133 plus 2.0 L 54675 28/0 25/0 53 0 0 9882 28/0 25/0 53 Training 
GSE23848 (Beech et 
al., 2010) 




(Ellsworth et al., 2014) 
A HG U133A 2.0 PBMC 22277 102/36 60/180 378 0 24 7676 94/36 57/167 354 Training 
GSE59867 (Maciejak et 
al., 2015) 
A Exon 1.0 ST WB 33297 85/26 0/0 111 0 3 7936 82/26 0/0 108 Testing 
E-GEOD-12288 
(Sinnaeve et al., 2009) 




et al., 2016) 





et al., 2014) 
A Exon 1.0 ST WB 33297 11/58 0/0 69 0 0 11931 11/58 0/0 69 Testing 
E-GEOD-42296 (Mesko 
et al., 2013) 






et al., 2014) 
A HG U133 plus 2.0 WB 54675 91/45 57/33 226 0 16 5531 83/44 52/31 210 Training 
E-GEOD-42057 (Bahr 
et al., 2013) 
A HG U133 plus 2.0 WB 54675 52/42 22/20 136 3 4 6445 49/39 21/20 129 Testing 
ALS E-TABM-940 A HG U133 plus 2.0 WB 54675 27/26 18/19 90 3 10 10442 27/25 15/10 77 Training 
Total      
904/95
6 
486/533 2879 25 114  
870/90
6 
465/49 2740  
Each study is accompanied by its corresponding publication (if available), where individual study design can be obtained. When possible, datasets were obtained in their raw format, except for 
GSE63060, GSE63061, E-GEOD-41890, GSE23848, E-GEOD74143, E-GEOD-54629 and E-GEOD-42296 which were only available in a processed form where dataset had already been background 
corrected, log2 transformed and normalised by techniques stated in corresponding publications. Multiple datasets from the same disease existed in this study. The dataset with the larger number 
of diseased subjects was prioritised into the training set for better discovery. Study ID’s initiating with “GSE” and “E-GEOD” were obtained from GEO and ArrayExpress respectively. Abbreviations 





5.3.2 Training Set and Testing Set demographics 
Multiple datasets from the same disease were obtained for this study, with the largest dataset from 
each disease assigned to the training set to improve discovery. However, three AD datasets were 
available, and the two largest datasets were generated on the Illumina platform, and the third on the 
Affymetrix platform. To address any subtle differences in gene expression which may still exist in the 
data due to platform differences, the largest Illumina AD and the Affymetrix AD datasets were both 
assigned to the Training Set.  
Following dataset assignment, the training set consisted of 160 AD subjects and 1766 non-AD subjects, 
while the testing set consisted of 127 AD subjects and 687 Non-AD subjects. The Non-AD group in both 
the training and testing set consisted of subjects with either PD, MS, SCZ, BD, CD, RA, COPD or were 
relatively healthy. Only one ALS dataset suitable for this study was identified and was deemed too small 
to split into the training and testing set. Therefore, the ALS dataset was assigned to the training set, 
allowing the machine learning algorithm to learn multiple disease expression signatures, which could 
further aid in differentiating AD from Non-AD subjects. Samples in the training set were up-sampled to 
prevent biasing the majority classes during model development. This resulted in “AD vs healthy” 
classification model consisting of 160 AD samples and 160 complimentary healthy control samples, and 
the “AD vs mixed controls” being trained on 6318 AD samples and 6318 non-AD samples. The “AD vs 
mixed controls” training set contains significantly more samples as the pooled controls consisted of 702 
samples; therefore, the remaining 8 disease classes were up-sampled to the same sample size which 
totalled 6318 samples. The AD samples were then up-sampled to 6318 to balance the training set. An 










AD vs healthy control AD vs mixed control 
Alzheimer's Disease 160* 6318 (160*) 127 
Parkinson's Disease 0 702 (50) 40 
Multiple Sclerosis 0 702 (122*) 25 
Schizophrenia 0 702 (97*) 56* 
Bipolar Disorder 0 702 (28) 20 
Cardiovascular Disease 0 702 (235*) 108 
Rheumatoid Arthritis 0 702 (353) 88* 
Chronic Obstructive Pulmonary Disease 0 702 (127) 88 
ALS 0 702 (52) 0 
Pooled Controls 160 (127*) 702* 262 
Entire datasets from each disease were assigned to either the “Training Set” for classification model development or the 
“Testing Set” for validation purposes. Datasets with a larger number of diseased subjects were prioritised into the training 
set to increase discovery. Two classification models were developed, the first was developed using only the 160 AD and 
associated 127 control samples, which were up-sampled to 160 to develop the “AD vs healthy control” classification model. 
The pooled controls in the “AD vs healthy control” training set originates only from AD datasets and can be regarded as 
cognitive healthy controls. The second classification model was developed using all datasets and diseases available in the 
training set and is referred to as the “AD vs mixed control” classification model, where samples in the minority classes are up-
sampled to match the 702 samples in the pooled controls. The mixed control group totalled 6318 samples. Therefore, the AD 
group was up-sampled to 6318 to create a balanced training set. Sample numbers provided in brackets are before up-
sampling. Sample numbers with an asterisk (*) indicates multiple datasets were available, and subject numbers shown are a 
sum across these datasets.  
5.3.3 “AD vs healthy control” classification model development and performance 
The “AD vs healthy control” classification model was developed using only the two AD datasets 
(GSE63060 and E-GEOD-6613) available in the training set, which after up-sampling consisted of 160 
AD and 160 cognitive healthy controls. The model was initially built using default parameters which 
selected 126 predictive features from the available 1681 genes, resulting in a cross-validation test 
logloss mean of 0.47 (0.21 SD). Further refinement of the model identified 74 predictive genes and the 
optimum hyperparameters as eta=0.12, max_depth=10, gamma=0, min_child_weight=1, subsample=1, 
colsample_bytree=1, alpha=0, lambda= 1 and nrounds =63, which improved the test logloss mean to 
0.27 (0.1 SD). 
The “AD vs healthy control” classification model was validated on the independent testing set and 
achieved a sensitivity of 58.0%, specificity of 30.0% and a balanced accuracy of 44.3% (additional 
classification performance metrics are provided in Table 5.3). The probability predictions of individual 




diseases and controls, demonstrating an increased false-positive rate and the inability of the 
classification model to confidently assign a positive (0) or negative (1) class to each subject.  
A ROC curve was generated for the “AD vs healthy control” classification model performance (Figure 
5.4), which demonstrates a low TP rate in comparison to random and the AUC score of 0.49 suggests 
this “test is not useful” as a diagnostic test. The clinical utility values (CUI +ve = 0.08, CUI -ve = 0.24) 
mirrors the AUC score interpretation, as the CUI values suggest the classification model is “poor” at 
detecting the presence and absence of AD and based on current validation results, has no real clinical 
utility. 
5.3.4 “AD vs mixed control” classification model development and performance 
The “AD vs mixed control” classification model was developed on the entire training set, which after 
up-sampling consisted of 6318 AD and 6318 non-AD subjects. The classification model was built using 
default parameters which selected 231 genes from the available 1681 genes as predictive features and 
resulted in cross-validation test logloss mean of 0.015 (0.009 SD). Further refinement of the model 
identified 28 predictive features, eta=0.08, max_depth=6, gamma=0, min_child_weight=1, 
subsample=1, colsample_bytree=1, alpha=0, lambda=0.9 and nrounds=139 as the optimum parameters 
which improved the cross-validation test logloss mean to 0.009 (0.005 SD). 
The “AD vs mixed control” classification model was further validated on the testing set and achieving 
46.5% sensitivity, 95.6% specificity, and balanced accuracy of 71.0% (additional classification 
performance metric are provided in Table 5.3).  
Table 5.3: Classification model performance 
  
“AD vs healthy control” 
classification model 
“AD vs mixed control” 
classification model 
Sensitivity 58.3% 46.5% 
Specificity 30.3% 95.6% 
Balanced Accuracy 44.3% 71.0% 
PPV 13.4% 66.3% 
NPV 79.7% 90.6% 
AUC 0.49 0.84 
AUC Rating Test not useful Very good 
CUI +ve 0.08 0.31 
CUI +ve Rating Poor Poor 
CUI -ve 0.24 0.87 
CUI -ve Rating Poor Excellent 
The table provides the performance measurements form validating the “AD vs Healthy Control” and the “AD vs Mixed 




The performance of this classification model improves on the typical “AD vs healthy control” 
classification model in all performance metrics, except for sensitivity, where a decrease in performance 
is observed from 58% to 46.5%. Nevertheless, due to the “AD vs mixed control” classification model 
predicting less false positives, an increase in PPV (66.3%) is observed when compared to the “AD vs 
healthy control” classification model (PPV = 13.4%). Furthermore, as illustrated in Figure 5.3b, the 
probability predictions for individuals in the testing set are more correctly and confidently predicted 
when compared to the typical “AD vs healthy control” classification model, only misclassifying 21 
pooled controls (8% of total pooled controls), 2 CD (2% of CD subjects), and 7 SCZ (13% of SCZ subjects) 
as AD. The “AD vs mixed control” classification model ROC curve (Figure 5.4) achieves an improved AUC 
score of 0.84 which translates to a “very good” diagnostic test, however, the clinical utility values (CUI 
+ve = 0.31 and CUI -ve = 0.87) suggests this classification model is “poor” in the detection of AD but 
“excellent” to rule out “AD”.  
 
Figure 5.3: Shows the probability prediction of the testing set samples being AD (0) or non-AD (1). Subjects in the testing set 
represent a heterogeneous ageing population with subjects being clinically diagnosed with various mental-health related 
disorders, neurodegenerative diseases, age-related diseases or are relatively healthy. a) illustrates the confidence of the “AD vs 
healthy control” classification model distinguishing subjects in the testing set and b) illustrates the confidence of the “AD vs 
mixed control” classification model in predicting the same testing set. Controls represent pooled non-diseased subjects from all 
datasets. Diseases are abbreviated as follows; AD = Alzheimer’s disease, BD = Bipolar disease, CD = Coronary Artery disease, 
COPD = Chronic Obstructive Pulmonary Disease, MS = Multiple Sclerosis, PD = Parkinson’s Disease, RA = Rheumatoid Arthritis 
and SCZ = Schizophrenia.  
5.3.5 “AD vs mixed control” classification model’s predictive features 
The variable importance was calculated for the 28 predictive genes (gene list provided in 




provides the greatest predictive value with a relative importance value of 0.7. GSEA performed on the 
28 genes identified four biological processes significantly enriched; WNT ligand biogenesis and 
trafficking (p-value= 9.56e-4, q-value=0.04), Alzheimer disease (p-value= 3.70e-3, q-value=0.05), 
 
Figure 5.4: AD classification model ROC curves. The blue line represents the typical “AD vs healthy control” classification model’s 
ROC curve which is trained using AD and complimentary healthy control subjects. The red line represents the “AD vs mixed 
control” classification model’s ROC curve, which is trained using AD and non-AD diseased and healthy control subjects. The ROC 
curves were generated from the performance of both classification models in the testing set and demonstrate an improved TP 
and FP rate with the “AD vs mixed control” classification model, which achieved an improved AUC value of 0.84 when compared 
to the typical “AD vs healthy” classification approach which achieved an AUC score of 0.49 
Herpes simplex infection (p-value= 4.61e-3, q-value=0.05), and Huntington disease (p-value= 5.19e-3, 
q-value=0.05). Additional information on gene overlap between the 28 predictive genes and biological 





Figure 5.5: Relative Importance of the 20 most predictive genes for the “AD vs mixed control” classification model  
5.4 Discussion 
Previous attempts to identify blood-derived gene expression profiling for AD diagnosis have relied on 
the typical approach of training machine learning algorithms on AD and cognitively healthy subjects 
only, inadvertently leading to classification models learning expression signatures that may be of 
general illness rather than being disease-specific. Validating such a classification model in a 
heterogeneous ageing population may fail to distinguish AD from similar mental health disorders, 
neurodegenerative diseases, age-related disorders and cognitively healthy individuals. To address this 
issue, this study developed an “AD vs mixed control” classification model based on a training set 
comprised of AD, PD, MS, BD, SCZ, CD, RA, COPD, ALS and a set of pooled healthy individuals totalling 




pooled controls representing the largest class consisting of 702 samples. Therefore, to avoid sampling 
bias during the classification model development, the individual classes in the mixed control group were 
each up-sampled with replacement to 702, which totalled 6318 samples. The AD group were then up-
sampled to 6318, classification model developed, optimised and evaluated in an external independent 
cohort comprised of similar diseases and controls totalling 814 subjects. 
5.4.1 The typical “AD vs healthy control” classification model performs poorly in a 
heterogeneous ageing population 
The typical approach of developing a classification model trained on AD and complimentary cognitive 
healthy control subjects produced a model with a sensitivity of 58.3% in an independent cohort of 127 
AD subjects. The performance of this model is slightly better than a previous attempt which attained a 
sensitivity of 56.8% when validated in an independent testing set of 118 AD subjects (Voyle et al., 2016). 
However, when evaluating this typical AD classification model in a heterogeneous ageing population, a 
process often neglected in previous studies, a very low specificity of 30.3% was attained which equated 
to a low PPV of only 13.4%. PD is the second most common cause of dementia (‘2018 Alzheimer’s 
disease facts and figures includes a special report on the financial and personal benefits of early 
diagnosis’, 2018) and was seen to be most misclassified as AD. However, since misclassification was 
observed in all groups including large portions of the controls, this classification model is most likely 
not capturing signals of AD, dementia or general illness, but is most likely a result of technical noise, 
individual study batch effects and overfitting. This is mirrored in the model’s performance metrics 
which translates to a “poor” clinical utility in detecting the presence and absence of AD. Overall, the 
typical approach of AD classification model development failed to accurately distinguish AD subjects in 
a heterogeneous ageing population consisting of PD, MS, BD, SCZ, CD, RA, COPD, ALS and relatively 
healthy controls.  
5.4.2 The “AD vs mixed control” classification model outperforms the typical “AD vs healthy 
control” classification model 
In contrast, the “AD vs mixed control” classification model attained a validation PPV of 66.3% and NPV 
of 90.6% on the same testing set, which outperforms the validation PPV of 13.4% and NPV of 79.9% 
achieved by the “AD vs healthy control” classification model. However, this improvement was at the 
cost of sensitivity, which was reduced from 58.3% (“AD vs healthy control”) to 46.4% (“AD vs mixed 
control”). Nevertheless, an overall increase in the clinical utility of the “AD vs mixed control” 
classification model was measured and according to the recommended CUI interpretations in (Mitchell, 




The performance of the “AD vs mixed control” classification model can be suggested to be superior due 
to the increased number of samples in the training set. The “AD vs healthy control” classification model 
was developed using 160 AD samples while the “AD vs mixed controls” classification model was 
developed using 6318 AD samples. However, it is important to note the AD samples in both training 
sets originated from the same subjects, with AD sample numbers in the “AD vs mixed control” training 
set up-sampled to account for the variation of sample sizes across the individual classes in the mixed 
control group. Therefore, the increased performance achieved by the “AD vs mixed control” 
classification model is most likely the result of incorporating additional related neurological and age-
related disorders into the classification model development process, which aided in the identification 
of a more AD-specific expression signature than the typical approach of using only AD and 
corresponding control samples. Although this improved the ability to distinguish AD from other related 
diseases and cognitively healthy controls, the sensitivity of the model was reduced and needs to be 
further enhanced for this type of research to be beneficial in the clinical setting. 
5.4.3 Predictive features are enriched for Herpes Simplex Infection 
The underlying replication of predictive genes across blood-based transcriptomic biomarker studies are 
inconsistent (Ein-Dor et al., 2005; Haury, Gestraud and Vert, 2011; Venet, Dumont and Detours, 2011; 
Siavelis et al., 2016a). Nevertheless, sets of genes within independent studies have been able to 
consistently distinguish AD from complimentary controls (Siavelis et al., 2016a). Therefore, the 
predictive features in this study warrant further investigation to assess their biological relevance to AD. 
The “AD vs mixed control” classification model differentiates AD from other diseases and healthy 
controls using the relationship of 28 genes. GSEA identified “Herpes simplex infection” as one of the 
biological pathways being significantly enriched prior to multiple corrections, with an overlap of 3 genes 
(CDC34, HCFC1 and HLA-DMA). This suggests gene expression changes associated with this process are 
measurable in blood and may contribute towards identifying AD subjects. Pathogenic viral components 
have been long suspected of playing an essential role in the onset and progression of AD. A recent study 
identified common viral species in normal and ageing brains, with an increased human herpesvirus 6A 
and human herpesvirus 7 in AD brains (Readhead et al., 2018). In addition, this thesis (chapter 3) 
identified genes involved with “interspecies interactions” were specifically enriched in AD brains when 
taking into account expression changes in related neurological disorders, findings which have been 
published in the Journal of Alzheimer’s Disease (Patel, Dobson and Newhouse, 2019). The current 
observation extends the previous suggestions of viral involvement in AD brains to blood, as the 
expression of blood-derived genes involved in the “Herpes simplex infection” can be used to distinguish 




5.4.4 Predictive features consist of age-related markers  
Age is one of the most significant risk factors for AD, and the prevalence of the disease is known to 
increase with age. A meta-analysis study investigating blood transcriptional changes associated with 
age in 14,983 humans, identified 1,496 differentially expressed genes with chronical age (Peters et al., 
2015), of which three genes (LDHB, AARS and ABR) are in the “AD vs mixed control” classification 
model’s 28 predictive genes. The classification models most predictive gene LDHB is ranked 28th in the 
meta-analysis study and was also observed to be negatively associated with age in the brain, specifically 
the frontal cortex and cerebellum (Peters et al., 2015). The datasets used in this study were publicly 
available, and as such, were accompanied with limited phenotypic information, including age. 
Therefore, age was not accounted for during the classification model developmental process. However, 
as this study uses a variety of age-related diseases, in addition to the 3 AD datasets, and study designs 
generally incorporate complementary age-matched controls, it is highly unlikely the classification 
model is predicting age alone but is more likely using a combination of signals including age to 
distinguish AD. Without age information for all subjects, this study is unable to conclude how age is 
influencing the model prediction process. 
5.4.5 Gene expression profiling as a blood-derived biomarker for AD  
A drive to identify accessible biomarkers for AD diagnosis has resulted in a field that has explored CSF 
and blood-derived components. Blood-derived biomarkers are particularly attractive due to their less 
invasive nature. Studies involving blood transcriptomic levels have demonstrated some capability of 
distinguishing AD from healthy controls  (Fehlbaum-Beurdeley et al., 2010; Booij et al., 2011; Lunnon 
et al., 2013; Roed et al., 2013; Voyle et al., 2016); however, small sample size and lack of independent 
validation datasets most likely led to overfitting and variable results. In addition replication of the 
underlying predictive genes across AD blood-based transcriptomic biomarker studies have also been 
found to be inconsistent (Siavelis et al., 2016a), suggesting a robust, reproducible AD blood gene 
expression signature has still not been identified. 
This study applied an alternative strategy to identify AD subjects by incorporating other diseases into 
the classification model developmental process, which in comparison to the typical AD vs healthy 
control approach, resulted in a model with an overall improved model performance when applied to a 
heterogeneous ageing population. Although the current clinical utility of the “AD vs mixed control” 
classification model is “excellent” in ruling out AD, the sensitivity of the test needs to be further 
improved for this type of research to be beneficial in the clinical setting. With the advances in new 
sequencing technologies and the ability to scan the whole transcriptome, additional gene-expression 




potential of blood-based transcriptomic classification model distinguishing AD from a heterogeneous 
ageing population.  
5.4.6 Limitations 
All data used in this study were publicly available, and as such, many were accompanied by limited 
phenotypic information, including basic sex information, which was predicted based on gene expression 
when missing. Therefore, this study was unable to incorporate additional phenotypic information 
during the classification model building process, which has been shown to improve model performance 
(Voyle et al., 2016). Information such as comorbidities, age and medications are unknowns which could 
be affecting performance in this study. For instance, control subjects in this study that originated from 
non-AD datasets were screened negative for their corresponding disease of interest but were not 
screened for cognitive function. i.e. control subjects from the CD datasets were included in their 
retrospective dataset if they did not have CD, they were not necessarily checked for cognitive 
impairment. Therefore, some misclassified control subjects may indeed be on the AD spectrum, and 
it's important to note subjects from the pooled control group were most misclassified as AD by the “AD 
s mixed control” classification model. However, it is also important to note the training set used to 
develop the “AD vs mixed control” classification model also contains these controls which have not 
been screened for AD.  If these controls or age-related disease subjects are comorbid with AD, the 
classification model may have inadvertently learned to be biased towards a subgroup of AD subjects 
with no comorbid with any other disease, hence the low sensitivity validation performance when 
introducing additional datasets into the classification model developmental process. 
This study involved a number of subjects clinically diagnosed with age-related diseases, and most likely, 
are on some sort of therapeutic treatment to manage or treat the underlying disease, another piece of 
vital information generally missing from publicly available datasets and from this study. As therapeutic 
drugs have been well-known to affect gene expression profiling, including memantine, a common drug 
used to treat AD symptoms (Huang et al., 2015), the “AD vs mixed control” classification model may 
have inadvertently learnt gene expression perturbations due to therapeutic treatment rather than 
disease biology, and would, therefore, fail in the clinical setting to diagnose AD subjects who are not 
already on medication. To address this issue along with co-morbidity, clear and detailed phenotypic 
information would be needed for all subjects, which is encouraged for future studies planning to submit 
genetic data to the public domain. 
This study used datasets generated on 11 different microarray BeadArrays, resulting in datasets ranging 
from 22277-54715 probes prior to any QC. Coupled with differences in BeadArrays designs across 




across all datasets. This ensured gender-specific expression changes were captured; however, this may 
have also inadvertently lost some disease-specific changes. To address this issue, these subjects need 
to be expression profiled on the same microarray platform and ideally the same expression BeadArray, 
which currently doesn’t exist in the public domain. The advances in sequencing technologies which can 
capture expression changes across the whole transcriptome can potentially solve this issue and future 
studies are encouraged to replicate this study design with RNA-Seq data with detailed phenotypic 
information when/if available, albeit, this may bring new challenges. 
5.5 Conclusion  
This study relied on publicly available microarray gene expression data, which too often lacks detailed 
phenotypic information for appropriate data analysis and needs to be addressed by future studies. 
Nevertheless, with the available phenotypic information and limited common “reliably detected” genes 
across the different microarray platforms and BeadArrays, this study, albeit it has many limitations, 
demonstrated the typical approach of developing an AD blood-based gene expression classification 
model using only AD and complimentary healthy controls fails to accurately distinguish AD from a 
heterogeneous ageing population. However, incorporating additional related neurological and age-
related diseases into the classification model development process can result in a model with improved 
“predictive power” in distinguishing AD from a heterogeneous ageing population. Due to a number of 
limitations, further work is required in order to identify a robust blood transcriptomic signature more 





 Chapter 6: Discussion 
6.1 Summary of principal findings 
The aim of this thesis was to analyse inhouse and existing transcriptomic data to further understand 
the genetic and biological mechanisms associated with AD. The thesis began with chapter 2 
investigating the first human brain microarray gene expression profiling of Asymptomatic AD (AsymAD) 
subjects who were clinically free from dementia; however, upon autopsy were discovered to be 
consistent with mild AD pathology. The aim of this chapter was to identify early brain transcriptomic 
changes and identify new potential therapeutic targets for early disease intervention. The third chapter 
combined novel and existing AD brain microarray gene expression studies in the largest known AD 
meta-analysis to date. Additional non-AD neurological disorders (PD, BD, Schizophrenia, MDD and HD) 
were incorporated into the analysis to identify specific molecular changes associated with AD brains. 
Furthermore, both brain regions spared and affected by hallmark AD pathology were analysed to reveal 
transcriptomic changes and disease mechanisms most likely involved with hallmark AD pathology. 
The fourth chapter reprocessed the CMap database using up-to-date processing techniques and 
created an automated drug repositioning pipeline consisting of four different search algorithms. The 
AsymAD and AD brain transcriptomic signatures discovered in this thesis were repurposed to identify 
relevant candidate compounds that may intervene with the disease during the asymptomatic and 
symptomatic stage. Finally, in chapter 5, a machine learning approach was used in an attempt to 
identify a blood-based gene expression biomarker which could discriminate AD from cognitive healthy 
and age-related diseased subjects. The principal findings from each chapter are summarised in the 
following section. 
6.1.1 Chapter 2: Transcriptomic Analysis of Probable Asymptomatic AD and AD Brains 
A significant increase of transcriptomic activity in the FC brain region of AsymAD subjects was detected, 
suggesting fundamental changes in AD may initially begin within the FC brain region prior to clinical 
symptoms of AD. In addition, overactivation of the brain “glutamate-glutamine cycle” and disruption to 
the brain energy pathways in both AsymAD and AD subjects was detected. Further analysis using 
protein-protein interaction networks detected a shift from an already increased cell proliferation in 
AsymAD subjects to stress response and removal of amyloidogenic proteins in AD subjects. 
6.1.2 Chapter 3: A Meta-analysis of Alzheimer’s Disease Brain Transcriptomic Data 
The meta-analysis identified 323, 435, 1023 and 828 DEG’s specific to AD TL, FL, PL and CB brain regions 
respectively. Seven of these genes were consistently perturbed across all AD brain regions with SPCS1 




control to identify nineteen genes (ALDOA, GABBR1, TUBA1A, GAPDH, DNM3, KLC1, COX6C, ACTG1, 
CLTA, SLC25A5, PRNP, FDFT1, RHOQ, B2M, SPP1, WAC, UBA1, EIF4H and CLDND1) that may be involved 
in hallmark AD pathology. Furthermore, biological processes often reported as disrupted in AD were 
observed to be tissue-specific, with only the “metabolism of proteins” and viral components specifically 
enriched across AD brains.  
6.1.3 Chapter 4: Automated Drug-repositioning from a disease expression signature 
An automated drug repositioning pipeline was developed to query the reprocessed CMap database 
using a disease gene expression profile and four different algorithms to identify candidate compounds 
for disease intervention. Validation suggested three methods had the potential for drug repositioning; 
however, different methods were observed to be tissue-specific. Nevertheless, analysis of the CMap 
database identified tacrine (FDA approved for AD), thioperamide (FDA approved for cognitive 
impairment) and epirizole (FDA approved for anti-inflammatory disease) as candidate compounds for 
AsymAD but not AD patients. Furthermore, an anti-biotic candidate compound paromomycin was 
repurposed for AD. Through a literature review, the candidate compounds were found to be relevant 
to the disease; however, the work undertaken in this chapter was merely exploratory, and candidate 
compounds require further functional investigations. 
6.1.4 Chapter 5: Working Towards a Blood-Derived Gene Expression Biomarker Specific for 
Alzheimer's Disease 
The addition of related neurological and age-related disorders into the classification model 
development process identified a more AD-specific expression signature. The classification model 
achieved 66.3% PPV and 90.6% NPV when differentiating AD from Parkinson’s Disease, Multiple 
Sclerosis, Amyotrophic Lateral Sclerosis, Bipolar Disorder, Schizophrenia, Coronary Artery Disease, 
Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease, and cognitively healthy subjects. Further 
investigation identified the predictive features were significantly enriched for “Herpes simplex 
infection” and age-related markers. Despite the improved specificity, a decrease in sensitivity was 
observed, and therefore, further improvement is still required in order to identify a reliable blood 
transcriptomic signature specific to AD.  
6.2 Implications of findings 
Much further work is still needed in this field to gain an insight into early and specific signatures of AD. 




6.2.1 Robust QC pipeline to process publicly available microarray gene expression data 
This thesis provides a robust QC pipeline for processing raw Illumina and Affymetrix generated 
microarray gene expression data and makes it widely accessible as detailed in the “A Meta-Analysis of 
Alzheimer’s Disease Brain Transcriptomic Data” peer-reviewed publication. Typically, an arbitrary cut-
off or a fixed expression percentile threshold is used to determine if a gene is reliably detected, but this 
does not take into consideration the variation of probe quality across different platforms and 
expression arrays. As discovered in the “Chapter 5: Working Towards a Blood-Derived Gene Expression 
Biomarker Specific for Alzheimer's Disease”, simply using common probes across different microarray 
platforms and expression arrays leads to variation in gene expression across samples, with obvious 
platform-specific batch effects observed. This can be largely explained by different platforms having 
different probe designs to target different transcripts of the same gene, leading to significant 
discrepancies and even absence in the measurement of the same gene by different platforms (Barnes 
et al., 2005). However, when incorporating only probes deemed “reliably detected” by the data 
processing pipeline developed in this thesis, which uses a variety of literature defined house-keeping 
genes to determine if a gene is “reliably detected”, this obvious platform-specific batch effect 
disappears. The application of this QC data processing pipeline is particularly useful when processing 
publicly available data, which as discovered in this thesis, is too often available in a “processed format 
only” where some probes have already been subset to those deemed “reliably detected” by 
corresponding authors. 
6.2.2 Monitoring the FC brain region of the elderly may identify patients at risk of AD 
Molecular changes in AD were found to initially begin in the FC brain region prior to the manifestation 
of clinical symptoms. This mirrors changes described in a longitudinal study involving ageing controls, 
where PET scans were used to detect increased activity in the medial frontal cortex in subjects who 
subsequently acquired cognitive impairment (Beason-Held et al., 2013). Therefore, this thesis provides 
further evidence to clinically monitor brain activities in the FC of elderly patients to identify possible 
patients at risk of AD for early disease intervention. 
6.2.3 Clinical treatment for AD may be useful in AsymAD 
A significant overactivation of the “glutamate-glutamine cycle” in brains of probable asymptomatic AD 
subjects was identified, providing a possible therapeutic target for early disease intervention. 
Memantine is a compound that affects the “glutamate-glutamine cycle” and is already a clinically 
established treatment used for the symptomatic relief in AD patients. Memantine blocks N-methyl-d-
aspartate (NMDA) receptors, preventing excitotoxicity caused by neurotransmitters such as glutamate, 




CMap database identified tacrine as one of the most significant candidate compounds, which once 
again is an FDA approved treatment for AD. Together, this suggests these compounds to treat AD may 
also be effective in the asymptomatic stage of the disease, although it's important to note identification 
of these patients in the symptomatic phase would be a challenge in itself, and these treatments do not 
change the pathology of the disease; however, they may possibly prolong the onset of disease 
symptoms and therefore require further investigation.  
6.2.4 Identification of new genes associated with AD that may be of therapeutic benefit 
Meta-analysis identified seven genes (down-regulated NDUFS5, SOD1, SPCS1 and up-regulated OGT, 
PURA, RERE, ZFP36L1) specifically perturbed across AD brains and not in similar brain regions of 
Schizophrenia, BD, HD, MDD or PD. The expression patterns of three of these genes (SPCS1, PURA and 
ZF36L1) were available in the RNA-Seq database Agora, which was found to relatively mirror microarray 
expression patterns. Subsequently, the AMP-AD consortia have nominated SPCS1 gene as a druggable 
target for AD based on expression patterns and additional network genomics and epigenomic elements. 
This provides confidence the remaining genes identified in this thesis may also be of therapeutic benefit 
and warrant further investigation. 
6.2.5 Identification of new genes associated with hallmark AD pathology 
Nineteen genes (ALDOA, GABBR1, TUBA1A, GAPDH, DNM3, KLC1, COX6C, ACTG1, CLTA, SLC25A5, 
PRNP, FDFT1, RHOQ, B2M, SPP1, WAC, UBA1, EIF4H and CLDND1) were identified to be associated 
specifically with hallmark AD pathology. Ten of these genes (DNM3, GABBR1, GAPDH, PRPN, FDFT1, 
KLC1, TUBA1A, CLTA, COX6C and SLC25A5) were previously reported to be associated with AD, with five 
genes (DNM3, GABBR1, GAPDH, PRPN and FDFT1) specifically suggested to be involved in the pathology 
of the disease. Therefore, this thesis further validates five genes are possibly associated with hallmark 
AD pathology, specifically NFT, whilst providing an additional fourteen candidate genes for further 
investigation. 
6.2.6 Publicly available web-based application to explore gene expression changes in AD 
brains 
The transcriptomic brain changes identified in this thesis which represent changes from healthy ageing 
to AsymAD and then further to AD, have been made publicly available through an easy to access R shiny 
web-based application (https://phidatalab-shiny.rosalind.kcl.ac.uk/ADbrainDE/). This allows future 
researchers to query specific genes and obtain expression patterns through the course of the disease 




6.2.7 Gene expression data processing framework for the clinical environment 
A microarray gene expression data processing framework was demonstrated in this thesis where 
datasets can be independently processed, and gene expression values directly compared to one 
another without the need to use additional information from a reference dataset to adjust gene 
expression values. This framework was demonstrated in the “Working Towards a Blood-Derived Gene 
Expression Biomarker Specific for Alzheimer’s Disease” chapter where datasets in the training set were 
independently processed to build the classification model, and the validation set was independently 
processed and normalised without using gene expression variation information from the training set. 
This framework would allow for a real-world clinical application if such a transcriptomic based 
diagnostic test was developed, allowing new samples to be independently processed and diagnosis 
predicted without using prior expression variation knowledge from the data used to build the 
classification model, avoiding possible prediction biases. 
6.2.8 Developing disease-specific classification models based on gene expression data 
This thesis demonstrates to the research community the potential pitfalls of developing an AD blood-
based gene expression classification model developed solely on cases and complimentary healthy 
controls. This typical approach may capture markers for illness and technical noise rather than biology 
specific to the disease, and as demonstrated in this thesis, when validating in an ageing heterogeneous 
population, the typical classification model fails to accurately distinguish AD from related disorders. 
However, incorporating related disorders into the classification model development process can aid in 
identifying a more AD-specific expression signature, with improved ability to distinguish AD from other 
related diseases and cognitively healthy controls. The approach used to build the classification model 
is most likely applicable to other disorders and can be used to refine a specific disease gene expression 
signatures. 
6.2.9 A blood-based diagnostic test with excellent clinical utility for AD screening 
The AD blood-based transcriptomic signature identified in this thesis has ”excellent” clinical utility for 
screening; however, the utility is “poor” in identifying AD. Although improvement has been made when 
compared to the typical approach of building a blood-based AD classification model using simply AD 
subjects and complimentary healthy controls, further investigation is still required before a robust 
blood-based gene expression signature for clinical utility can be achieved, if any.  
6.2.10 Bacterial and viral components in AD need further investigation 
Throughout this thesis, bacterial and viral aspects have been identified to be associated with AD. Firstly, 
the meta-analysis identified various biological components enriched across all AD brain regions, 




biological components remain enriched and all four are indicative of interspecies interactions. 
Secondly, drug repositioning the AD brain gene expression signature identified paromomycin, an 
antibiotic to treat bacterial infections as the most significant candidate compound. Thirdly, the blood-
based gene expression signature used to differentiate between AD from a heterogeneous ageing 
population was based on 28 predictive genes which were found to be most significantly enriched for 
“Herpes simplex infection”. Aβ has been suggested to be an antimicrobial peptide and has been shown 
to protect against fungal and bacterial infections (Kumar et al., 2016). Previous research has suggested 
bacterial involvement in AD (Sethi et al., 2016; Readhead et al., 2018), while another identified common 
viral species in normal and ageing brains, with an increased human herpesvirus 6A and human 
herpesvirus 7 in AD brains (Readhead et al., 2018). The findings in this thesis reinforce bacterial and 
viral components may be involved in AD, prompting further investigation. 
6.3 Limitations 
The broader limitations of the thesis are presented here, with specific limitations addressed within 
individual chapters.  
6.3.1 Microarray technologies 
A big limitation of this thesis is the technology used to generate the data. Gene expression microarrays 
were designed to measure the expression of specific genes based on pre-defined probes and therefore 
are restricted to known variations. Therefore, microarrays may not be the ideal approach for 
transcriptomic biomarker discoveries. RNA-Seq provide many benefits over microarray technologies, 
including  longer base pair reads for more precise mapping to the genome as microarray short reads 
can be limited due to the repetitiveness of the genome, has a larger dynamic range of expression 
measurement and has been suggested to be more reproducible (Wang, Gerstein and Snyder, 2009).  
However, as this thesis primarily relies on publicly available datasets, larger microarray datasets were 
more readily and abundantly available in comparison to RNA-Seq, making the analysis undertaken in 
this thesis possible. 
6.3.2 Publicly available gene expression datasets lacked detailed phenotypic and sample 
processing information 
Publicly available datasets lacked vital sample processing information, making it impossible to adjust 
for systematic errors introduced when samples are processed in multiple batches, a term often known 
as “batch effects”. Therefore, this thesis incorporated best practices to estimate and correct for both 
known and hidden batch effects using SVA and COMBAT to ensure data is comparable between 





In addition, many publicly available datasets lacked detailed phenotypic information such as gender, 
ethnicity, comorbidity, BRAAK staging, NFT, neuronal loss, age of disease onset, APOE status, rate of 
cognitive decline measures and disease duration. These influential factors, if known, could have been 
incorporated into the study design or data processing pipelines in an attempt to address their effects 
on the results.  
Gene expression measurements can also be influenced by medication, which due to the lack of detailed 
phenotypic information accompanying datasets used in this thesis, it is unknown if subjects throughout 
this thesis were on any medication that may have influenced gene expression measurements. Clinically 
diagnosed AD subjects would have most likely been on medication for symptomatic relief through 
compounds such as memantine, which was found to influence gene expression in the “Automated 
Drug-repositioning of Transcriptomic Disease Signature” chapter. Therefore, the gene expression 
signatures captured in this thesis may be the result of the disease in combination with medication. 
Nevertheless, as none of the current FDA approved medications for AD affects the underlying pathology 
of the disease, the AD gene expression signatures identified in this thesis would have most likely 
captured biology relevant to AD, especially when associating with hallmark AD pathology. 
6.4 Future directions  
The “implications of findings” in combination with the thesis “limitations” sections outlined above have 
highlighted several future directions; however, a more general outline is provided below. 
6.4.1 Validation of genes associated with AD 
Several key genes perturbed in the brains of both asymptomatic and symptomatic AD have been 
identified using microarray gene expression datasets. Some of these genes have been previously 
associated with AD, while many are novel genes requiring further validation through additional 
technologies such as PCR or RNA-Seq. Providing these genes are found to be associated with AD, further 
investigations can attempt to identify the effects of these genes in AD through knockout mouse models. 
6.4.2 An ensemble approach for drug repositioning and biomarker discovery 
Drug repositioning was performed using four independent techniques to repurpose the CMap 
database. An ensemble of some of these methods may be more effective than the current single 
method approach and warrants further investigation. Similarly, the blood-based AD classification model 
was developed with a single machine learning approach; however, an ensemble of machine learning 
algorithms may be more effective in identifying a robust gene expression signature specific to AD as it 




6.4.3 Blood-based gene expression disease multi-classifier 
This thesis aimed to identify a blood-based gene expression signature to identify AD from an ageing 
heterogeneous population consisting of multiple disorders. Typically, a patient could be given such a 
blood test if symptoms were suggestive of dementia, which can be caused by many disorders including 
AD. A multi-classification model that can specifically identify or indicate the most likely cause of 
symptoms would be more beneficial. Therefore, future researchers are encouraged to explore this 
avenue using larger RNA-Seq datasets with detailed phenotypic information including comorbidity.  
6.4.4 Biomarker for early detection of AD 
The ability to detect AD early, during the asymptomatic phase of the disease would be extremely 
beneficial. This would allow an opportunity for the development of potential treatments to halt the 
disease early prior to clinical symptoms, which may be more effective than attempting to reverse the 
hallmark AD pathology that already exists in clinically diagnosed AD patients. Therefore, researchers 
are further encouraged to investigate biomarkers to identify these patients, which may be achieved 
through monitoring the neuronal activity of the FC brain region of elderly patients through imaging 
techniques such as PET. 
6.4.5 Integration of biological, clinical and physical measurements to further advance the 
understanding of AD 
The advances in technologies to measure an individual’s biological and physical state provides an 
opportunity to combine genetics, transcriptomic, proteomic, brain imaging, physical state 
measurements from wearable devices and clinical symptoms to greatly advance the understanding of 
the risks, development and course of the disease. This can further help with the development of early 
diagnosis, define a definitive diagnosis of the disease or identify subgroups, and can provide an 
opportunity to provide individual orientated treatment. 
6.4.6 Bacterial involvement in AD 
With RNA-Seq technologies increasingly being used to profile AD and data being made publicly 
available, an opportunity may exist to investigate bacterial involvement in AD. One of the advantages 
of RNA-Seq over microarray technologies is the ability to be free from pre-defined probes, allowing 
measurement of annotation-independent transcription. Therefore, to infer biological relevance, the 
transcripts measured in RNA-Seq need to be aligned to a reference sequence. This provides an 
opportunity to align AD RNA-Seq transcripts to bacterial genomes to identify bacterial strains possibly 





The increase in life expectancy has profoundly increased the ageing population, which, unfortunately, 
is also accompanied by a rise in age-related disorders including AD. The most common form of dementia 
is AD, which was first described over a century ago, however, to date, there still exists a lack of 
understanding molecular changes specific to the disease, a clinically established robust blood-based 
biomarker for accurate disease diagnosis and a lack of therapeutic treatments.   
This thesis was the first to explore the emergence of transcriptomic changes in the human brain from 
healthy ageing through to probable AsymAD and then further to AD. The results suggest molecular 
changes in AD may initially begin in the frontal cortex and disruptions in the energy cycle, and 
overactivation of the “glutamate-glutamine cycle” is already apparent in the asymptomatic phase of 
the disease. Compounds to target this pathway already exist. Memantine, an FDA approved treatment 
for AD, blocks NMDA receptors, preventing excitotoxicity caused by neurotransmitters such as 
glutamate, which can temporarily increase cognition. In addition, candidate compounds tacrine and 
thioperamide, which are also FDA approved to treat the symptoms of AD and cognitive impairment 
respectively, were repurposed for AsymAD in this thesis.  This suggests FDA approved compounds to 
treat AD and general cognitive impairment may also be effective treatment options in the early phase 
of the disease, prior to clinical symptoms of AD, albeit the challenge remains to identify these patients 
and these compounds are known to only provide temporary symptomatic relief and do not change the 
underlying pathology of the disease. 
The most extensive human AD microarray transcriptomic meta-analysis study to date was also 
performed in this thesis, which identified several genes specific to AD brains. Nineteen genes were 
discovered to be associated with hallmark AD pathology and seven genes were observed to be 
consistently perturbed across AD brains, with SPCS1 gene expression pattern found to replicate in RNA-
Seq data. Subsequently, the AMP-AD consortia have nominated SPCS1 gene as a druggable target for 
AD based on expression patterns and additional network genomics and epigenomic elements. This 
provides additional confidence the remaining genes identified in this thesis may also be of therapeutic 
benefit.  
Non-AD neurological disorders and age-related diseases were incorporated into this thesis to aid in the 
identification of biology that may be specific to AD, rather than general illness.  This resulted in the 
discovery of bacterial and viral components being specifically enriched in the blood and brains of AD 
patients. Furthermore, repurposing the AD disease signature identified an antibiotic as the most 
significant candidate compound to treat AD. Together with recent literature, a bacterial and viral 




neurological and age-related diseases during the AD classification model development process results 
in a model with improved “predictive power” in distinguishing AD from a heterogeneous ageing 
population. However, further improvement is still required in order to identify a robust blood 
transcriptomic signature more specific to AD before clinical utility is considered.  
Overall the work undertaken in this thesis provides new insight into the biological changes occurring in 
both the asymptomatic and symptomatic phase of the disease, demonstrates a framework for a 
possible blood-based transcriptomic diagnosis test, provides new potential therapeutic targets and 
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Supplementary Table 2.1: Significance testing of gender, age and PM delay between diagnosis groups 
Tissue Comparison 
Gender Age PM Delay 
P-value P-value P-value 
Cerebellum 
AD vs AsymAD 0.25 0.00 0.03 
AD vs CO 0.77 0.11 0.01 
AsymAD vs CO 0.15 0.00 0.55 
Entorhinal Cortex 
AD vs AsymAD 0.60 0.00 0.01 
AD vs CO 0.37 0.38 0.04 
AsymAD vs CO 0.14 0.01 0.22 
Frontal Cortex 
AD vs AsymAD 0.99 0.00 0.12 
AD vs CO 0.15 0.06 0.01 
AsymAD vs CO 0.11 0.00 0.86 
Temporal Cortex 
AD vs AsymAD 0.42 0.00 0.03 
AD vs CO 0.39 0.05 0.02 
AsymAD vs CO 0.11 0.01 0.45 
The table provides the Mann Whitney U test results which suggest Age is significantly lower in the control groups.  “AsymAD 
vs CO” represents a comparison between the control and AsymAD group. “AD vs AsymAD” represents a comparison between 
the AsymAD and AD group. “AD vs CO” represents a comparison between the control and AD group. Abbreviation: PM = Post 
Mortem 
 
 Supplementary Table 2.2: Differentially expression analysis results when accounting for age 










DEG (with age) 
Entorhinal Cortex AD vs CO 34 16 3518 1690 1435 
  AD vs AsymAD 34 28 3518 1904 1942 
  AsymAD vs CO 28 16 3518 19 1 
Temporal Cortex AD vs CO 45 24 3518 1517 1383 
  AD vs AsymAD 45 28 3518 1546 1532 
  AsymAD vs CO 28 24 3518 253 56 
Frontal Cortex AD vs CO 38 21 3518 299 195 
  AD vs AsymAD 38 32 3518 52 40 
  CO_AD vs CO 32 21 3518 398 436 
Cerebellum AD vs CO 36 18 3518 176 76 
  AD vs CO_AD 36 27 3518 13 13 
  CO_AD vs CO 27 18 3518 1 1 
The table shows the effects of incorporating age into the model when performing differential expression analysis. In general, 
the number of differentially expressed genes is reduced when accounting for age. A gene is regarded to be significantly 
differentially expressed when the adjusted p-value is ≤ 0.05. “AsymAD vs CO” represents a comparison between the control 
and AsymAD group. “AD vs AsymAD” represents a comparison between the AsymAD and AD group. “AD vs CO” represents a 




6.5.1 MRC-LBB brain expression explorer 
The “MRC-LBB brain expression explorer” R shiny web application provides gene-level results to the 
broader research community. The application was developed in R using the “shiny” framework (version 
0.14) and is hosted on the KCL Rosalind OpenStack service (http://rosalind.kcl.ac.uk/). The application 
can be accessed at https://phidatalab-shiny.rosalind.kcl.ac.uk/ADbrainDE/, and the raw code is 
accessible at https://doi.org/10.5281/zenodo.1400644. 
The application allows users to query a gene of interest and observe the change in expression of this 
gene between the three phenotype groups (cognitive healthy controls, AsymAD and AD subjects) and 
across the four different brain regions (entorhinal cortex, temporal cortex, frontal cortex and 
cerebellum). The differential expression results are also provided for the gene of interest, providing the 
user with the ability to determine if the gene is significantly differentially expressed and how the gene 
is regulated between the phenotype groups. Furthermore, this information is graphically displayed in 
the form of boxplots to help the user explore and understand the expression changes further. A 
screenshot of the application is provided in Supplementary Figure 2.1 
To use the application, users can select any one of the 3518 genes deemed as reliably detected in the 
study from the “Select Gene” drop-down menu. Selecting a gene will automatically populate the 
boxplots and table of differential expression results. Users can use the “Plot by Phenotype or TISSUE” 
drop-down menu to display results grouped by brain regions of by phenotype. The table of results will 
display twelve rows of result, each being a different analysis of brain region by phenotype. The table 
provides the differential expression logFC and associated p-value and FDR adjusted p-value for the 


















Supplementary Table 4.1: Count of CMap compounds approved to treat diseases 
Disease N.o. treatments in the CMap database 





Fungal infection 15 
Diabetes mellitus 14 
Angina 11 
Rheumatoid arthritis 11 
Anaesthesia 10 
Parkinson's disease 10 
Allergic rhinitis 9 
Breast cancer 9 
Inflammatory diseases 9 
Malaria 8 
Nausea 8 
Anxiety disorder 7 
Cancers 7 
Congestive heart failure 7 
Epilepsy 7 
High blood pressure 7 
Osteoarthritis 7 
Urinary tract infections 7 
Vomiting 7 
Asthma 6 
Bipolar disorder 6 
Acne vulgaris 5 
Arthritis 5 
Cancer 5 
Cardiovascular disease 5 
Oedema 5 
Gout 5 
HIV infections 5 
Tuberculosis 5 
Ventricular arrhythmias 5 
Alcohol use disorders 4 
Allergy 4 
Chronic obstructive pulmonary disease 4 
Dysmenorrhea 4 
Oedema associated with congestive heart failure 4 
Glaucoma 4 
Major depressive disorder 4 




Open-angle glaucoma 4 
Peptic ulcer disease 4 
Prostate cancer 4 
Psychotic disorders 4 
Worm infections 4 
Alzheimer's disease 3 
Benign prostatic hyperplasia 3 
Cough 3 
Cushing's disease 3 
Heart failure 3 
Hormone replacement therapy 3 
Hypercholesterolemia 3 
Hyperlipidemia 3 
Musculoskeletal disease 3 
Obesity 3 
Tachyarrhythmias 3 
Viral infections 3 
Acid-reflux disorders 2 
Acute promyelocytic leukaemia 2 
Allergic conjunctivitis 2 
Angina pectoris 2 
Ankylosing spondylitis 2 
Atrial fibrillation 2 
Brain cancer 2 
Cancer pain 2 
Candida infection 2 
Cerebrovascular disorders 2 
Cognitive impairment 2 
Colorectal cancer 2 
Constipation 2 
Cutaneous T-cell lymphoma 2 
Dermatitis 2 
Diarrhoea 2 
Erectile dysfunction 2 
Gastroesophageal reflux disease 2 
Hay fever 2 
Hepatitis C virus infection 2 
Herpes simplex virus infection 2 
Hyperthyroidism 2 
Hypotension 2 
Infectious disease 2 
Melanoma 2 
Migraine 2 
Multiple myeloma 2 





Parasitic infection 2 
Premature labour 2 
Pseudomonas infection 2 
Psoriasis 2 
Pulmonary arterial hypertension 2 
Skin allergies 2 
Vertigo Meniere's disease 2 
Vitiligo 2 
Vulnerary 2 
Wound healing 2 
Acquired nystagmus 1 
Active rheumatoid arthritis 1 
Acute and chronic intestinal amebiasis 1 
Acute asthma 1 
Acute diarrhoea 1 
Acute gouty arthritis 1 
Acute hepatic failure and alcoholic cirrhosis of the liver 1 
Acute ischemic stroke 1 
Acute malaria 1 
Acute myeloid leukaemia 1 
Acute pain 1 
Addiction 1 
Advanced breast and endometrium carcinoma 1 
Advanced gum disease 1 
Alcoholic hepatitis 1 
Allergic disorders 1 
Amebiasis 1 
Amoebiasis 1 
Amyotrophic lateral sclerosis 1 
Analgesic 1 
Anaemia 1 




Athlete's foot 1 
Atrophic vaginitis 1 
Attention deficit hyperactivity disorder 1 
Bacterial respiratory tract infection 1 
Bladder disease 1 
Blood clotting disorder 1 
Brain ischaemia 1 
Bronchial asthma 1 
Bronchitis 1 
Bronchodilator 1 




Cardiac arrhythmias 1 
Cardiogenic shock 1 
Central nervous system disease 1 
Cerebral infarction 1 
Cerebral salt-wasting syndrome 1 
Cerebral stimulant 1 
Cerebral vasospasm 1 
Cerebrovascular ischaemia 1 
Cestode infection 1 
Chemotherapy-induced nausea and vomiting 1 
Chemotherapy or radiotherapy-induced mucositis 1 
Chronic breathing disorders 1 
Chronic lymphocytic leukaemia 1 
Chronic pain 1 
chronic periodontitis 1 
Chronic stable angina 1 
Cocaine addiction 1 
Cognitive disorders 1 
Colon cancer 1 
Complex partial seizures 1 
Condyloma 1 
Congestive cardiac insufficiency 1 
Conjunctivitis 1 
Coronary artery disease 1 
Coronary heart disease 1 
Crohn's disease 1 
Cystic fibrosis 1 
Dementia 1 
Dermal necrosis 1 
Dermatitis herpetiformis 1 
Dermatological disease 1 
Dermatomycosis 1 
Diagnosis of mydriasis 1 




Epileptic conditions 1 
Excessive bleeding 1 
Eye Inflammation 1 
Female genital tract inflammation 1 
Female infertility 1 
Flatworms infection 1 
Folate deficiency 1 
Fungal urinary tract infection 1 




Gastrointestinal disorders 1 
Gastrointestinal problems 1 
Glioma 1 
Gonorrheal vaginitis 1 
Gram-negative bacterial infection 1 
Hematologic malignancies 1 
Hepatitis virus infection 1 
High cholesterol levels 2 
High triglyceride levels 1 
Hodgkin's lymphoma 1 
Hormonal contraceptives 1 
Hormonally-responsive breast cancer 1 







Inflammation and itching 1 
Inflammatory bowel disease 1 
Influenza virus A infection 1 
Insecticide 1 
Insomnia 1 
Intermittent claudication 1 
Intestinal strongyloidiasis due to nematode parasite 1 
Irregularities 1 
Irritable bowel syndrome 1 
Itching 1 
Jock itch 1 
Joint and muscular pain 1 
Kidney cancer 1 
Fluid retention 1 
Lymphatic filariasis 1 
Maintenance of normal sinus rhythm 1 
Male impotence 1 
Malignant hyperthermia 1 
Malignant melanoma 1 
Medical abortion 1 
Menopausal and postmenopausal disorders 1 
Menorrhagia 1 
Menstrual disorders 1 
Metastatic breast cancer 1 
Metastatic islet cell carcinoma 1 
Migraine headaches 1 




Miosis during ocular surgery 1 
Morning sickness 1 
MRSA infection 1 
Muscle Relaxant 1 
Muscle spasm 1 
Mycobacterium avium complex disease 1 
Mycobacterium tuberculosis infection 1 
Myelodysplastic Syndromes 1 
Narcotic depression 1 
Nasal congestion 1 
Nausea and vomiting 1 
Neuropathic pain 1 
Non-infectious rhinitis 1 
Non-insulin dependent diabetes 1 
NSAID-related gastric ulcer 1 
Ocular disease 1 
Ocular hypertension 1 
Oedema and hypertension 1 
Oral contraceptives 1 
Organophosphate poisoning 1 
Organ rejection 1 
Orthostatic hypotension 1 
Otitis media 1 
Ovarian cancer 1 
Paget's disease 1 
Pancreatic cancer 1 
Pancreatic disorders 1 
Pancreatitis 1 
Partial seizures 1 
Pediatric eye examinations 1 
Peripheral nerve damage 1 
Peripheral vascular disease 1 
Peripheral vasoconstriction 1 
Photosensitizer 1 
Piscicide 1 
Pneumocystis carinii pneumonia 1 
Poison intoxication 1 
Prostate tumour 1 
Pruritus 1 
Psychomotor agitation 1 
Psychoses 1 
Pulmonary embolism 1 
Pulmonary hypertension 1 
Rheumatoid arthritis 1 






Senile dementia 1 
Skin infections 1 
Skin photodamage 1 
Sleep disorders 1 
Solid tumours 1 
Spasm 1 
Spasms 1 
Spinal anaesthesia 1 
Spinal cord injuries 1 
Stabilize muscle contractions 1 
Stroke 1 
Substance dependence 1 
Thromboembolic disorders 1 
Thrombosis 1 
Tinea pedis 1 
Trypanosomiasis 1 
Ulcerative colitis 1 
Urinary incontinence 1 
Urinary retention 1 
Vascular disease 1 
Vasodilator, diuretic 1 
Vitamin deficiency 1 
Xerophthalmia 1 
Xerostomia 1 
X-rays imaging 1 
The TTD contained information on 31,614 drug-disease relations and were used to identify diseases which can be treated by 
any of the 1146 CMap compounds. The CMap database contains 1121 unique compounds, with some compounds 
experimentally repeated at different concentrations and therefore, generated 1146 expression profiles. Only 612 CMap 
compounds annotated to 299 different diseases; however, due to multiple drug-disease combinations, 768 CMap drug-






















Gene Description Gain Cover Frequency 
1 3945 LDHB lactate dehydrogenase B  0.70 0.22 0.06 
2 51780 KDM3B lysine (K)-specific demethylase 3B  0.13 0.12 0.07 
3 29087 THYN1 thymocyte nuclear protein 1  0.04 0.02 0.06 
4 23013 SPEN 
spen homolog, transcriptional regulator 
(Drosophila)  
0.04 0.02 0.04 
5 9535 GMFG glia maturation factor, gamma  0.01 0.04 0.06 
6 55737 VPS35 
vacuolar protein sorting 35 homolog (S. 
cerevisiae)  
0.01 0.01 0.03 
7 9559 VPS26A 
vacuolar protein sorting 26 homolog A (S. 
pombe)  
0.01 0.01 0.02 
8 4694 NDUFA1 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 1, 7.5kDa  
0.01 0.04 0.05 
9 529 ATP6V1E1 
ATPase, H+ transporting, lysosomal 31kDa, V1 
subunit E1  
0.01 0.06 0.03 
10 9736 USP34 ubiquitin specific peptidase 34  0.01 0.01 0.04 
11 317 APAF1 apoptotic peptidase activating factor 1  0.01 0.00 0.02 
12 6625 SNRNP70 small nuclear ribonucleoprotein 70kDa (U1)  0.01 0.05 0.02 
13 3054 HCFC1 host cell factor C1 (VP16-accessory protein)  0.00 0.01 0.05 
14 997 CDC34 cell division cycle 34 homolog (S. cerevisiae)  0.00 0.00 0.02 
15 3108 HLA-DMA 
major histocompatibility complex, class II, DM 
alpha  
0.00 0.06 0.05 
16 3028 HSD17B10 hydroxysteroid (17-beta) dehydrogenase 10  0.00 0.02 0.03 
17 23526 HMHA1 histocompatibility (minor) HA-1  0.00 0.04 0.02 
18 10695 CNPY3 canopy 3 homolog (zebrafish)  0.00 0.04 0.02 
19 51283 BFAR bifunctional apoptosis regulator  0.00 0.04 0.06 
20 27095 TRAPPC3 trafficking protein particle complex 3  0.00 0.02 0.04 
21 6166 RPL36AL ribosomal protein L36a-like  0.00 0.02 0.04 
22 7832 BTG2 BTG family, member 2  0.00 0.06 0.04 
23 2976 GTF3C2 
general transcription factor IIIC, polypeptide 
2, beta 110kDa  
0.00 0.00 0.03 
24 5436 POLR2G 
polymerase (RNA) II (DNA directed) 
polypeptide G  
0.00 0.06 0.01 
25 93487 MAPK1IP1L 
mitogen-activated protein kinase 1 
interacting protein 1-like  
0.00 0.01 0.03 
26 6742 SSBP1 
single-stranded DNA binding protein 1, 
mitochondrial  
0.00 0.02 0.04 
27 16 AARS alanyl-tRNA synthetase  0.00 0.00 0.02 
28 29 ABR active BCR-related  0.00 0.00 0.02 
The “AD vs mixed control” classification model uses 28 predictive features for patient diagnosis. Variable importance was 










Gene Overlap p-value q-value 
WNT ligand biogenesis and 
trafficking 
Reactome VPS35; VPS26A 9.56E-04 3.82E-02 
Alzheimer disease - Homo 
sapiens (human) 
KEGG HSD17B10; APAF1; NDUFA1 3.70E-03 5.19E-02 
Herpes simplex infection - 
Homo sapiens (human) 
KEGG CDC34; HCFC1; HLA-DMA 4.61E-03 5.19E-02 
Huntington disease - Homo 
sapiens (human) 
KEGG POLR2G; APAF1; NDUFA1 5.19E-03 5.19E-02 
GSEA was performed on the 28 predictive genes of the “AD vs mixed control” classification model. The most significant 
results (p≤0.05) are provided above. 
 
 
